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ABSTRACT 
MicroRNAs (miRNA) are a class of non-coding RNAs with approximately 18 to 28 nt, 
which are important in post-transcriptional gene regulation. In this study, potential 
single nucleotide variant within seed region sequence of mature miRNAs of Homo 
sapiens was identified. Mature miRNA sequences of Homo sapiens were collected from 
miRBase database. A total of 1344 mature miRNA sequences were used to compare 
with single nucleotide variant sequence in UCSC database to search for candidate 
miRNA variant. Fourty-two mature miRNAs that have single nucleotide variant on 
seed-region were identified. Prediction of the secondary structure with MFOLD had 
identified a total of fourteen potential miRNAs that have a single nucleotide variant on 
the seed region. Two mature miRNAs with SNP on their seed-region had been chosen 
to validate experimentally with real-time PCR approach; miR124-3 (miRBase ID 
MI0000445) and miR-662 (miRBase ID MI0003670). These two potential single 
nucleotide variant on the seed region sequence of mature miRNAs were found to 
enhance the expression of its mature miRNA. The nucleotide change on the seed region 
of miR124-3 and miR-662 is suspected to provide stable secondary structure of pri-
miRNA and pre-miRNA compare to the wild-type allele of miRNAs. The increased  
expression of specific miRNAs could possibly render the miRNA to act as an oncomiR 
or vice versa as a  tumour suppressor miRNA, hence this study emphasizes that a single 
nucleotide change on the seed-region of mature miRNA could potentially lead to 
widespread phenotypic effects and broadens our understanding on miRNA biogenesis.  
 
 
 
ii 
ABSTRAK 
MicroRNAs (miRNA) adalah kelas bukan pengekodan pernas dengan kira-kira 18-28 nt, 
yang penting dalam peraturan gen pasca-transkripsi. Dalam kajian ini, potensi varian 
tunggal nukleotida dalam urutan rantau benih miRNAs matang Homo sapiens telah 
dikenal pasti. MiRNA urutan matang Homo sapiens telah dikumpulkan dari pangkalan 
data miRBase. Sebanyak 1344 urutan miRNA matang telah digunakan untuk 
membandingkan dengan urutan varian nukleotida tunggal dalam pangkalan data UCSC 
untuk mencari calon miRNA varian. Empat puluh dua miRNAs matang yang 
mempunyai varian nukleotida tunggal pada benih rantau telah dikenalpasti. Ramalan 
struktur menengah dengan MFOLD telah mengenal pasti sebanyak empat belas 
miRNAs potensi yang mempunyai varian tunggal nukleotida pada rantau benih. Dua 
miRNAs matang dengan SNP pada benih-kawasan telah dipilih untuk mengesahkan uji 
kaji dengan pendekatan PCR masa sebenar; miR124-3 (miRBase ID MI0000445) dan 
Mir-662 (miRBase ID MI0003670). Kedua-dua varian potensi tunggal nukleotida pada 
urutan rantau benih miRNAs matang telah didapati untuk meningkatkan ungkapan 
miRNA matang itu. Perubahan nukleotida kepada rantau benih daripada miR124-3 dan 
mir-662 disyaki menyediakan struktur menengah stabil pri-miRNA dan pra-miRNA 
berbanding allele liar-jenis miRNAs. Ungkapan peningkatan miRNAs tertentu mungkin 
boleh menyebabkan miRNA untuk bertindak sebagai oncomiR atau sebaliknya sebagai 
penindas miRNA tumor, maka kajian ini menekankan bahawa perubahan nukleotida 
tunggal pada benih rantau miRNA matang berpotensi membawa kepada kesan fenotip 
meluas dan meluaskan pemahaman kita pada biogenesis miRNA. 
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CHAPTER 1      INTRODUCTION 
1.1      Introduction 
In 1990s, two research groups - Lee et al. (1993) and Wightman et al. (1991) 
have independently discovered a small 22 nt RNA from the lin-4 gene. They found that 
lin-4 gene sequence complement that of the lin-14 gene, and negatively regulates lin-14 
expression in Caenorhabditis elegans. These classes of small non-coding RNAs are 
later known as microRNAs (miRNAs). In general, miRNAs function to downregulate 
gene expression by cleaving or inhibiting the translation of their target gene transcript. 
They are important in signaling, cell fate identity, organ differentiation and 
development, stress responses, disease and carcinogenesis (Lai, 2003). Up to date, 
more than 24,521 miRNAs have been identified from 133 species including primates, 
rodent, birds, fish, worms, flies, plant and viruses (miRBase Release 20.0, June 2013). 
 
Hypothetically, defect in miRNA biogenesis or aberrant miRNA expression 
level may lead to disorganized cellular processes and eventually cause human diseases. 
For example, miR-107 was significantly down regulated in Alzheimer’s disease 
(Garofalo et al., 2008; Nelson et al., 2008); miR-133b show very low expression level 
in Parkinson’s disease and miR-1 is over expressed in individuals with coronary artery 
disease (Garcia and Miska, 2005; Rooij et al., 2006).  
 
 Single nucleotide polymorphisms (SNPs) are the most common DNA variation 
found in human genome and contribute to human disorders or cancers. Single 
nucleotide variation within the seed region of a mature miRNA sequence may 
contribute to a different expression of miRNA, including post transcription miRNA 
processing and miRNA stability and functions. Besides that, nucleotides variation 
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within the seed region of mature miRNA that are phenotypic neutral may contribute to 
the evolution of miRNAs with new or altered function that resulted in the production of 
novel miRNAs with more specialized functions (Sun et al., 2010).   
 
This study on single nucleotide variant within the seed region of mature miRNA 
sequence ultimately explored the post-processing of the affected miRNA. The 
knowledge gained from this study provides insights into how SNPs within seed regions 
may influence the biogenesis of a miRNA. 
 
1.2      Literature Review 
1.2.1       Organization of human genome  
A genome is an organism’s complete set of double stranded deoxyribonucleic 
acid (DNA). Each genome contains important information to build and to maintain one 
organism. In human, the entire genome consists of approximately 3.2 billion DNA base 
pairs which are organized in 24 distinct chromosomes (Vogel and Motulsky, 1997; 
Venter et al., 2001; Bonham et al., 2005). Human genome project has revealed that 
there are about 30,000 genes (two percentage of the total DNA content) that are 
responsible for coding ribonucleic acid (RNA). RNA involves in producing functional 
proteins, such as coding, structural and regulatory (Vogel and Motulsky, 1997; Venter 
et al., 2001; Collins, 2003; Kidd et al., 2004; Bonham et al., 2005; Sampo Sammalisto, 
2008).  
 
One individual receives one chromosome of each type from each parent. 
Therefore, each individual has its own sets of 22 autosomal chromosome pairs (Figure 
1-1) and a pair of sex chromosome, either XX (female) or XY (male) (Vogel and 
Motulsky, 1997; Sampo Sammalisto, 2008). Majority of the human genetic information 
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is identical among all human beings, yet each individual’s genetic code still differs 
slightly. It has been shown that any two human individuals that are about 99.8% to   
99.5% genetically identical, they share only the most important genetic material. The 
remaining 0.2% to 0.5% difference, which represents sixteen to fifteen million gene 
variant, can occur in different combinations which are enough to cause individual 
uniqueness (Venter et al., 2001; Collins, 2003; Kidd et al., 2004; Bonham et al., 2005).    
 
 
 
Figure 1-1: Structure of DNA and chromosome. Double stranded DNA is tightly  
coiled within each chromosome. 
(Figure from Sharma, N.S., 2005 - Molecular Structure of Genes and Chromosomes) 
 
1.2.1.1     Human genetic variation 
Genetic variation slowly leads to the genetic diversity of human beings (Vogel 
and Motulsky, 1997; Brooker, 2005; Li, 2012). It represents the total amount of genetic 
characteristic obtained within human. The genetic differences that occurred in between 
human can be found in both individual and population level (Snustad and Simmons, 
2003; Jorde et al., 2004; Kidd et al., 2004; Brooker, 2005; Frazer et al., 2009). In the 
individual level, there is no two humans with identical genetic. Even monozygotic twins 
have genetic differences due to copy number variation and mutations. In population 
level, alleles occur at different frequencies in different population that is especially 
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geographically and ancestrally divert (Vogel and Motulsky, 1997; Snustad and 
Simmons, 2003; Jorde et al., 2004; Wong et al., 2007; Frazer et al., 2009).   
 
Genetic variation in human genome exists as various levels, from single base 
pair to thousand kilo base pairs (Snustad and Simmons, 2003; Brooker, 2005; Wong et 
al., 2007). The causes of these variations are the genetic recombination, random 
assortment, mutational event and evolutionary forces (natural selection and genetic drift) 
(Vogel and Motulsky, 1997; Snustad and Simmons, 2003; Svetlanov and Cohen, 2004; 
Brooker, 2005; Sampo Sammalisto, 2008; Frazer et al., 2009). There are common and 
rare variant: common variant are synonymous with polymorphisms with a minor allele 
frequency of at least one percent, while rare variant are those with a minor allele 
frequency less than one percent (Vogel and Motulsky, 1997; Snustad and Simmons, 
2003; Frazer et al., 2009). In addition, genetic variant have been discussed in the terms 
of nucleotide composition – single nucleotide variant and structural variant (Figure 1-2). 
The vast majority of genetic variant are hypothesized to be neutral that do not contribute 
to phenotypic variation (Vogel and Motulsky, 1997; Snustad and Simmons, 2003; 
Brooker, 2005; Frazer et al., 2009). 
  
   
Figure 1-2: Classes of human genetic variant.  (Figure from Frazer et al., 2009) 
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1.2.1.2     Single nucleotide variant 
Single nucleotide variant are classified when a single nucleotide (adenine-A, 
thymine-T, cytosine-C or guanine-G) is altered in the DNA sequence (Vogel and 
Motulsky, 1997; Snustad and Simmons, 2003; Brooker, 2005; Frazer et al., 2009). 
Single nucleotide polymorphisms (SNPs) are the most common single nucleotide 
variation among individuals (Figure 1-3). SNPs are estimated to occur at 1 out of every 
1,250 bases in human genome (Vogel and Motulsky, 1997; Syvänen, 2001; Venter et al., 
2001; Sampo Sammalisto, 2008; Frazer et al., 2009). Survey of the sequencing results 
show that there are at least 30 million SNPs occur in human genome (Venter et al., 2001; 
Duan et al., 2007; Frazer et al., 2009). There are almost two million of validated SNPs 
in public available databases – SNP Consortium, International Hapmap Project, UCSC 
Genome Bioinformatics site and National Center for Biotechnology Information (NCBI) 
(Syvänen, 2001; Kidd et al., 2004; Frazer et al., 2009).  
 
SNPs are innumerable rare and novel, in some cases segregate only in a nuclear 
family or a single individual (Frazer et al., 2009). Only a small proportion of SNPs 
(<1%) give impact at the phenotypic level (Syvänen, 2001; Venter et al., 2001). This is 
because only SNPs that occur in the coding regions and regulatory regions of the genes 
will alter the amino acid sequences of proteins and gene expression. These alterations 
cause most of the dominantly or recessively inherited monogenic disorders (Vogel and 
Motulsky, 1997; Syvänen, 2001; Venter et al., 2001; Snustad and Simmons, 2003; 
Brooker, 2005; Li, 2012). Therefore, these SNPs are routinely analyzed for diagnostic 
and pharmacogenetic purposes. However, SNPs that located in the non-coding regions 
of the genome are yet to study their impact on phenotype (Vogel and Motulsky, 1997; 
Syvänen, 2001; Brooker, 2005; Li, 2012). SNPs are useful as markers in common and 
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multifactorial disorders, besides population genetics and evolutionary studies (Syvänen, 
2001; Kwok and Chen, 2003; Snustad and Simmons, 2003; Brooker, 2005). 
 
 
Figure 1-3: Single nucleotide polymorphisms (SNPs) in human population. 
(Figure from http://www.celera.com/celera/cdx_discover) 
 
1.2.2     MicroRNA (miRNA) in human 
To date, miRNAs have been found in plant and animal multicellular organisms 
(Carrington and Ambros, 2003; Millar and Waterhouse, 2005). According to the 
miRNA Registry Database – Release 20.0, June 2013 (http://www.sanger.ac.uk), 24,521 
miRNA genes have been identified in 133 species, such as plant, primates, metazoan, 
vertebrates, amphibian, arthropoda, mammalian, DNA viruses, and single cellular algae. 
These include 1872 Homo sapiens miRNAs, 223 Caenorhabditis elegans miRNAs, 238 
Drosophila melanogaster miRNAs, 346 Danio rerio miRNAs, 734 Gallus gallus 
(chicken) miRNAs and etc (Jones, 2004; Jones et al., 2006; Jones et al., 2008). Animal 
miRNAs are evolutionarily conserved for at least 400 million years old (Millar and 
Waterhouse, 2005).  
 
MicroRNAs are produced to provide essential regulation of developmental 
processes (Bartel, 2004; Millar and Waterhouse, 2005; Kusenda et al., 2006; Meola et 
al., 2009; Kunej et al., 2012). These miRNAs have the length of about 18-28 nt which 
7 
are excised from endogenously encoded hairpin RNAs. MicroRNA negatively regulate 
their 3’ UTR target genes by translational inhibition or degradation of mRNA (Ambros, 
2004; Cullen, 2004; Lippman and Martienssen, 2004; Gregory and Shiekhattar, 2005; 
Millar and Waterhouse, 2005; Lee et al., 2006; Saetrom et al., 2006; Zambon et al., 
2006; Reddy et al., 2007; Asikainen et al., 2008; Kunej et al., 2012). Significant 
numbers of human miRNAs are encoded within the introns of precursor mRNAs 
(Ambros, 2004; Bartel, 2004; Lee et al., 2004; Du and Zamore, 2005; Kusenda et al., 
2006; Zeng, 2006; Kim et al., 2007; Meola et al., 2009).  These intron-coded miRNAs 
are in the same orientation as the pre- mRNA, which suggest each processed transcript 
will produce one translatable mRNA and one functional miRNA (Millar and 
Waterhouse, 2005; Kim and Nam, 2006). 
 
1.2.2.1      Characteristic of microRNA 
There are several structural characteristics that are conserved among all miRNAs 
to distinguish them from random or genomic hairpins of similar lengths (Ambros et al., 
2003; Saetrom et al., 2006; Kim and Nam, 2006; Zhang et al., 2006). It must follow 
certain features in order to be classified as miRNA. First, the 18-28 nt of mature 
miRNA sequence should be found within one arm of the hairpin structure that is lack of 
large bulges or internal loops. The stem-looped secondary structures of miRNAs are 
well conserved in humans (Ambros et al., 2003; Kim and Nam, 2006; Zhang et al., 
2006; Kunej et al., 2012). Secondly, the stable precursor hairpins have multiple foldings 
with the lowest negative minimal folding free energy (MFE) and highest negative 
minimal folding free energy index (MFEI) compared to other RNAs (Ambros et al., 
2003; Bonnet et al., 2004; Zhang et al., 2006; Zhang et al., 2007; Kunej et al., 2012). 
Several parameters were considered to obtain MFEI: adjusted minimal folding free 
energy (combination of minimal folding free energy and length of pre-miRNA), length 
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of RNAs and GC content. Most pre-miRNAs had an MFEI greater than 0.95 kcal/mol 
while other RNAs ranged between 0.5-0.7 kcal/mol (Ambros et al., 2003; Bonnet et al., 
2004; Layton et al., 2005; Zhang et al., 2006). Third, these small miRNAs are believed 
to be evolutionarily or phylogenetically conserved in closely related species (Ambros et 
al., 2003; Kim and Nam, 2006; Saetrom et al., 2006; Zeng, 2006). Fourth, all miRNAs 
have high complementarity to their targeted 3’ UTR mRNA, either precise 
complementarity in plant or imperfect complementarity in animals. In animal miRNAs, 
Watson–Crick base pairing between six or seven nucleotides in the target mRNA's 
3′UTR and nucleotides 2–7 or 2–8 (the “seed sequence”) of the miRNA's 5′ end is 
required (Du and Zamore, 2005; Kim and Nam, 2006; Zhang et al., 2006). As a result, a 
single miRNA can regulate hundreds or thousands of different 3’ UTR mRNA targets. 
Conversely, several miRNAs can bind cooperatively to a single 3’ UTR mRNA target 
(Du and Zamore, 2005; Kim and Nam, 2006; Lee et al., 2006; Zhang et al., 2006). 
 
1.2.2.2      MicroRNA biogenesis 
MicroRNA resides in the intergenic (40%) or intragenic (60%) regions. It is an 
endogenous transcript that can self-complement to form imperfect stem loop structures 
(Ambros, 2004; Bartel, 2004; Cullen, 2004; Gregory and Shiekhattar, 2005; Lee et al., 
2006; Saetrom et al., 2006; Zambon et al., 2006; Asikainen et al., 2008; Meola et al., 
2009). A single miRNA is located on one arm of a hairpin precursor transcript. 
Sometimes one pri-miRNA transcript consists of several hairpins that give rise to 
different miRNAs which are known as polycistronic miRNA transcripts (Ambros et al., 
2003; Du and Zamore, 2005; Millar and Waterhouse, 2005; Kim and Nam, 2006; Kim 
and Kim, 2007; Meola et al., 2009).  
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Initially, miRNAs are transcribed from long primary transcripts (pri-miRNAs) 
that varies from 400-3,000 bases by RNA polymerase II enzyme. Primary transcript is 5’ 
capped and polyadenylated (Bartel, 2004; Du and Zamore, 2005; Kim and Nam, 2006; 
Kusenda et al., 2006; Lee et al., 2006; Saetrom et al., 2006; Meola et al., 2009; Winter 
et al., 2009; Ryan et al., 2010). These pri-miRNAs are then cleaved into 60-100 nt, stem 
loop precursor miRNAs (pre-miRNAs) by Drosha-DGCR8 complex (RNase III 
endonuclease) (Denli et al., 2004; Du and Zamore, 2005; Kusenda et al., 2006; Zeng, 
2006; Kim and Kim, 2007; Reddy et al., 2007; Meola et al., 2009; Winter et al., 2009). 
The Drosha-DGCR8 complex which is also known as microprocessor complex, 
recognized and cleaved at the ‘ssRNA–dsRNA junction-anchoring’ structure which is 
embedded within pri-miRNA (Figure 1-4) It is a stem of approximately 33 base pairs 
(bp) with a terminal loop and flanking segment. Drosha-DGCR8 cleaves at ~11 bp from 
the stem ssRNA junction that is critical for the processing of pre-miRNA (Han et al., 
2006; Yeom et al., 2006; Duan et al., 2007). Processed pre-miRNAs are exported out of 
the nucleus to cytoplasm by RAN-GTPase/exportin-5 (Bartel, 2004; Krol et al., 2004; 
Lee et al., 2006; Kim and Nam, 2006; Kim and Kim, 2007; Reddy et al., 2007; Winter 
et al., 2009) and succeedingly cleaved by RNase III Dicer to release a double stranded 
miRNA/miRNA complementary duplex of 18-28 nt, with a 2 nt 3’ overhang (Du and 
Zamore, 2005; Gregory et al., 2005; Kim and Nam, 2006; Saetrom et al., 2006Reddy et 
al., 2007; Winter et al., 2009; Kunej et al., 2012; Slaby et al., 2012). Only mature 
miRNA will associate with RNA-induced Silencing Complex (RISC) (Gregory et al., 
2005; Kim and Nam, 2006; Saetrom et al., 2006; Zhang et al., 2006; Reddy et al., 2007; 
Slaby et al., 2012) or ribonucleoprotein (RNP) complex (Mourelatos et al., 2002; Bartel, 
2004; Lee et al., 2004; Kim and Nam, 2006; Kusenda et al., 2006; Reddy et al., 2007; 
Meola et al., 2009; Winter et al., 2009). While the other miRNA complementary 
(miRNA*) strand is usually degraded, although recently miRNA* has been found to 
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play similar role as miRNA (Du and Zamore, 2005; Lee et al., 2006; Saetrom et al., 
2006;  Meola et al., 2009; Slaby et al., 2012).  
 
        
 
Figure 1-4: The ‘ssRNA–dsRNA junction-anchoring’ model for pri-miRNA processing. 
(Figure from Han et al., 2006) 
 
This miRNA-protein complex is responsible for the post-transcriptional 
regulation at transcription level or/and translation level. MicroRNA mediates 
degradation based on its base pair complementary to its 3’ UTR mRNA target: partial 
complement will result in inhibition of protein translation and 3’ UTR mRNA target 
cleavage  for those who have perfect complementary (Ambros, 2004; Bartel, 2004; Kim 
and Nam, 2006; Zambon et al., 2006; Reddy et al., 2007; Meola et al., 2009; Slaby et 
al., 2012). In the recognition of 3’ UTR mRNA target by miRNA, a perfect 
complementarity is usually restricted to the seed region (2-7 or 2-8 nt of the 5’ region of 
mature miRNA) of the 3’ region of the untranslated region of mRNA target (Figure 1-5) 
(Du and Zamore, 2005; Kim and Nam, 2006; Meola et al., 2009; Winter et al., 2009).  
 
 
Figure 1-5: Secondary structure of Let-7b.  
Red circles are the mature miRNA sequence of Let-7b; seed region is located the 2
nd
 to 
8
th
 nt of 5’ end of mature miRNA. (Figure from Mishra and Bertino, 2009) 
 
5’ 
3’ 
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1.2.2.3      Biological functions of human microRNA 
At present, many reports indicate that a single miRNA is able to repress a large 
set of 3’ UTR targets, resulting in low protein expression levels within the miRNA-
expressing cells (Ambros, 2004; Bartel, 2004; Kim and Nam, 2006; Kusenda et al., 
2006; Zhang et al., 2006; Meola et al., 2009). Example in C. elegans, absent of let-7 
causes failure in transition of larva to adult (Hammond, 2006; Kusenda et al., 2006). In 
addition, miRNAs are known to involve in cell proliferation and apoptosis, as they 
regulate pathways that are controlled by p53, MYC and RAS genes (Lai, 2003; Ambros, 
2004; Bartel, 2004; Hammond, 2006; Zhang et al., 2006; Cho, 2007). For instance, 
some miRNA clusters have been shown to act as a functional switch between 
proliferation and apoptosis of cell (Plasterk, 2006; Treiber et al., 2012). Besides, 
miRNAs play role in the determination of timing and maintenance of tissue or cell 
identity. High miRNA expression level is found in certain tissue or cell type or at 
particular developmental stage (Zeng and Cullen, 2003; Ambros, 2004; Bartel, 2004; 
Du and Zamore, 2005; Zhang et al., 2006). These small miRNA also take place in 
responding to environmental stresses, immune system, and neurological processes 
besides playing an important role in biological processes (Zeng and Cullen, 2003; Bartel, 
2004; Du and Zamore, 2005; Kusenda et al., 2006; Zhang et al., 2006; Wiemer, 2007; 
Garofalo et al., 2008; Meola et al., 2009; Treiber et al., 2012). 
 
1.2.3      Type of genetic variations in microRNA  
MicroRNA sequences are known to be well conserved, but variations do take 
place in miRNA with low frequency (Lai, 2003; Saunders et al., 2007; Yu et al., 2007; 
Chen et al., 2008). Many miRNA variant may not have significant phenotypes as 
several different miRNAs are able to target the same 3’ UTR mRNA transcript where 
miRNAs would compensate for each other. Moreover, most of the predicted single 
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nucleotide variant within seed region of mature miRNA sequence are likely neutral or in 
a mutation selection balance (Du and Zamore, 2005; Kim and Nam, 2006; Lee et al., 
2006; Zhang et al., 2006; Borel and Antonarakis, 2008). Not much miRNA variants are 
discovered since the rare or common genomic variant are not fully identified. After 
miRNAs are better characterized and more public available genomic variations database, 
more studies on miRNA variant can be done in the near future (Borel and Antonarakis, 
2008; Lai, 2003; Saunders et al., 2007; Yu et al., 2007; Chen et al., 2008).    
 
 
 
Figure 1-6: Summary of types of miRNAvariant.   (Figure from Meola et al., 2009) 
 
There are four main types of  sequence variations (Figure 1-6) that may affect 
miRNA function: variation within pri-miRNA or pre-miRNA sequences (Iwai and 
Naraba, 2005; Diederichs and Haber, 2006; Wu et al., 2008), variations in mature 
miRNA sequence (Iwai and Naraba, 2005; Duan et al., 2007; Borel and Antonarakis, 
2008; Mencìa et al., 2009), variations in the binding target site of 3’ UTR mRNA 
(Abelson et al., 2005 ; Saunders et al., 2007; Yu et al., 2007; Chen et al., 2008; Shen et 
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al., 2008), and variations in genes or proteins that are involved in miRNA processing 
and regulation (Diederichs and Haber, 2007; Yu et al., 2007; Meola et al., 2009; 
Boominathan, 2010). In this study, variations in mature miRNA sequence are 
emphasized. 
 
1.2.3.1      Genetic variations in mature microRNA sequences 
Point mutations within the mature miRNA sequences are known to be causal 
factors of diseases (Iwai and Naraba, 2005; Duan et al., 2007; Borel and Antonarakis, 
2008; Wu et al., 2008;  Mencìa et al., 2009; Meola et al., 2009). Variation within 
mature miRNA was first discovered to have extensive biological effect by Duan and 
colleagues (2007). They worked on variation in miRNA, in particular a single 
nucleotide polymorphism (SNP), rs12975333, at the 8
th
 nt of the 5’ end of mature     
miR-125a. This variation on mature miR-125a had lowered the expression of miR-125a. 
Down-regulation of miR-125a is suspected to play an important role in the pathogenesis 
of breast cancer and non-small cell lung cancer (Duan et al., 2007; Borel and 
Antonarakis, 2008; Jiang et al., 2010; Mencìa et al., 2009; Meola et al., 2009). In 
addition, single nucleotide variation in human mature miR-96 (a single base change 
A>T in the seed region of 5’-end) was the first example of miRNA implicating human 
Mendelian disorder (Mencìa et al., 2009; Meola et al., 2009). However, the occurrence 
of variations in functional seed region is less than 1% which is relatively rare, as the 
seed region is well conserved (Saunders et al., 2007; Yu et al., 2007; Chen et al., 2008).  
 
Hypothetically, variation within mature miRNA sequence causes pri-miRNA 
unable to process into pre-miRNA normally, thus destabilize the interaction with 3’ 
UTR mRNA targets and hence reduced the efficiency of mRNA target inhibition (Duan 
et al., 2007; Georges et al., 2007; Borel and Antonarakis, 2008; Horikawa et al., 2008; 
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Wu et al., 2008; Yu et al., 2008; Mencìa et al., 2009; Meola et al., 2009). Few studies 
also stated that variation in mature miRNA may potentially alter the normal biological 
processes by either changing the processing or target recognition of miRNAs (Borel and 
Antonarakis, 2008; Wu et al., 2008; Mencìa et al., 2009; Meola et al., 2009; Slaby et al., 
2012). The pri-miRNA processing is an important and critical step in miRNA 
biogenesis, as it determines the sequence of the mature miRNA. Therefore any 
alteration in the miRNA processing is believed to affect the expression level of mature 
miRNAs (Borel and Antonarakis, 2008; Wu et al., 2008; Mencìa et al., 2009; Slaby et 
al., 2012). Consequently, this may affect the function of miRNA in miRNA-mRNA 
target interaction. Therefore one small sequence variation at the mature miRNA-binding 
sites would not only affect the interaction of miRNA and mRNA, but also has a huge 
effect on hundreds of their  miRNA targets (Duan et al., 2007; Yu et al., 2007; Borel 
and Antonarakis, 2008; Wu et al., 2008; Mencìa et al., 2009; Meola et al., 2009). If the 
miRNA targets are oncogene or tumour suppressor genes, these genes might contribute 
to the development of cancers (Diederichs and Haber, 2006; Yu et al., 2007; Wu et al., 
2008; Kunej et al., 2012; Slaby et al., 2012). 
 
1.2.3.2      Relationship of microRNA to diseases and cancer 
miRNA has been found to play a critical role in the development of human 
diseases and cancer (Kusenda et al., 2006; Garofalo et al., 2008; Sassen et al., 2008; 
Sethupathy and Collin, 2008; Meola et al., 2009; Slaby et al., 2012). Defection in 
miRNA functions or aberrant miRNA expression level may lead to abnormal miRNA 
biogenesis and eventually cause disorder or diseases (Kusenda et al., 2006; Garofalo et 
al., 2008; Sassen et al., 2008; Sethupathy and Collin, 2008; Meola et al., 2009). This 
can be caused by either cis factors (chromosome alterations, epigenetic modifications, 
mutation of promoter element and polymorphisms within miRNA sequences) or trans 
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factors (polymorphisms in miRNA target sites and functional mutation in proteins that 
involved in miRNA transcription, processing and targeting) (Sethupathy and Collin, 
2008). 
 
Currently, numerous evidences suggest that human diseases are correlated with 
presence of miRNA. In Alzheimer’s disease, miR-107 was significantly down regulated 
and miR-125b was upregulated in brain (Garofalo et al., 2008; Nelson et al., 2008; Patel 
et al., 2008; Martino et al., 2009; Zeng, 2009). Similarly, in Parkinson patient, their 
midbrain show very low expression level of miR-133b compare to the normal human 
(Garofalo et al., 2008; Nelson et al., 2008; Martino et al., 2009; Zeng, 2009). 
MicroRNAs have been shown to regulate genes that are involved in cardiac function 
and heart development. miR-1 is over-expressed in individuals with coronary artery 
disease (Garcia and miska, 2005; Rooij et al., 2006; Wiemer, 2007; Garofalo et al., 
2008; Meola et al., 2009). Moreover, miRNA expression levels also greatly differ in 
fragile X syndrome (Kusenda et al., 2006; Garofalo et al., 2008; Dai et al., 2009), 
Tourette’s syndrome (Wiemer, 2007), schizophrenia (Garcia and miska, 2005; Garofalo 
et al., 2008; Feng et al., 2009), and Duchenne muscular dystrophy (Wiemer, 2007; 
Garofalo et al., 2008).  
 
Meanwhile, significant increase or decrease of miRNA expression level may 
change the pathways that are involved in tumour cell proliferation, and hence promote 
cancer progression and/or tumour formation (Garcia and miska, 2005; Gregory and 
Shiekhattar, 2005; Garzon et al., 2006; Gaur et al., 2007; Winter et al., 2009; Kunej et 
al., 2012). In cancer, miRNAs that target oncogenes are known to act as tumour 
suppressors; miRNAs that target tumour suppressors have a role as oncogene (Garcia 
and miska, 2005; Garzon et al., 2006; Zhang et al., 2007). For example, miR-15a and 
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miR-16-1 in chronic lymphocytic leukaemia, and let-7 in lung cancer and non-small cell 
lung cancer are found to have tumour suppressing activity (Garcia and miska, 2005; 
Garzon et al., 2006; Hammond, 2006; Kusenda et al., 2006; Cho, 2007; Pan et al., 2007; 
Garofalo et al., 2008; Xia, 2008) while miR-372 and miR-373 in testicular germ cell 
tumour, miR-21 in breast cancer and miR-155 in Hodgkin’s Burkitt lymphoma have 
oncogenic potential (Garcia and miska, 2005; Garzon et al., 2006; Cho, 2007; Pan et al., 
2007; Garofalo et al., 2008; Xia, 2008). 
 
1.2.4      Future prospects of microRNA  
The discovery and understanding of miRNA roles in various biological and 
pathological processes will offer many possible therapeutic applications. The concept of 
one miRNA modulates hundreds to thousands of mRNAs will provide new window for 
diagnostics and prognostics therapy of many human diseases, including cancer (Du and 
Zamore, 2005; Cho, 2007; Garzon et al., 2006; Kim and Nam, 2006; Kusenda et al., 
2006; Lee et al., 2006; Meola et al., 2009; Zhang et al., 2006; Garofalo et al., 2008). 
MicroRNA with different expression profile can be used as biomarkers to detect and 
classify diseases or tumors according to the differentiation and developmental states 
(Garcia and miska, 2005; Gregory and Shiekhattar, 2005; Garzon et al., 2006; Zhang et 
al., 2007). In addition, miRNA itself can function as tumour suppressors to prevent or 
cure diseases (Garcia and miska, 2005; Hammond, 2006; Cho, 2007). Future therapies 
could be the innovation of mimicking or antagonizing miRNA action on multiple targets 
with small molecules of artificial miRNA or anti-miRNA, to treat diseases or cancers 
that are difficult to cure (Garcia and miska, 2005; Zhang et al., 2007; Garofalo et al., 
2008).  
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1.3      Objectives 
MicroRNAs are important regulators of development, cell signaling, stress 
responses, and involved in antiviral defences (Zeng and Cullen, 2003; Bartel, 2004; Du 
and Zamore, 2005; Kusenda et al., 2006; Kunej et al., 2012; Slaby et al., 2012). 
Sequence variation in miRNA gene has potention contribution to human disease 
pathogenesis. In this study, I hypothesized that single nucleotide variant in the seed-
regions of mature miRNA might altered the biogenesis of miRNA, therefore up-
regulation or down-regulation of  mature miRNA expression level, might affects the 
stable processing of mature miRNA. Hence this would contribute to the pathogenesis of 
human diseases (Kusenda et al., 2006; Garofalo et al., 2008; Sassen et al., 2008; 
Sethupathy and Collin, 2008; Meola et al., 2009).  
 
Therefore this study aims to achieve the following: 
1. To identify single nucleotide variant within the seed region sequence of mature 
miRNAs by screening single nucleotide polymorphisms databases (dbSNP) against 
miRNA databases. 
2. To study the effects of single nucleotide variant within seed region of mature miRNA 
sequence toward miRNA bio-processing. 
 
Discovery of single nucleotide variant within seed region of mature miRNA 
sequence gives a great opportunity to explore the potential connection between variant 
miRNA genes and their 3’ UTR mRNA targets (Garcia and miska, 2005; Zhang et al., 
2007; Garofalo et al., 2008). This study would provide new insights into pharmaceutical 
research and therapeutic interventions. 
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CHAPTER 2      MATERIALS AND METHODS 
2.1     Materials 
Component of PCR: 
10X Optimized  DyNAzyme
TM
 Buffer [10 mM Tris (pH 8.8) 
50 M  KCl, 1.5 mM MgCl2 
0.1 %  Triton® X-100] 
0.2 mM of deoxyribonucleotide triphosphates (dNTP) 
0.33 µM of forward (F1) and reverse primers (R1) 
0.03 U of DyNAzyme
TM
 II DNA polymerase 
 
Component of Cloning and Transformation: 
Vector: pcDNA™ 3.3-TOPO® TA (Invitrogen) for miR-125a  
 PCR 4-TOPO vector (Invitrogen) for miR-124-3 
        pGEM®-T Easy Vector Systems (Promega) for miR-662 
Salt solution (200 mM NaCl, 10 mM MgCl2) 
One Shot® TOP 10 E.coli competent cells 
S.O.C. medium (Super Optimal broth with catabolic repression) 
Ampicillin (100 µg/ml) 
 
Component of Ligation: 
pcDNA
 TM
 3.1/Zeo (-) vector (Invitrogen) 
pcDNA™ 3.3-TOPO® TA vector (miR-125a); PCR 4-TOPO (miR-124-3) and 
pGEM®-T Easy vectors(miR-662) 
Restriction enzyme: HindIII, XbaI and EcoRI  
 T4 DNA Ligase 
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T4 DNA Ligase Reaction Buffer [50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP and 
10 mM Dithiothreitol (pH 7.5)] 
 
Component of Mutagenesis: 
10X PCR Buffer (300 mM Tris [pH 9.0] 
200 mM salts consisting of Na
+
 and NH4
2+
 and 20 mM Mg
2+
) 
 0.12 mM of deoxyribonucleotide triphosphates (dNTP) 
0.3 µM of each mutagenic forward and reverse primer  
0.05 U of i-pfu DNA polymerase (iNtRON) 
T4 DNA Ligase and Reaction Buffer [50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP 
and 10 mM Dithiothreitol (pH 7.5)] 
 
Component of Cell Culture: 
Human Embryonic Kidney 293T (HEK293T) adherent cells 
DMEM-5 (Dulbecco's Modified Eagle Medium) 
5% (v/v) fetal bovine serum (FBS)  
100 µg/ml penicillin/streptomycin 
 
Component of HEK293T Cell Transfection: 
Green Fluorescent Protein control vector, pEGFP (Clontech) 
pcDNA
TM
 3.1 plasmid : wild-type allele of pri-miRNAs and pri-miRNA variant 
Opti-MEM I Reduced Serum Medium (serum-free and without antibiotics) 
Fugene® HD Transfection Reagent (Roche) 
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Component of Total RNA Extraction: 
Extraction buffer [4M of guanidine isothiocyanate, 0.02M of sodium citrate, 0.5% 
of sarcosyl and 0.1M of mercaptoethanol] 
2M sodium acetate (pH 4) 
Acidic phenol  
chloroform:isoamylalcohol (24:1) 
isopropanol 
DEPC-treated water 
DNase enzyme and buffer 
 
Component of cDNA synthesis: 
(a) Reverse transcription (RT) reaction for pri-miRNA and pre-miRNA :  
1 X RT Buffer 
       4 mM of 25 X dNTP mix 
1 X RT random primers 
2.5 U of MultiScribe
TM 
Reverse Transcriptase 
 
(b) Reverse transcription (RT) reaction for mature miRNA :  
1 X RT buffer 
1 mM dNTP mix 
0.25 U RNase inhibitor 
3.33 U of MultiScribe
TM 
Reverse Transcriptase  
3 µl of 5 X TaqMan® MicroRNA RT primer 
 
Component of TaqMan miRNA Real Time PCR: 
1 X TaqMan® Fast Advanced Master Mix (2X)  
1 X of TaqMan or Custom TaqMan Gene Expression Assay (20X) 
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Component of SYBR Green Real Time PCR: 
1 X of Power SYBR Green PCR Master Mix (2X) [SYBR Green 1 Dye, AmpliTaq 
Gold DNA Polymerase LD, dNTPs with dUTP/dTTP blend, Passive Reference 1 
and optimized buffer component]  
50 nM of forward and reverse primers 
 
2.2     Methods 
2.2.1      MicroRNA database  
During this study was designed, the published sequences of Homo sapiens 
miRNAs were downloaded from miRBase Registry, Trust Sanger Institute 
(http://microrna.sanger.ac.uk/sequences/; Release 16.0, September 2010) (Jones, 2004; 
Jones et al, 2006; Jones et al, 2008). A total of 1048 hairpin pre-miRNA sequences of 
Home sapiens were obtained. All the sequences of pre-miRNA contained sequence of 
mature miRNAs. Within these 1048 hairpin precursor entries, there are 1344 of mature 
miRNA sequences. This is because some hairpin precursors may contain two functional 
mature miRNAs. The chromosomal coordinates for these 1046 pre-miRNAs were also 
obtained from miRBase Registry version 16.0.  
 
 
2.2.2      Local Alignment of miRNA and SNP databases 
Local alignment between hairpin pre-miRNA sequences and a wide range of 
single nucleotide polymorphisms (SNP) sequences in SNP database were carried out 
using BLAT (Basic Local Alignment Search Tool - Like Alignment Tool) (Kent, 2002). 
BLAT is available via web interface at UCSC Genome browser 
(http://genome.ucsc.edu/). SNP databases used were dbSNP version 131 and 132.  
BLAT program is able to scan relatively short matches rapidly, and extends into high-
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scoring pairs. Parameters used were by default and assembly chosen is “Feb. 2009 
(GRCh37/hg19)”. 
 
From the BLAT search results, the highest score and identity of near-perfect 
match sequences were chosen. Variant allele of SNP sequence that falls on the pre-
miRNA sequences were chosen. Type of variant allele on pre-miRNA and mature 
miRNA sequences were recorded. Single nucleotide variant within seed region 
sequence of mature miRNAs were chosen and recorded. The genomic coordinates of 
these selected miRNAs were confirmed to match with the related SNPs. The potential 
single nucleotide variant within seed region sequence of mature miRNAs was used as a 
template for the secondary structures prediction by using MFOLD program (section 
2.2.3). Figure 2-1 shows the flow of selecting potential single nucleotide variant within 
the seed region sequence of mature miRNAs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1: Flowchart for bioinformatics approaches to identify potential single 
nucleotide variation within seed region sequence of mature miRNAs. 
 
Potential single nucleotide variantion within seed 
region sequence of mature miRNAs 
Prediction of miRNA SNPs structure by MFOLD 
3.2 
Homo sapiens hairpin  
pre-miRNA sequences  
(miRBase Registry) 
Homo sapiens Single Nucleotide 
Polymorphisms database 
(UCSC) 
Mutant allele of SNP that fall on 
pre-miRNA sequences  
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2.2.3      Prediction of potential single nucleotide variant within pre-miRNAs using 
secondary RNA structures 
The selected pre-miRNAs from BLAT analysis were subjected to secondary 
structure prediction using a publicly available web-based computational software 
MFOLD version 3.2 (http://mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form). The 
outputs of MFOLD include minimum free energy (MFE), the number of nucleotides, 
location of the matched region, and the number of arms per structure (Zhang et al., 
2007). Both wild-type and single nucleotide variant of the same pre-miRNAs were 
deposited into the software for prediction of the most stable secondary structure. The 
minimal folding energy (MFE), expressed in kcal/mol, is a method of calculating the 
thermodynamic stability of the secondary structure of RNA. A stable secondary 
structure of pre-miRNA has a high negative the minimal folding energy (MFE). 
Minimal folding free energies of pre-miRNAs were estimated using the program 
MFOLD with default parameter values (Ambros et al., 2003; Zuker, 2003; Bonnet et al., 
2004; Zhang et al., 2006; Zhang et al., 2007). The suitable secondary structure outputs 
were first selected based on the high negative minimal folding energy.  
 
Theoretically, change of one nucleotide may alter the secondary structure of the 
wild-type allele of pre-miRNA transcript. Single nucleotide variant within pre-miRNA 
sequence that has secondary structure with base pair mismatch (guanine–uracil pairing), 
decreased minimal free energy values or enlarged RNA bulges at the seed region of 
mature miRNA will first be selected. These conformation changes may alter the 
processing of pre-miRNA into functional mature miRNA and hence affect the binding 
of mature miRNA to 3’ UTR target genes. For the single nucleotide variant within seed 
region of mature miRNA sequence that did not affect hydrogen bonds or minimal free 
energy of the predicted secondary structure were excluded from this study.   
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2.2.4      Construction of DNA plasmid  
2.2.4.1     Genomic DNA extraction from blood 
Positive control (blood sample of Homo sapiens) was provided by NPC lab 
(University of Malaya). Normal human genomic DNA was isolated by using 
conventional phenol-chloroform method. Plasma was separated from the whole blood 
by centrifuging at 402 X g for 5 minutes at room temperature. Approximately 8 ml of 
1X RCLB (Red Cell Lysis Buffer: 10 mM Tris-HCL [pH 8.0], 5 mM MgCl2, 0.32M 
sucorse and 0.75% Triton X-100) was added to 2ml of blood and centrifuged at 2,191 X 
g for 10 minutes at 10°C. This step is to lyse the erythrocytes. The pellet was 
resuspended in 4 ml of RCLB and centrifugation with the same condition was repeated. 
If the red cells persisted, pellet was washed again. Tubes containing the pellet was air-
dried. After the pellet had dried, 80µl of 10 X Proteinase K buffer, 20µl of 20mg/ml 
Proteinase K, 40µl of 20% Sodium Dodecyl Sulfate (SDS) solution and 400µl of 
distilled water were added to the pellet. The mixture was incubated overnight at 37°C 
waterbath. On the second day, tube containing pellet mixture was removed from 
waterbath and cooled to room temperature before proceeding. Then, 200µl of 6M 
sodium chloride (NaCl) was added and vortexed vigorously for 2-3 minutes. All the 
mixture solution was transferred into a new tube and equal amount of phenol-
chloroform was added. The solution was centrifugated at 14,400g for 30 minutes at 
10°C, the clear aqeuous supernatant was transferred to a new tube and 900µl of chilled 
absolute ethanol was added. Mixture was incubated at -20°C for 1 hour.  Later, 
centrifugation at 14,400g for 5 minutes at 4°C was performed to remove the absolute 
ethanol. The pellet was washed with 1 ml of 70% ethanol and the ethanol was removed 
after centrifugation at 14,400g for 5 minutes at 4 °C. After that, the pellet was 
resuspended in 100µl of TE buffer [10mM Tris (pH 8.0), 1mM EDTA]. 
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2.2.4.2      Agarose gel electrophoresis 
The quality of the genomic DNA was inspected by agarsoe gel electrophoresis.  
Approximately 5µl of genomic DNA and 1µl of loading DNA dye per well were loaded 
onto 0.8% agarose gel (0.16g agarose and 20ml of Tris-Borate-EDTA [TBE buffer: Tris 
base, boric acid and 0.05M EDTA with pH 8.0]). The gel was run at 150V for 40 min, 
in 1 X TBE buffer.   
 
2.2.4.3      Quantification and quality of genomic DNA  
Quantification of DNA was done in a UV Spectrophotometer with the 
absorbance at 260 and 280nm. Protein shows optimal absorbance at 280nm wavelength, 
thereby quantitate the amount of contaminating protein present in the sample. Therefore, 
the ratio of the absorbance at 260nm/280nm indicates the purity of DNA sample. The 
acceptable range is from 1.7 to 1.9. 
 
2.2.4.4      Primer design for Polymerase Chain Reaction (PCR) and mutagenesis 
Primers that annealled pri-miRNA were used to amplify pri-miRNA from 
human genomic DNA by using PCR. Although the length of pri-miRNA varies 
significantly, approximately 100bp flanking sequences on either side of pre-miRNA is 
sufficient for miRNA biogenesis (Duan et al., 2007). Thus, focus was given on 
approximately 450bp that covers the mature miRNA and 200bp of flanking sequences 
on each side.  
 
In this study, two pairs of forward and reverse PCR primers (Table 2.1) were 
designed: miR-124-3 and miR-662 and miR-125a. The primers were designed with the 
aid of “FastPCR” and “BioEdit” software that were downloaded from 
www.biocenter.helsinki.fi/bi/Programs/download.htm and www.mbio.ncsu.edu 
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respectively. Besides, two pairs of primers for single nucleotide variation were designed 
for each mature single nucleotide variation within seed region of mature miRNA 
sequence (Table 2.2). The desired mutant nucleotide was placed in the centre of both 
forward and reverse mutagenic primers. Stratagene’s web-based—QuikChange ® 
Primer Design Program, a publicly available web-based was used 
(http://www.stratagene.com/qcprimerdesign).  
 
Table 2.1: Primers sequences for PCR: ranging from 20-22nt; 50-60% of  GC content 
and melting temperature within 55-58°C. 
 
Applications Primer Sequences 
Polymerase chain 
reaction (PCR) : 
recognized           
pri-miRNA 
miR125a-wF 5’-CAC AGT GGA TCC TCT GAC TCC-3' 
miR125a-wR 5’-CCA TCG TGT GGG TCT CAA GG-3' 
miR124-wF 5’-AAA GGG GAG AAG TGT GGG CTC-3' 
miR124-wR 5’-GCA TTG TTC GCC GGA TTT GTC C-3' 
miR662-wF 5’-ATA CCT GAG GTG GAG GCC TG -3' 
miR662-wR 5’-CAC AGG TCA CAG CCA GCA TAC C-3' 
 
Table 2.2: Primers sequences for mutagenesis: ranging from 30-45nt, at least 40% of 
GC content and melting temperature greater or equal to 78°C . 
 
Applications Primer Sequences 
Site-directed 
mutagenesis 
miR125a-mF 
5’-GCC AGT CTC TAG GTC CCT GAT ACC CTT 
TAA CC-3’ 
miR125a-mR 
5’-GGT TAA AGG GTA TCA GGG ACC TAG AGA 
CTG GC -3’ 
miR124-mF 
5’-GGA CCT TGA TTT AAT GTC TAT ACA ATT 
AAT GCA CGC GGT GAA TGC-3’ 
miR124-mR 
5’-GCA TTC ACC GCG TGC ATT AAT TGT ATA 
GAC ATT AAA TCA AGG TCC-3’ 
miR662-mF 
5’-CTG AAG GTC TCC CAC ATT GTG GCC CAG 
CAG-3’ 
miR662-mR 
5’-CTG CTG GGC CAC AAT GTG GGA GAC CTT 
CAG-3’ 
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2.2.4.5      Polymerase chain reaction (PCR) amplification 
Two pri-miRNA sequences were first amplified from genomic DNA (blood 
provided from NPC lab) by using PCR. Each amplification reactions was performed in a 
15µl volume that contained 10X Optimized  DyNAzyme
TM
 Buffer [10mM Tris (pH 8.8), 
50mM KCl, 1.5mM MgCl2, 0.1% Triton® X-100], 0.2mM of deoxyribonucleotide 
triphosphates (dNTP), 0.33µM of forward (F1) and reverse primers (R1), and 0.03U of 
DyNAzyme
TM
 II DNA polymerase (Finnzymes).  Extracted genomic DNA (20ng/µl) 
was added and PCR was performed in Veriti Thermal Cyler (Applied Biosystems). The 
ampliﬁcation was repeated for 35 cycles: denaturation for 30s at 94°C, primer annealing 
for 30s and enzymatic chain extension for 40s at 72°C, followed by a single terminal 
extension at 72°C for 5 min. Distilled water was used a template as negative control. 
The fragment sizes of PCR products were visualized with ethidium bromide followed 
by gel electrophoresis (as mentioned in section 2.4.2). Agarose gel of 1.5% was 
prepared. VC 100 bp Plus DNA ladder (Vivantis) was used to compare the fragmented 
size.  
 
2.2.4.6      Purification of PCR products 
Polymerase chain reaction products were purified using PureLink
TM
 Gel 
Extraction Kit (Invitrogen). PCR product purification was carried out following 
manufacturer’s instructions. Briefly, the DNA fragment of interest were excised from 
the agarose gel, transferred into microcentrifuge tubes resuspended in Gel Solubilization 
buffer. The mixture was incubated at 50 ºC for 15 minutes until the gel was completely 
dissolved. The dissolved gel slice was transferred to a spin column and centrifuged at 
10,500 g for 1 min. The flow-through in the collection tube was discarded and washed 
with Washing Buffer added to the column and centrifuged at 10500 g for 1 min.     
Flow-through was again discarded, the spin column dried and placed in a 1.5ml 
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microcentrifuge tube. Purified DNA was eluted with 30µl of nuclease free water, 
incubated at room temperature for 2 min and centrifuged for 1 min to collect the DNA 
The microcentrifuge tubes containing eluted DNA was stored at -20ºC. Gel 
electrophoresis (as section 2.4.2) was run to confirm the size of DNA obtained. 
  
2.2.4.7      Cloning and transformation of pri-microRNA 
Purified DNA fragment of pri-miRNAs were cloned into different vectors: 
pcDNA™ 3.3-TOPO® TA (Invitrogen) for miR-125a, PCR 4-TOPO vector (Invitrogen) 
for miR-124-3 and pGEM®-T Easy Vector Systems (Promega) for miR-662. A mixture 
of 4µl of fresh PCR product, 1µl of TOPO® or pGEM®-T Easy vector and 1µl of salt 
solution (200 mM NaCl, 10 mM MgCl2) was added. The TOPO cloning reaction was 
incubated at room temperature for 15 minutes, while pGEM®-T Easy cloning reaction 
was incubated at 4ºC overnight. One Shot® TOP 10 E.coli competent cell is used as a 
host for transformation. Incubation on ice for 5 minutes was performed after 5µl of 
cloning reaction was added into 50µl of chemically competent cell. Plasmid was 
introduced by heat shock for 30 seconds at 42ºC and the competent cells were 
immediately transferred to ice. Then S.O.C. medium (Super Optimal broth with 
catabolic repression) was added and the transformants were incubated in shaker 
incubator at 37ºC for 1 hour with the speed of 200rpm. Finally transformants were 
plated on LB agar plates supplemented with ampicillin (100µg/ml) for selection. 
Presence of plasmid was confirmed by performing colony PCR. The primers used are 
specific forward primer and reverse primer of vector.    
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2.2.4.8      DNA Plasmid extraction 
Colonies with positive transformant were cultured for 16 hours at 37ºC in 10ml 
of Luria-Bertani broth containing 100µg/ml of ampicillin. Glycerol stock of 800µl 
bacterial culture was kept before proceeding to plasmid extraction. Bacterial cells were 
harvested by centrifugation at 6,000g for 15 min at 15ºC. Bacterial cell pellets were    
re-suspended in 250µl of re-suspension buffer (QIAprep Miniprep, Qiagen). Next, 
250µl of lysis buffer was added into the tube and immediately another 300µl of 
neutralization buffer was added. This mixture was bought for centrifugation at 18,000g 
for 10 minutes. All clear supernatant was transferred to a QiAprep spin column with the 
maximum volume of 750µl. Supernatant passes through with the aid of centrifugation at 
18,000g for 1 minute. Then, 500µl of binding buffer was added, followed by 
centrifugation and subsequently 750µl of washing buffer. Washing step was repeated 
twice and finally eluted with 30µl of nuclease free water. Yields were determined by 
observing DNA on 0.8% of agarose gel and UV absorbance from a spectrophotometer.  
 
2.2.4.9      DNA sequencing  
The cloned DNA fragment from all two plasmid (pcDNA™ 3.3-TOPO® TA for 
miR-125a, PCR 4-TOPO vector for miR-124-3 and pGEM®-T Easy Vector Systems for 
miR-662) were sequenced to validate its identity. DNA sequencing was performed 
using a commercial sequencing service (Next Gene Scientific).  
 
2.2.4.10      Sub-cloning into pcDNA vector 
The correct sequence of pri-miRNA was then sub-cloned into a mammalian 
expression vector, pcDNA
 TM
 3.1/Zeo (-) vector (Invitrogen). Both PCR 4-TOPO and 
pGEM®-T Easy vectors were cut with same restriction enzyme, EcoRI. Three µg/µl of 
cut DNA fragment was cloned into 5µg/µl of pcDNA vector with the aid of T4 DNA 
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Ligase and T4 DNA Ligase Reaction Buffer [50mM Tris-HCl, 10mM MgCl2, 
1mM ATP and 10mM Dithiothreitol (pH 7.5)]. This ligation was then transformed into 
One Shot® TOP 10 E. coli competent cell. Transformants with the insert were selected 
by PCR. Sequencing was used to confirm the orientation of the inserted DNA. Glycerol 
stock was prepared for clones that contained correct sequence of each wild-type allele 
of pri-miRNA. 
 
2.2.4.11     Mutagenesis 
Mutagenesis was performed by amplifying the entire plasmid with primers that 
contained the desired single nucleotide mutation to the seed region of 5’-end mature 
miRNA sequence (Figure 2-2). Red bar represent the mutant site in the plasmid. 
 
                   
 
Figure 2-2: Primers A and B contained desire single nucleotide mutation were used to 
amplify the entire plasmid.  
(Figure from http://openwetware.org/wiki/Image:SDMHorn1a.tif) 
 
The recipe of mutagenesis reactions in a volume of 25µl were 10X PCR Buffer 
(300mM Tris [pH 9.0], 200mM salts consisting of Na
+
 and NH4
2+
 and 20mM Mg
2+
), 
0.12mM of deoxyribonucleotide triphosphates (dNTP), 0.3µM of each mutagenic 
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forward and reverse primers and 0.05U of i-pfu DNA polymerase (iNtRON). 
Approximately 50ng/µl clone of pcDNA
TM
 3.1/Zeo (-) vector that contained correct 
inserted DNA was added into the mixture for mutagenesis. Amplification was 
performed at 95ºC for 1 minute as initial denaturation, followed by 25 cycles of 
denaturation at 93ºC for 30 seconds, annealing at 55ºC for 30 seconds and extension at 
72ºC for 9 minutes. Ligation reaction was performed by adding 4.4µl of PCR product to 
0.2µl of T4 DNA Ligase and 0.4µl of T4 DNA Ligase Reaction Buffer [50mM Tris-
HCl, 10mM MgCl2, 1mM ATP and 10mM Dithiothreitol (pH 7.5)]. The ligation 
reaction was incubated overnight at 16ºC. Heat shock transformation was performed 
and positive transformants were selected through colony PCR and confirmed by 
sequencing.  
 
2.2.4.12      Sequence alignment 
DNA sequences of plasmids for both subcloned pcDNA and mutagenized 
pcDNA were analysed by alignment with pri-miRNA sequences obtained from 
miRBase database. The publicly available software MEGA 4 (Molecular Evolutionary 
Genetics Analysis) was used (http://www.megasoftware.net/mega4/mega.html).  
 
2.2.5      Cell culture and transfection 
2.2.5.1      Revival of frozen HEK293T cells 
Human Embryonic Kidney 293T (HEK293T) adherent cells were kindly 
provided by Institute of Medical Research (IMR). HEK293T cells were chosen because 
of undetectable or very low levels expression of the studied miRNAs. Cryovial 
containing HEK293T was thawed in a 37ºC water-bath for 2 minutes.  Cells were added 
drop-wise into 8ml of pre-warmed growth medium DMEM-5 (Dulbecco's Modified 
Eagle Medium, Invitrogen; contains 4,500mg/L D-glucose and L-glutamine) to dilute 
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the DMSO. This DMEM-5 medium contained 5% (v/v) fetal bovine serum (FBS) and 
100µg/ml penicillin/streptomycin. Centrifugation at 110 X g for 5 minutes was 
performed. The cell pellets was resuspended with 5ml of DMED-20 (20% (v/v) FBS 
and 100µg/ml penicillin/streptomycin) and was added into 25cm
2
 tissue culture flask for 
overnight incubation. Incubation was performed in a humidified 37°C, 5% CO2 
incubator.  
 
2.2.5.2      Trypsinizing and subculturing cells 
Cells were examined microscopically for healthiness and confluency (80-90%). 
Cells were detached by trypsin treatment and sub-cultured. All DMEM-20 medium was 
removed from culture flask with sterile serological pipettes. Pre-warmed trypsin (3 ml) 
(TrypLE™ Express Stable Trypsin Replacement Enzyme, Invitrogen) was added to 
cover adherent cell layer in the culture flask. Next, the flask was incubated at 
humidified 37°C CO2 incubator for 5 minutes. Cell detachment was checked under 
microscope. Trypsin activity was inhibited by adding 4 ml of DMED-10 medium (10% 
(v/v) FBS and 100µg/ml penicillin/streptomycin) to the detached cells. The cells were 
centrifugated at 110 X g for 5 minutes to pellet the cells. HEK293T cells were then re-
suspended with 1ml of DMEM-10 medium. Re-suspended cells were transferred to new 
75cm
2
 culture flasks that have been labelled appropriately (cell type, date and passage 
number). The cells were cultured at 37°C 5% CO2 incubator overnight. After 2 days, 
several passages were repeated for all confluent secondary cultures by replacing fresh 
medium.  
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2.2.5.3      Cell number count 
Determining cell seeding density and cell viability is important to ensure 
consistency and reproducibility of experiment. Dilution was prepared by mixing 50µl of 
cells and 450µl of trypan blue solution. Cells were allowed to settle for a few seconds 
before cell count is performed. The cells should be evenly distributed on the counting 
chamber (Figure 2-3). A hand-held counter was used to count the cells on all five 
squares.  
 
The number of cells was determined by following calculations:  
 
  
 
 
 
 
 
Figure 2-3: Counting chamber with nine squares.  
The four corner squares (1, 2, 3, and 4) and the central square (5). (Figure from http://3-
b-s.org/cell-count-using-hemocytometer-p-159259.html) 
 
 
 
I  : cells/ml = average count per square × dilution factor × 10
4
* 
II: total cells = cells/ml × total original volume of cell suspension from which sample 
was taken. 
* The number 10
4
 is the volume correction factor for the hemacytometer. Each square 
is 1 × 1 mm with the depth of 0.1 mm. 
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2.2.5.4      Transfection 
HEK 293T cells were sub-cultured in 6-well plates at 1 x 10
5
 cells/ml the day 
prior to transfection. Cells were cultured to reach a density of greater than 80% 
confluency at the time of transfection. The transfection experiment consists of Green 
Fluorescent Protein control vector - pEGFP (Clontech), an empty vector of pcDNA
TM
 
3.1, three wells containing wild-type allele of pri-miRNA and the remaining three wells 
contained pri-miRNA variant (Figure 2-4). Transfection complexes were prepared by 
adding 5µl of Fugene® HD Transfection Reagent (Roche) to 1µg of plasmid DNA that 
was diluted with Opti-MEM I Reduced Serum Medium (serum-free and without 
antibiotics), as shown in Table 2.3. The transfection complexes were incubated at room 
temperature for 15 minutes. Well-mixed transfection complexes were added in a drop-
wise manner to all wells that contained cells. Wells were swirl to ensure even 
distribution of transfection complex. Then, the 6-wells plates were incubated at 37°C in 
CO2 incubator for 48 hours. Each transfection was technically repeated three times to 
check for the reproducibility of the results. pEGFP transfected cells were checked under 
fluorescence microscope for the consistency and efficiency of transfection.  
 
 
 
 
 
 
v 
 
 
Figure 2-4:Transfection plates consist of one empty vector, three wild-type allele of  
pri-miRNA, three pri-miRNA variant and five empty wells. 
Empty 
Vector 
(EV) 
Wild Type 
miR-124-3 
Wild Type 
miR-125a 
Mutant  
miR-124-3 
Mutant  
miR-125a 
 
Mutant  
miR-662 
Wild Type 
miR-662 
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Table 2.3: Recipe for transfection complexes. 
 
 Component 1x reaction quantity 
DNA 1 µg (4µl) 
Fugene 5µl 
Buffer 96µl 
 
2.2.6      Quantification experiment 
2.2.6.1      Total RNA extraction  
Freshly transfected cell cultures were used for total RNA extraction, using the 
acid guanidine isothiocyanate-phenol: chloroform extraction method (Chomczynski & 
Sacchi, 1987; Chomczynski & Sacchi, 2006). For HEK293T adherent cells, collection 
of cells were done by discarding the culture medium. Cells in each well was washed and 
lysed with 400µl of cold extraction buffer, solution D [4M of guanidine isothiocyanate, 
0.02M of sodium citrate, 0.5% of sarcosyl and 0.1M of mercaptoethanol]. Then, lysed 
cells were transferred from the 6-wells plate to new microcentrifuge tubes.  Lysed cells 
were pre-warmed at 65°C for 10 minutes before adding 40µl of 2M sodium acetate (pH 
4). The mixture was mixed vigorously for 20 seconds. A volume of acidic phenol was 
added and mixed by vortex. Next, 80µl of chloroform: isoamylalcohol (24:1) was added 
and was mixed well. After the cells were placed on ice for 10 minutes, centrifugation at 
16,100g for 15 minutes at 6°C was performed. The upper aqueous phase that contained 
total RNA was carefully transferred to a clean microcentrifuge tubes. The extraction 
was repeated twice with acidic phenol and centrifuge with the same conditions. A 
volume of cold isopropanol was added to the clear supernatant. The mixture was 
incubated at -20°C overnight. On the second day, the tube was centrifuged at 16,100g 
for 30 minutes at 6°C. After that, the supernatant was discarded. The pellet was washed 
with 75% ethanol and was centrifuged at the speed of 16,100g for 10 minutes at 6°C. 
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This washing step was repeated twice. The cell pellet was allowed to air-dry for 10-15 
minutes. Finally the pellet was re-suspended in 40µl of DEPC-treated water and was 
kept at – 2°C.  
 
Later, the total RNA quality was checked on 1% agarose gel and by NanoDrop 
spectrophotometer. Values from UV absorbance at 260nm were used to access RNA 
quantity. The determined absorbance values at 260nm (A260) values were multiplied 
with the dilution factor and then RNA concentration (µg/ml) can be calculated by 
equations. 
 Total RNA  = 40 X A260 value    
The ratio of the absorbance at 260nm / absorbance at 280nm indicates the purity of 
RNA sample. The acceptable range is from 1.9 to 2.1. 
 
2.2.6.2      DNase treatment 
All extracted total RNA was treated with 1µl of DNase buffer and 1µl of DNase 
enzyme to remove contaminating genomic DNA. Treated RNA was placed in room 
temperature for 15 minutes and at 65°C for 20 minutes after adding 1µl of EDTA to 
stop DNase activity. 
 
2.2.6.3     cDNA synthesis 
(a) cDNA for SYBR Green Real Time PCR 
Single stranded cDNA was synthesized from DNase treated total RNA by using High 
Capacity cDNA Reverse Transcription Kits (Applied Biosystems). This single stranded 
cDNA was used as the template to study the expression level of pri-miRNA and pre-
miRNA. A volume of 2 µl of reverse transcription (RT) reaction that contained 1 X RT 
Buffer, 4mM of 25 X dNTP mix, 1 X RT random primers and 2.5U of MultiScribe
TM 
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Reverse Transcriptase was prepared. The reverse transcription mixture was mixed well 
with 2µg of RNA. A thermal cycler was used to perform reverse transcription with the 
conditions of 1 cycle of incubation at 25°C for 10 minutes, reverse transcription at 37°C 
for 120 minutes and denaturation of double stranded RNA at 85°C for 5 minutes.  
 
 (b) cDNA for Taqman Real Time PCR 
To study mature miRNAs that have only about 18-28nt, TaqMan® MicroRNA Reverse 
Transcription Kit (Applied Biosystems) that uses specific miRNA primers (looped RT 
primer) was used to synthesis cDNA. This single stranded cDNA is reverse transcribed 
from the DNAse treated total RNA. Reverse transcription reaction was prepared in a 
total volume of 15µl that consists of 1 X RT buffer, 1mM dNTP mix, 0.25U RNase 
inhibitor, 3.33U of MultiScribe
TM 
Reverse Transcriptase and 3µl of 5 X TaqMan® 
MicroRNA RT primer (Figure 2-5). The input amount of small RNA was 10ng per 15µl 
RT reaction. Reverse transcription was run with thermal cycler by holding incubation at 
16°C for 30 minutes, reverse transcription at 42°C for 30 minutes and denaturation of 
double stranded RNA at 85°C for 5 minutes. All the newly synthesized cDNAs were 
kept at 4°C for short term storage or at -20°C for long term storage. 
 
                         
Figure 2-5: Reverse transcription of short single stranded mature miRNA using specific 
looped RT primer manufactured by Applied Biosystems. 
(Figure from http://www3.appliedbiosystems.com/cms/groups/mcb_support/document 
/generaldocument/cms_042167.pdf) 
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2.2.6.4      Primer design for SYBR Green Real Time Polymerase Chain Reaction 
One pair of specific primer was designed to recognize each pri-miRNA (F1 and 
R1) and one pair for both pri-miRNA and pre-miRNA (F2 and R2) sequences (Figure 
2-6). The sequences of primers for each miRNA sets were shown in Table 2.4. These 
primers are used for quantification of pri-miRNA and pre-miRNA expression level by 
using SYBR Green real time PCR (qPCR). These primers were designed using Primer 
Express® Version 3.0 Software with the following guidelines (primer length is 20 bases, 
GC content is 30-80% and melting temperature is 58-60°C). The optimal length for 
amplicons to work efficiently is 50 to 150 base pair.  
 
              
 
Figure 2-6: The position of primers that recognized pri-miRNA alone (F1 and R1)       
or both pre-miRNA and pri-miRNA (F2 and R2).  
 
Table 2.4: Primer sequences used in quantitative SYBR Green Real Time PCR.  
 
Pri-miRNA primer 
F1 and R1 
Pri-125a-F1 5’-GCA CAC CAT GTT GCC AGT CT-3’ 
Pri-125a-R1 5’-TCC CAA GAA CCT CAC CTG TGA -3’ 
Pri-124-F1 5’-TGC GTG TTC ACA GCG GAC C-3’ 
Pri-124-R1 5’-ATG AGA AAG GAG CGG CGG-3’ 
Pri-662-F1 5’-TAT GCT GGC TGT GAC CTG TGA-3’ 
Pri-662-R1 5’-AAA CAA CAG ATG GCT GGC AAC T-3’ 
Pre-miRNA primer 
F2 and R2 
Pre-125a-F2 5’-TGC CAG TCT CTA GGT CCC TGA-3’ 
Pre-125a-R2 5’-GAC GCC AGG TCC CAA GAA CCT -3’ 
Pre-124-F2 5’-TGA GGG CCC CTC TGC GTG TTC AC-3’ 
Pre-124-R2 5’-AGG CGC CTC TCT TGG CAT TCA C-3’ 
Pre-662-F2 5’-GGC CTT CTG AAG GTC TCC CA-3’ 
Pre-662-R2 5’-GCA ACG TGA CTG CGC TGC TG-3’ 
F2 
R2 
F1 R1 
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2.2.6.5     SYBR Green Real Time PCR of pri-miRNA and pre-miRNA  
Wild-type allele and variant allele of pri-miRNA or/and pre-miRNA expression 
level were quantified using Power SYBR® Green PCR master mix (Applied 
Biosystems). Before quantifying the expression level of pri-miRNA and pre-miRNA, 
primer specificity and efficiency were checked by performing a serial dilution followed 
by a standard curve generated by real time PCR machine, ABI 7500 PCR system, 
(Applied Biosystems). Efficiency of gene-specific primers was calculated using the 
formula:  E = 10 -1/slope - 126, where slope refers to the slope of the standard curve. 
Gene-specific primers that showed a single peak of dissociation curve were used to 
perform quantitative of real time PCR.  
 
The amplification reactions were performed in a 12.5µl reaction that contained 
1X of Power SYBR Green PCR Master Mix (2X) and 50nM of forward and reverse 
primers (F1 and R1 for pri-miRNA; F2 and R2 for pre-miRNA). The template used was 
cDNA (60ng/µl) transcribed from HEK 293T cells. ABI 7500 PCR system, 9600 
emulation mode, was used to preform SYBR Green Real Time PCR with the conditions 
of 1 cycle of UNG incubation at 50°C for 2 minutes, polymerase activation at 95°C for 
10 minutes and 40 cycles of denaturation at 95°C for 15 seconds and annealing or 
extension at 60°C for 1 minutes. The thermal denaturation step was run to determine the 
number of products that were present in the reaction. All reactions were run in 
triplicates, including no template control and internal control. GAPDH and beta-actin 
genes were the two internal controls used in SYBR Green real time PCR. Three 
technical repeats were performed to confirm the result consistency. The cycle number at 
which the reaction crossed an arbitrarily placed threshold (CT) was determined for each 
gene. The relative amount of each pri-miRNA or pre-miRNA to internal controls was 
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obtained by using the equation 2
-∆∆CT
 method. The relative gene expression was 
transformed to Log10 in order to simplify the presentation of data. 
 
2.2.6.6     TaqMan miRNA Real Time PCR of mature miRNA 
Real Time quantitative PCR was performed according to the standard protocols 
of ABI 7500 system, standard mode (Applied Biosystems). TaqMan® microRNA 
assays (Applied Biosystems) was used to quantify mature miRNA expression level. 
Each individual RT reaction has a unique set of PCR primers and TaqMan probe 
designed for it. Custom made TaqMan Gene Expression Assay was designed for the 
mature miRNA variant, since the probe is specific. A volume of 12.5µl final reaction 
was prepared by adding 1 X TaqMan® Fast Advanced Master Mix (2X) and 1 X of 
TaqMan or Custom TaqMan Gene Expression Assay (20X). Approximately 200 ng/µl 
of single stranded cDNA of mature miRNA was used. The thermal-cycling profile was 
performed at 1 cycle of UNG incubation at 50°C for 2 minutes, polymerase activation at 
95°C for 20 seconds and 40 cycles of denaturation at 95°C for 3 seconds and annealing 
or extension at 60°C for 32 seconds. The real time PCR reactions were performed in 
triplicates. RNU44 and miRNA-16 were used as the internal control in this TaqMan 
miRNA real time PCR. Three technical repeats were performed. The relative amount of 
each mature miRNA to internal controls was obtained by using the equation 2
-∆∆ CT
 
method. The relative gene expression was transformed to Log10 in order to simplify the 
presentation of data. Student’s paired two-tailed T-test was used to calculate the 
significant differences of miRNA expression. 
 
 
 
 delta CT (∆ CT) = CT miRNA - CT internal control or endogenous control 
 delta delta CT (∆∆ CT) = ∆ CT miRNA - ∆ CT empty vector 
 Relative Quantification = 2-∆∆ CT 
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CHAPTER 3      RESULTS 
3.1      BLAT search for single nucleotide variation within seed region sequence of 
mature miRNAs  
From the BLAT search of 1048 pre-miRNAs and their 1344 mature miRNAs 
sequences, a total of 453 single nucleotide variants were found in 299 pre-miRNAs and 
151 single nucleotide variant were found in 127 mature miRNAs of Homo sapiens. 
From these 151 single nucleotide variant on mature miRNAs, 42 were found on the seed 
region of 36 mature miRNAs (miRBase 12.0 - miRBase14.0), as shown in Table 3.1. 
This is because few sets of single nucleotide variant matched to the same mature 
miRNA sequence. Among these 42 single nucleotide variant, 12 single nucleotide 
variant on seed region of mature miRNAs (miRBase 16.0) were not available during the 
selection of candidation miRNAs for functional study. They are miR-3117, miR-3118-2, 
miR-3118-3, miR-3124, miR-3128, miR-3161, miR-3618, miR-3689b, miR-3910-2, miR-3939, 
miR-4257 and miR-4293.  
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Table 3.1: Potential single nucleotide variant within seed region sequence of mature miRNAs by homology search (BLAT result)  
miRNA Mature miRNA Sequence SNP ID Position Strand Allele 
hsa-mir-122 MI0000442 
5’-TGGAGTGTGACAATGGTGTTTG-3’ 
5’-AACGCCATTATCACACTAAATA-3’ (*) 
rs41292412 chr18:56118358-56118358 + C/T 
hsa-mir-124-3 MI0000445 
5’-CGTGTTCACAGCGGACCTTGAT-3’ 
5’-TAAGGCACGCGGTGAATGCC-3’ (*) 
rs34059726 chr20:61809907-61809907 + G/T 
hsa-mir-125a MI0000469 
5’-TCCCTGAGACCCTTTAACCTGTGA-3’ 
5’-ACAGGTGAGGTTCTTGGGAGCC-3’ (*) 
rs12975333 chr19:56888340-56888340 + G/T 
hsa-mir-146a MI0000477 
5’-TGAGAACTGAATTCCATGGGTT-3’ 
5’-CCTCTGAAATTCAGTTCTTCAG-3’ (*) 
rs2910164 chr5:159844996-159844996 + C/G 
hsa-mir-221 MI0000298 
5’-ACCTGGCATACAATGTAGATTT-3’ 
5’-AGCTACATTGTCTGCTGGGTTT-3’ (*) 
rs113054794 chrX:45605666-45605666 + A/C 
hsa-mir-379 MI0000787 
5’-TGGTAGACTATGGAACGTAGG-3’ 
5’-TATGTAACATGGTCCACTAACT-3’ (*) 
rs61991156 chr14:101488414-101488414 + A/G 
hsa-mir-431 MI0001721 
5’-TGTCTTGCAGGCCGTCATGCA-3’ 
5’-CAGGTCGTCTTGCAGGGCTTCT-3’ (*) 
rs12884005 chr14:101347408-101347408 + A/G 
hsa-mir-449c MI0003823 
5’-TAGGCAGTGTATTGCTAGCGGCTGT-3’   
5’-TTGCTAGTTGCACTCCTCTCTGT-3’ (*) 
rs35770269 chr5:54468124-54468124 + A/T 
hsa-mir-499 MI0003183 
5’-TTAAGACTTGCAGTGATGTTT-3’ 
5’-AACATCACAGCAAGTCTGTGCT-3’ (*) 
rs3746444 chr20:33578251-33578251 - C/T 
hsa-mir-513a-1 MI0003191 
5’-TTCACAGGGAGGTGTCAT-3’ 
5’-TAAATTTCACCTTTCTGAGAAGG-3’ (*) 
rs35027589 chrX:146295068-146295067 - -/C 
hsa-mir-518d MI0003171 
5’-CTCTAGAGGGAAGCACTTTCTG-3’ 
5’-CAAAGCGCTTCCCTTTGGAGC-3’ (*) 
rs73602910 chr19:54238189-54238189 + A/G 
hsa-mir-518e MI0003169 
5’-CTCTAGAGGGAAGCGCTTTCTG-3’ 
5’-AAAGCGCTTCCCTTCAGAG-3’ (*) 
rs74177813 chr19:54233109-54233109 + -/C 
5’-CTCTAGAGGGAAGCGCTTTCTG-3’ 
5’-AAAGCGCTTCCCTTCAGAG-3’ (*) 
rs34416818 chr19:54233113-54233112 + -/A 
5’-CTCTAGAGGGAAGCGCTTTCTG-3’ 
5’-AAAGCGCTTCCCTTCAGAG-3’ (*) 
rs74177814 chr19:54233114-54233113 + -/G 
hsa-mir-557 MI0003563 5’-GTTTGCACGGGTGGGCCTTGTCT-3’ rs78825966 chr1:168344829-168344829 + C/T 
hsa-mir-585 MI0003592 5’-TGGGCGTATCTGTATGCTA-3’ rs62376935 chr5:168690635-168690635 + C/T 
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Table 3.1: continued 
     
miRNA Mature miRNA Sequence SNP ID Position Strand Allele 
hsa-mir-605 MI0003618 5’-TAAATCCCATGGTGCCTTCTCCT-3’ rs113212828 chr10:53059349-53059349 + A/G 
hsa-mir-627 MI0003641 5’-GTAGTGAGTCTCTAAGAAAAGAGGA-3’  rs2620381 chr15:42491848-42491848 + A/C 
hsa-mir-662 MI0003670 5’-TCCCACGTTGTGGCCCAGCAG-3’ rs9745376 chr16:820249-820249 + A/G 
hsa-mir-936 MI0005758 5’-ACAGTAGAGGGAGGAATCGCAG-3’ rs79924817 chr10:105807928-105807928 + C/T 
hsa-mir-938 MI0005760 5’-TGCCCTTAAAGGTGAACCCAGT-3’ rs12416605 chr10:29891260-29891260 + C/T 
hsa-mir-941-4 MI0005766 5’-CACCCGGCTGTGTGCACATGTGC-3’ rs76606291 chr20:62551216-62551216 + A/G 
hsa-mir-1268 MI0006405 5’-CGGGCGTGGTGGTGGGGG-3’ rs28599926 chr15:22513271-22513271 + C/T 
hsa-mir-1276 MI0006416 5’-TAAAGAGCCCTGTGGAGACA-3’ rs34381260 chr15:86313795-86313794 + -/T 
hsa-mir-1299 MI0006359 5’-TTCTGGAATCCTACGTGAGGGA-3’ rs76266132 chr9:69002317-69002317 + C/T 
hsa-mir-1304 MI0006371 
5’-TTTGAGGCTACAGTGAGATGTG-3’ rs79759099 chr11:93466909-93466909 + A/G 
5’-TTTGAGGCTACAGTGAGATGTG-3’ rs76857625 chr11:93466910-93466910 + A/G 
hsa-mir-3117 MI0014130 5’-ATAGGACTCATATAGTGCCAG-3’ rs12402181 chr1:67094171-67094171 + A/G 
hsa-mir-3118-2 MI0014132 5’-TGTGACTGCATTATGAAAATTCT-3’ rs11488501 chr1:143424165-143424165 + C/T 
hsa-mir-3118-3 MI0014133 5’-TGTGACTGCATTATGAAAATTCT-3’ rs11488501 chr1:143424165-143424165 + C/T 
hsa-mir-3124 MI0014140 5’-TTCGCGGGCGAAGGCAAAGTC-3’ rs12081872 chr1:249120584-249120584 + C/T 
hsa-mir-3128 MI0014145 5’-TCTGGCAAGTAAAAAACTCTCAT-3’ rs61130794 chr2:178120681-178120681 + G/T 
hsa-mir-3161 MI0014191 
5’-CTGATAAGAACAGAGGCCCAGAT-3’ rs11382316 chr11:48118350-48118349 + -/A 
5’-CTGATAAGAACAGAGGCCCAGAT-3’ rs35834266 chr11:48118351-48118350 + -/A 
hsa-mir-3618 MI0016008 5’-TGTCTACATTAATGAAAAGAGC-3’ rs12159555 chr22:20073323-20073323 + C/G 
hsa-mir-3689b MI0016411 5’-TGTGATATCATGGTTCCTGGGA-3’ rs116838571 chr9:137742067-137742067 + A/T 
hsa-mir-3910-2 MI0016431 5’-AAAAGGCATAAAACCAAGACA-3’ rs76084273 chr9:94398600-94398600 + A/C 
hsa-mir-3939 MI0016596 
5’-TACGCGCAGACCACAGGATGTC-3’ rs76608449 chr6:167411333-167411333 + C/G 
5’-TACGCGCAGACCACAGGATGTC-3’ rs75823810 chr6:167411334-167411334 + C/T 
5’-TACGCGCAGACCACAGGATGTC-3’ rs73024232 chr6:167411337-167411337 + A/G 
hsa-mir-4257 MI0015856 5’-CCAGAGGTGGGGACTGAG-3’ rs74743733 chr1:150524468-150524468 + A/G 
hsa-mir-4293 MI0015826 5’-CAGCCTGACAGGAACAG-3’ rs12220909 chr10:14425221-14425221 + C/G 
Asterisk (*) shows the mature miRNA sequence from the complementary miRNA that is functional.  
The red coloured, bold and underlined nucleotide indicates the variant allele. Blue highlighted columns show the potential single nucleotide variant 
within seed region sequence of mature miRNAs by homology search after secondary structural prediction (MFOLD). 
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3.2      Prediction of secondary RNA structures for the wild-type allele and variant 
allele of pre-miRNAs 
Secondary stem loop structures of these 42 single nucleotide variant that were 
found within the seed region sequences of 5’-end mature miRNAs was predicted by 
using MFOLD web server. After individual and careful checking of the secondary 
structures for 42 pairs of wild-type and variant allele , only 14 sets of single nucleotide 
variant within seed region sequence of mature miRNAs were found to show structural 
difference and  minimal folding free energy deviation, as shown in Figure 3-1. Among 
these single nucleotide variant within seed region sequence of mature miRNAs,       
miR-125a, miR-124-3 and miR-662 were randomly chosen as the study subjects. 
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  miR-124-3               miR-124-3 mutant                miR-125a          miR-125a mutant                  
                          SNP ID:  rs34059726                                   SNP ID:  rs12975333 
                     
Figure 3-1: Secondary structures of the wild type allele and variant allele pre-miRNAs 
as predicted by MFOLD.  
The mature miRNA sequences were shadowed and the black circle indicates the variant 
allele. Minimal folding free energies (dG) calculated by MFOLD were indicated.              
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      miR-662      miR-662 mutant 
            SNP ID:  rs9745376 
 
Figure 3.1 (continued) 
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miR-941-4                  miR941-4 mutant               miR-1276   miR1276 mutant 
            SNP ID:  rs76606291                                  SNP ID:  rs34381260 
        
Figure 3.1 (continued) 
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      miR-3118-2      miR-3118-2 mutant                 miR-3118-3 miR-3118-3 mutant 
      SNP ID:  rs11488501                           SNP ID:  rs11488501 
 
Figure 3.1 (continued) 
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    miR-3128        miR-3128 mutant           miR-3618         miR-3618 mutant 
           SNP ID:  rs11382316                                     SNP ID:  rs12159555 
 
Figure 3.1 (continued) 
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      miR-3161         miR-3161 mutant 1        miR-3161 mutant 2 
         SNP ID:  rs61130794         SNP ID:  rs35834266 
 
Figure 3.1 (continued) 
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        miR-3939          miR-3939 mutant 1      miR-3939 mutant 2      miR-3939 mutant 3 
                                    SNP ID:  rs76608449       SNP ID:  rs75823810      SNP ID:  rs73024232 
 
Figure 3.1 (continued) 
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3.3      Genomic DNA extracted from control human blood 
Human genomic DNA was successfully isolated from blood samples with the 
conventional phenol-chloroform extraction method (as mentioned in section 2.2.4.1). 
The absorbance ratio of 260nm over 280nm (A260/A280) from spectrophotometer was 
1.74, which indicate that the extracted DNA was relatively pure. The quality of DNA 
sample was determined by electrophoresis (Figure 3-2). DNA was run on a 0.8% 
agarose gel and visible bands were observed in the well corresponding to the high 
molecular weight of genomic DNA which is greater than 23 kilobase. No degradation of 
the genomic DNA was observed. 
 
      i)        ii)  
Figure 3-2: Genomic DNA from human blood.  
(i) NEB Lambda HindIII ladder (ii) Agarose gel of extracted human genomic DNA. 
Lane M indicates the Lambda HindIII ladder and lane 1 indicates genomic DNA with 
the size greater than 23kb. 
 
 
 
Lane    M     1   
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3.4      Polymerase Chain Reaction of wild type allele of pri- microRNAs  
In order to generate the wild-type allele of the pri-miRNAs studied, the wild-
type alleles (miR-125a, miR-124-3 and miR-662) were amplified from normal human 
genomic DNA by PCR. The PCR product was further purified using Gel extraction kit. 
Purified wild type allele of pri-miRNA bands were run on 1.5% agarose gel and visible 
bands were observed (Figure 3-3). Only one significant band with expected fragment 
size (between 400bp and 500bp) was seen from each PCR reaction, showing that the 
primers were specific enough to amplify wild-type pri-miRNA. 
 
i)     ii)  
Figure 3-3: PCR of wild type pri-miRNA fragment.    
(i) Vivantis 100 bp plus DNA ladder (ii) Purified PCR products of pri-miRNA with 
specific primers. Lane M is the 100 bp plus ladder lane 1 is pri-miR-125a (459 bp), lane 
2 is pri-miR-124-3 (399 bp) and lane 3 is pri-miR-662 (424 bp). 
 
 
 
 
  500 bp 
  400 bp 
Lane     M    1      2       3     M 
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3.5      Cloning and transformation of pri-miRNAs  
Purified PCR products of wild-type pri-miRNA were successfully cloned into 
PCR 4-TOPO vector or pGEM®-T Easy Vector. Colonies were picked for colony PCR 
(Figure 3-4) to select for positive transformant that contained the purified DNA 
fragment. The primers used in colony PCR are specific forward primer and reverse 
primer of vector to amplify the cloned DNA fragment. The bands right below the wells 
were the bacteria genomic DNA. Negative controls (without bacteria colony sample) 
were included. No band was observed in the negative controls showing no 
contamination. 
 
      i)           ii)  
 
Figure 3-4: Colony PCR of pri-miRNA fragment from bacteria colony:  
(i) Vivantis 100 bp plus DNA ladder (ii) Colony PCR of pri-miRNAs. Lane M is the 
100 bp plus ladder lane 1 is pri-miR-125a (459 bp), lane 3 is pri-miR-124-3 (399 bp) 
and lane 5 is pri-miR-662 (424 bp). Lanes 2, 4 and 6 are negative controls. 
 
 
 
  500 bp 
   400 bp 
Plasmid DNAs 
Lane     M   1    2    3    4    5    6   M   
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3.6      Plasmids of TA vector 
Positive transformant were successfully cultured in Luria-Bertani broth 
overnight. Plasmids were extracted by using DNA plasmid extraction kit and were run 
in 0.8% agarose gel to visualize the product of extraction (Figure 3-5). The estimated 
size of supercoiled plasmids and their insertions are 5.8 kb for miR-125a gene in 
pcDNA™ 3.3-TOPO® TA, 4 kb for miR-124-3 gene in PCR 4-TOPO vector and 3 kb 
for miR-662 gene in pGEM®-T Easy Vector. 
 
i)        ii)  
Figure 3-5: Plasmids containing wild type pri-miRNA:  
(i) Promega supercoiled DNA ladder (ii) Plasmids of positive clone on 0.8 % agarose 
gel. Lane M is the supercoiled DNA ladder, lane 1 is pcDNA – pri-miR-125a (5.8 Kb), 
lane 2 is PCR 4 TOPO – pri-miR-124-3 (4.35 Kb) and lane 3 is pGEM®-T – pri-miR-
662 (3.4 Kb). 
 
 
 
 
 
 
 
 
 Lane    M    1     2     3    M 
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PCR was performed on the extracted recombinant plasmids (plasmid pri-miR-
125a, plasmid pri-miR124-3 and plasmid pri-miR-662) and the PCR products were 
observed through 1.5% agarose gel electrophoresis (Figure 3-6). This was to confirm 
successful cloning of wild-type gene of pri-miRNA fragment into the extracted 
plasmids. The PCR product showing molecular weight greater than 3kb was the plasmid 
DNAs. Only primer dimers were observed in the negative control proving no DNA 
contamination in the PCR. Positive transformant were later subjected to sequencing 
(Figure 3-15 to Figure 3-17 ).  
 
  i)        ii)  
Figure 3-6: PCR of plasmid pri-miRNA:  
(i) Vivantis 100bp plus DNA ladder (ii) PCR of positive transformant on 1.5% agarose 
gel. Lane M is the 100bp plus ladder, lane 1 is pri-miR-125a (459 bp), lane 3 is pri-miR-
124-3 (399 bp) and lane 5 is pri-miR-662 (424 bp). Lanes 2, 4 and 6 are negative 
controls. 
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3.7      Subcloning of pri-miRNAs sequencing vectors to pcDNA
 TM
 3.1/Zeo (-) 
vector 
Positive transformant containing the correct wild-type allele pri-miRNA 
fragment were sub-cloned into mammalian expression vector, pcDNA
 TM
 3.1/Zeo (-) 
vector. Before sub-cloning, pcDNA
 TM
 3.1/Zeo (-) vector and the extracted plasmids 
were successfully cleaved with restriction enzymes to obtain a linearlized pcDNA
TM
 
vector (5kb) and the fragment of wild-type gene cleared from vector (Figure 3-7). The 
digested fragments were visualized using agarose gel electrophoresis. Bands between 
400bp and 500bp were the fragment of wile-type gene. 
 
i)            ii)  
Figure 3-7: Digested expression vector and wild type pri-miRNA fragment:  
(i) Linearlized pcDNATM 3.1 vector by restriction enzyme. Lane M-i is the supercoiled 
DNA ladder-and lane 1 is the linearlized pcDNA vector. (ii) Fragment of pri-miRNA 
genes to be subcloned into pcDNA TM 3.1 vector. Lane M-ii is the 100bp plus DNA 
ladder, lane 1 is pri-miR-125a (459 bp), lane 2 is pri-miR-124-3 (399 bp) and lane 3 is 
pri-miR-662 (424 bp). 
 
 
 
      6 Kb 
(Promega)    500 bp 
(VC) 
          
 M-i      1          
   3Kbp 
(VC) 
Empty vectors 
   Lane     M-ii       1          2         3       
4  
58 
Colony PCR was used to check the successful subcloning of wild-type allele pri-
miRNA fragment into the linearlized pcDNA
TM
 3.1 vectors (Figure 3-8). Few colonies 
were picked for PCR to increase the chances of obtaining positive transformant. The 
primers used are specific forward and reverse primers of pcDNA
TM
 vector to amplify 
the cloned wild-type gene of pri-miRNA fragment, since orientation of the insertion is 
important. No amplification was observed in the negative controls. 
 
i)         ii)  
Figure 3-8: PCR of pri-miRNA fragment from expression vector:  
(i) Vivantis 100 bp plus DNA ladder (ii) Colony PCR for pri-miRNAs that successfully 
subcloned into pcDNATM 3.1 vector. Lane M is 100 bp plus DNA ladder, lane 1 is 
pcDNA pri-miR-125a, lane 2 is pcDNA pri-miR-124-3 and lane 3 is pcDNA pri-miR-
662. Lanes 2, 4, 6 and 8 are negative controls with distilled water as template. 
 
 
 
 
 
 
 
  500 bp 
   400 bp 
  Lane   M   1   2     3   4    5    6    M   
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Positive clones identified through colony PCR were cultured in LB broth to 
obtain the pcDNA
TM 
3.1 vectors. Plasmids were successfully extracted and were run in 
0.8% agarose gel (Figure 3-9). The visible bands showed the expected molecular weight, 
corresponding to approximately 5 kb for all two supercoiled plasmids.  
 
i)          ii)  
Figure 3-9: Plasmid containing wild type pri-miRNA: 
(i) Promega supercoiled DNA ladder (ii) Plasmids of positive clone of pri-miRNAs in 
pcDNATM 3.1 vector. Lane M is supercoiled DNA ladder, lane 1 is pcDNA pri-miR-
125a, lane 2 is pcDNA pri-miR-124-3 and lane 3 is pcDNA pri-miR-662.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  5 kb 
 Lane   M       1        2       3       M   
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PCR was performed by using the extracted pcDNA plasmids as template. This is 
to confirm the succession of wild-type allele of pri-miRNA fragment inserted in the 
extracted plasmids before subjected for sequencing. Electrophoresis (1.5% of agarose 
gel) was run to check the products (Figure 3-10). Only primer dimers were observed in 
the negative control proving no DNA contamination in the PCR. Positive transformant 
were later subjected to sequencing (Figure 3.14, 3.15 and 3.16).  
 
                  i)          ii)  
 
Figure 3-10: PCR of positive clone of expression vector containing wild type pri-
miRNA: 
(i) Vivantis 100 bp plus DNA ladder (ii) PCR for positive clone of wild-type allele pri-
miRNAs in pcDNATM 3.1 vector. Lane M is supercoiled DNA ladder, lane 1 is 
pcDNA pri-miR-125a, lane 3 is pcDNA pri-miR-124-3 and lane 5 is pcDNA pri-miR-
662. Lanes 2, 4, 6 and 8 are negative controls with water as template. 
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3.8      Mutagenesis of pcDNA pri-miRNAs 
Site-directed mutagenesis of the wild-type allele of pri-miRNA fragment in 
pcDNA
TM 
3.1 vectors was successfully performed through conventional PCR methods 
(as mentioned in 2.2.4.11). The colonies obtained from mutagenesis were checked 
through colony PCR for selection of positive transformant.  The amplified products 
were visualized through 1.5% agarose gel electrophoresis (Figure 3-11). The primers 
used were specific forward and reverse primer of pcDNA TM 3.1/Zeo (-) vector to 
amplify and check orientation of the cloned mutagenized pri-miRNA fragment. 
  
i)        ii)  
Figure 3-11: PCR of mutagenized pri-miRNA fragment.  
(i) Vivantis 100 bp plus DNA ladder (ii) Colony PCR for pri-miRNAs that treated with 
site-directed mutagenesis. Lane M is the 100 bp plus DNA ladder, lane 1 is pcDNA pri-
miR-125aM, lane 3 is pcDNA pri-miR-124-3M, lane 5 is pcDNA pri-miR-662M. Lane 
2, 4, 6 and 8 are negative controls. 
 
 
 
 
 
 
  500 bp 
   400 bp 
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Colonies harbouring mutagenized pri-miRNA fragment were cultured in LB 
broth. All two supercoiled recombinant plasmids showed a molecular weight of 5kb, 
which corresponds to the total size of the mutagenized gene of pri-miRNA and the 
pcDNA vector (Figure 3-12).  
 
i)         ii)   
Figure 3-12: Positive transformant containing mutagenized pri-miRNA:  
(i) Promega supercoiled DNA ladder (ii) Plasmids of positive transformant for 
mutagenized pri-miRNAs. Lane M is the supercoiled DNA ladder, lane 1 is pcDNA pri-
miR-125aM, lane 2 is pcDNA pri-miR-124-3M and lane 3 is pcDNA pri-miR-662M. 
 
 
 
 
 
 
 
 
 
  5 kb 
    Lane    M       1         2        3       M   
63 
Introduction of the mutagenized allele to pcDNA plasmids were amplified and 
the PCR products were visualized using 1.5% agarose gel electrophoresis (Figure 3-13). 
Primers used are specific forward primer and reverse primer of vector. Plasmids 
harbouring the insertions of wild type and mutagenized gene of pri-miRNAs were sent 
for sequencing. 
 
                     i)          ii)  
Figure 3-13: PCR of mutagenized pri-miRNA fragment:  
(i) Vivantis 100 bp plus DNA ladder (ii) PCR of positive plasmids for mutagenized pri-
miRNAs. Lane M is the 100 bp DNA ladder, 1 is pcDNA pri-miR-125aM, lane 2 is 
pcDNA pri-miR-124-3M and lane 3 is pcDNA pri-miR-662M. Lane 2, 4, 6 and 8 are 
negative controls. 
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3.9      DNA sequencing and sequence alignment of pri-miRNAs from database, 
pcDNA pri-miRNAs and mutagenized pcDNA pri-miRNAs. 
DNA sequence from both recombinant plasmids that contained wild-type pri-
miRNA gene and mutagenized pri-miRNA gene were used to align with the sequence of 
pri-miRNA extracted from miRBase database. Sequencing was performed to confirm 
the sequence of wild type pri-miRNA gene and mutagenized pri-miRNA were 
individually introduced into the mammalian expression vector, pcDNA
TM 
3.1 vector. 
The sequence alignment showed that single nucleotide mutation was successfully 
introduced into the seed region of mature miRNA of all two wild-type of pri-miRNA 
(pri-miR-125a, pri-miR-124-3 and pri-miR-662). The mutagenized allele was designed 
based on the chosen SNP allele that was found to have homology match to the seed 
region of 5’-end mature miRNA (as shown in Table 3.1). In Figure 3-14, Figure 3-15 
and Figure 3-16, the dashed box indicates the mature miRNA sequence and the circled 
area was the site where mutagenesis took place. 
 
Figure 3-14: Sequence alignment of pri-miR-125a from miRBase database, 
recombinant plasmid of pri-miR-125a (pcDNA-miR-125a) and recombinant plasmid of 
mutagenized pri-miR-125a (pcDNA-miR-125aM).  
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Figure 3-15: Sequence alignment of pri-miR-124-3 from miRBase database, 
recombinant plasmid of pri-miR-124-3 (pcDNA-miR-124) and recombinant plasmid of 
mutagenized pri-miR-124-3 (pcDNA-miR-124M).  
 
 
Figure 3-16: Sequence alignment of pri-miR-662 from miRBase database, recombinant 
plasmid of pri-miR-662 (pcDNA-miR-662) and recombinant plasmid of mutagenized 
pri-miR-662 (pcDNA-miR-662M).  
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3.10     Cell culture 
pEGFP vector acted as a control to check the efficiency of transfection. The 
pEGFP vector (Clontech, United States) was transfected along with wild-type and 
variant of pri-miRNA gene in a six-well plate. The green fluorescence signals emitted 
from transfected HEK 293T cells were captured through fluorescent microscope. From 
cell count, the rate of transfection was more than 75% after comparing green fluorescent 
cells to the total HEK293T cells captured from light microscope. This showed good 
transfection efficiency (Figure 3-17). 
 
                      i)  
                     ii)  
Figure 3-17: Transfection rate was checked by comparing on the same spot of cells 
under microscope.  
(i) HEK 293T cells captured under light microscope and (ii) Green fluorescence cells 
that were captured thought fluorescent microscope.  
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3.11      RNA extraction from cell culture 
Total RNA was isolated from five transfected HEK 293T cells with the acid 
guanidine isothiocyanate-phenol: chloroform (as mentioned in section 2.2.6.1). RNA 
samples were visualized on a 1% agarose gel (Figure 3-18) and visible bands were 
observed in each well corresponding to expected sizes for ribosomal RNA (rRNA): 18S 
and 28S rRNA. The RNA extracted appeared to have good quality and without any sign 
of degradation. The A260/A280 ratio from spectrophotometer was approximately 2.0, 
which proved that the extracted RNA was clean.  
 
                                                  
Figure 3-18: Agarose gel of total RNA samples extracted from HEK 293T cells.  
Lane 1 is empty vector of pcDNA
TM
 3.1, lane 2 is from wild-type pri-miR-125a pcDNA 
plasmid, lane 3 is mutagenized pri-miR-125a pcDNA plasmid, lane 4 is wild-type pri-
miR-124-3 pcDNA plasmid, lane 5 is mutagenized pri-miR-124-3 pcDNA plasmid, lane 
6 is wild type pri-miR-662 pcDNA plasmid and lane 7 is mutagenized pri-miR-662 
pcDNA plasmid. 
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3.12      Statistical analysis of quantitative real time polymerase chain reaction 
(qRTPCR)  
3.12.1      TaqMan miRNA assay for mature miRNAs  
All two mature miRNA expression levels (miR-125a, miR-124-3 and miR-662) 
in transfected HEK 293T cells were quantified by using TaqMan miRNA Assay. This is 
because TaqMan miRNA probe has high specificity (Chen et al, 2005). Results 
generated from ABI SDS system was analyzed using Microsoft Excel. MicroRNA 
expression data is presented as fold difference relative to the mean between RNU44 and 
miR-16 based on the following equation: relative quantification, RQ = 2
- ∆∆CT
. A two-
dimension column was plotted to illustrate the results. 
 
Mature miRNA expression level was normalized to endogenous controls to 
obtain ∆CT values, and the fold difference is relative to the calibrator (empty vector) to 
obtain ∆∆CT values. The relative quantification (RQ) of mature miRNA was calculated 
by applying to the 2 
- ∆∆CT
 analyses. RQ value was converted to Log unit to better 
represent the data. 
 
Single nucleotide variations within seed region of mature miRNA sequence 
showed different expression level compared to the wild-type gene of miRNAs (Figure 
3-19). For the positive control (miR-125a) in this study, expression level of 
mutagenized allele miR-125a was upregulated 1.7 fold, pt-test = 1.12 x 10
-12
, compared to 
the wild-type allele miR-125a. The expression level of mutagenized allele of miR-124-3 
and mutagenized allele of miR-662 were both upregulated compared to the wild-type 
allele of miR-124-3 and wild type allele of miR-662 respectively. Mutagenized allele of 
miR-124-3 was upregulated 2.2 fold, pt-test = 5.16 x 10
-7
, while mutagenized allele of 
miR-662 was upregualted 1.9 fold, pt-test = 4.55 x 10
-4
 (refer to Apendix).   
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Figure 3-19: Comparision of relative quantification between miR-125a, miR-124-3 and 
miR-662. 
Relative expression level of mature miR-125a, miR-124-3 and miR-662 normalized to 
both RNU44 and miR-16 (endogenous controls). The relative expression levels were 
determined by ∆∆CT analyses. Transfection was repeated three times. P t-test < 0.05. 
 
 
3.12.2      Expression level of mutagenized miRNA gene relative to wild-type 
miRNA gene in percentage (%) 
The expression level of both wild-type and mutagenized pri-miRNAs and pre-
miRNAs were determined through SYBR Green Real Time PCR by using specific 
primers. Pri-miRNA and pre-miRNA expression level were normalized to internal 
controls (GAPDH and beta-actin) to obtain ∆CT values and relative to the calibrator 
(empty vector) to obtain ∆∆CT values. Relative expression levels of pri-miRNA (PRI), 
pri- and pre-miRNA (PRI + PRE) and mature miRNAs (miRNA) were plotted in two-
dimension column. The expression level of miRNA (pri, pri + pre and mature miRNA) 
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was quantitated by obtaining the ratio between mutagenized miRNA to wild-type 
miRNA.  
 
The results showed that the primary transcript of mutagenized miR-125a was 
increased by 16% when compared with wild-type miR-125a gene, while mutagenized 
pri- and pre-miR125a expression level was increased by 19%. However, mutagenized 
mature miR-125a expression level was 75% upregulated when compared to the wild-
type miR-125a gene (Figure 3-20 A). 
 
Chart in Figure 3-20 (B) showed that the expression level of mutagenized pri-
miR-124-3 was increased slightly by 12% compared to the wild-type pri-miR-124-3. 
For the expression level of mutagenized pri- and pre-miR-124-3, the chart showed that 
approximately 8% of increment after comparison with the wild-type gene. Meanwhile, 
the expression of mutagenized miR-124-3 in HEK 293T cells was increased to about 
120 % of wild-type miR-124-3.  
 
In Figure 3-20 (C), the expression of mutagenized pri-miR-662 was showed to 
be the same as the wild type of pri-miR662, while the expression of mutagenized pri- 
and pre-miR-662 was slightly inhibited by 13%.  On the other hand, the expression of 
mature form of mutagenized miR-662 was improved, 92% that of the wild-type allele of 
miR-662. 
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Figure 3-20: Quantitative Real Time PCR was used to measure the levels of pri-, pre- 
and mature forms of wild-type miRNA and mutagenized miRNA.  
(A) miR-125a/ miR-125aM, (B) miR-124-3/miR-124-3M, (C) miR-662/miR-662M, in 
the transfected cells. The relative expression levels were determined by ∆∆CT analyses. 
Three individual technical repeats were performed and each transfection was in 
duplicates. 
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CHAPTER 4      DISCUSSION 
4.1      Features of miRNA function  
MicroRNA, a group of small non-coding RNAs is known to play important roles 
in biological functions by regulating gene expression through translation inhibition. 
MicroRNAs was known to be involved in cell developmental (Ambros, 2004; Kim and 
Nam, 2006; Kusenda et al., 2006; Meola et al., 2009), cell proliferation, apoptosis, 
progression of human diseases (Lai, 2003; Ambros, 2004; Bartel, 2004; Hammond, 
2006; Cho, 2007), determination of timing and maintenance of tissue or cell identity 
(Zeng and Cullen, 2003; Ambros, 2004; Bartel, 2004; Zhang et al., 2006) and also in 
responding to environmental stresses, immune system, and neurological processes 
(Bartel, 2004; Du and Zamore, 2005; Wiemer, 2007; Garofalo et al., 2008; Meola et al., 
2009). Hypothetically, sequence variation within miRNA genes (pri-miRNA, pre-
miRNA or mature miRNA) would potentially affect the miRNA processing and/or 3’ 
UTR mRNA target selection (Iwai and Naraba, 2005; Shen and Yu, 2008; Wu et al., 
2008; Mencía et al., 2009; Sun et al., 2010). The expression profiles of miRNAs in 
human cancers and disorders had been extensively studied over the past decades. Many 
miRNAs were up- or down-regulated in various human cancers and disorder. This 
indicates that miRNAs play a role in tumorigenesis. However, compared with the 
comprehensive studies of miRNA expression profiling, associations between miRNA 
mutations with cancers or disorders are still larger unknown (Iwai and Naraba, 2005; 
Shen and Yu, 2008; Wu et al., 2008). 
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4.2      Genetic variation of miRNA sequences 
Data mining was performed to further investigate the functional role of miRNAs, 
by searching for homology between 1344 known miRNAs in human genome (from 
miRBase Release 16.0, Sept 2010) and SNPs database (from dbSNP131/132, UCSC 
Genome browser). A total amount of 42 SNPs in seed-region of mature miRNA were 
identified. These findings can conclude that miRNA genes have very low polymorphism 
density since most identified variations are not within the seed region, indicating pre-
miRNAs have a strong selective constraint (Borel and Antonarakis, 2008). These single 
nucleotide variant within seed region sequence of mature miRNAs could have complex 
influence by affecting miRNA biogenesis, functional strand selection and target 
selection. This study focused on the genetic variation within the seed region of 5’-end 
mature miRNA, rather than pri-miRNA or pre-miRNA because seed region base pairing 
is known to be a critical region for 3’UTR mRNA target recognition (Bartel, 2004; 
Ambros, 2004; Lee et al., 2006; Zambon et al., 2006). This would result in targets gain 
or loss. Theoretically, functional mutation found on the seed region would hugely 
impact mRNA-protein translation, further contributing to disease or cancer development. 
 
The RNA secondary structure of these 42 single nucleotide variant within seed 
region sequence of mature miRNAs was predicted by MFOLD program to examine how 
the variant allele could alter the secondary structure of related wild-type allele of 
miRNAs. Only 14 single nucleotide variant within seed region sequence of mature 
miRNAs showed base-pairing mismatches, increased minimal free energy values and 
the addition of an enlarged RNA bulge in the predicted secondary structure (as shown in 
Figure 3.1). Among these potential single nucleotide variants, 12 single nucleotide 
variant on the seed region of mature miRNAs were not available when this project was 
first conducted, as the miRBase database used was Release 13.0, March 2009. New 
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additional database containing these 12 single nucleotide variant were only available on 
Release 19.0, Aug 2012. They are miR-3117, miR-3118-2, miR-3118-3, miR-3124, miR-
3128, miR-3161, miR-3618, miR-3689b, miR-3910-2, miR-3939, miR-4257 and miR-4293. 
From the remaining single nucleotide variant within seed region sequence of mature 
miRNAs (miR-124-3, miR-125a, miR-662, miR-941-1 and miR-1276), miR-124-3 
variant (miR-124-3M) and miR-662 variant (miR-662M) were chosen as the study 
subjects. miR-125a was used as the positive control throughout the experiment, since 
study on miR-125a had been carried by Duan and his colleague (year 2007).   
  
Currently, no population study for miR-125a (SNP ID: rs12975333) and miR-
124-3 variant (SNP ID: rs 34059726) has been conducted and therefore no allele 
frequency data is available. The variation observed in miR-124-3 was a transversional 
substitution, with Guanine as the major allele, Thymine as the minor allele. Whereas for 
miR-662 (SNP ID: rs 9745376), association study was performed in the population of 
Bushman, European, Bantu and Nigeria (Saunders et al., 2007), Table 4.1. The variation 
in miR-662 variant was a transitional substitution, with Guanine as the major allele, 
Adenine as the minor allele. The 1000 Genomes project had reported the global minor 
allele frequency of this SNP (rs 9745376) to be 0.029.  
 
Table 4.1: Allele frequency of miR-662 in 4 populations (overall 178 individuals) 
 
 
 
Populations 
Allele Frequency 
Allele A (Wild Type) Allele G (Variant) 
Bushman 0.667 0.333 
European 0 1.000 
Bantu 1.000 0 
Nigeria 0.140 0.860 
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4.3      Pre-miRNA secondary structure prediction 
The selected secondary structure of two wild-type and variant allele of pre-
miRNAs showed increament in the negative minimal folding energy value, showed in 
Table 4.2. 
 
 Table 4.2: Minimal folding energy (MFE) value of miRNA secondary structure. 
 
microRNA 
Minimal Folding Energy (MFE) Value Energy Change 
(ΔΔG) Wild Type Allele Variant Allele 
miR-125a -46.1kcal/mol -40.0kcal/mol 6.1 kcal/mol 
miR-124-3 -40.30kcal/mol -32.20kcal/mol 8.1 kcal/mol 
miR-662 -47.40kcal/mol -46.30kcal/mol 1.1 kcal/mol 
 
  All pre-miRNAs containing variant allele showed less negative minimal folding 
energy compared to their wild-type pre-miRNA. Since stem looped secondary structures 
of miRNAs are well conserved in humans (Ambros et al., 2003; Kim and Nam, 2006; 
Zhang et al., 2006), every wild-type miRNA should has a unique secondary structure 
and the minimum free energy value represent the stable folding of secondary structure 
of one specific miRNA type. Deviation of the minimal folding energy value might 
affect the initiate stable structure of miRNA and hence alter the production of mature 
miRNA. These pre-miRNAs with variant allele seemed to strengthen the stability of the 
secondary structure. Hence, single nucleotide variantion within seed region sequence of 
mature miR124-3 and miR-662 also have the potential to influence the miRNA gene 
transcription, miRNA processing or the mRNA targeting.  
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4.4      Validation of wild-type and variant allele in two miRNA forms 
4.4.1     Single nucleotide variant in seed-region miR-124-3 and miR-662 enhanced 
the processing of mature miRNA  
Study from Duan and colleagues (2007) demonstrated that mutation at seed 
region of miR-125a, can reduced the expression level of pre- and mature miR-125a that 
containing the variant allele. Nucleotide variation at the eighth nucleotide upstream 
from the 5’ end of the mature miR-125a has proven to have a huge impact on Drosha-
DGCR8 processing of its RNA substrate (Duan et al., 2007). In my findings, the mature 
miR-125a showed an enhanced expression level which is different from Duan’s finding. 
This could possibly due to the different vector and cell line used. In my study, pcDNA 
TM 3.1/Zeo (-) vector with a Cytomegalovirus (CMV) enhancer-promoter from 
Invitrogen was used instead of pSM2 retroviral vector with u6 promoter from Open 
Biosystems. Additionally, HEK293T transient cell line was used in this study rather 
than the stable HEK293. HEK293T contained T-antigen SV40 that enhanced the 
amplification of transfected plasmid, increasing the transfection efficiency (Oka et al., 
2010). 
 
I found that G/T transversion at the fourth nucleotide upstream from the 5’ end 
of the mature miR-124-3 and G/A transition at the seventh nucleotide upstream from the 
5’ end of the mature miR-662 had enhanced expression of the mature miRNA variant. 
The variations that occurred at seed region within mature miR-124-3 and miR-662 had 
increased the expression level of mature miRNA variant, they may provide a more 
stable stem preceding the mature miRNA sequence through some unknown molecular 
event (Sun et al., 2010). The structural features of these two pre-miRNAs may have 
stabilized the enzyme-substrate complex by mediating protein-nucleic acid interactions 
between Dicer and its RNA substrate. Dicer itself has the intrinsic ability to differentiate 
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RNA substrates with different structure (Chakravarthy et al., 2010), since their cutting 
sites are secondary structure dependent and not sequence based (Sun et al., 2010). 
Therefore a stable enzyme-RNA substrate complex is believed to promote the Dicer-
mediated processing of mature miRNA (Chakravarthy et al., 2010). This could explain 
the 2.2 fold increase in production of mature miR-124-3 variant and 1.9 fold increase 
for mature miRNA of miR-662 variant. Further investigations such as Northern blot and 
reporter assay should be conducted to reconfirm these miRNAs that enhance processing 
of mature miRNA. It would be interesting to determine how the single nucleotide 
variation in the seed region of the miRNAs studied lead to increased expression of the 
miRNA variant. 
  
4.4.2     Single nucleotide variation in seed-region miR-124-3 and miR-662 do not 
affect pri- and pre-miRNA processing 
 The expression level of variant allele of pre-miRNA for miR-124-3 and miR-662 
remains almost similar to the wild-type allele of pre-miRNA expression. This showed 
that the variant allele on seed region on the 5’-end of mature miR-124-3 and miR-662 
did not affect the processing of pre-miRNA from pri-miRNA. This result was different 
from the finding by Duan and his colleague, which stated that SNP on seed region could 
reduce the expression of pre- and mature miRNA. This outcome could be due to the 
different position of the variation site in the miRNA that affect the recognition site of 
complex protein. Many studies have reported that pri-miRNA is processed by Drosha-
DGCR8 complex to produce pre-miRNA (Han et al., 2006; Yeom et al., 2006; Duan et 
al., 2007; Kunej et al., 2012; Slaby et al., 2012). Pre-miRNA was produced through the 
cleavage of approximately 22nt from the terminal stem-ssRNA junction by Drosha 
(Iwai and Naraba, 2005). If mutation causes a structural change or disrupt the stem 
integrity within this critical region of miRNA, processing and expression of miRNA 
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would be affected (Iwai and Naraba, 2005; Wu et al., 2008). Drosha-DGCR8 complex 
protein may bind to the pri-miRNA in one of two different orientations: productive 
processing (processing center is located ~11bp from the basal segment) and abortive 
processing (processing center is located ~11bp from the terminal loop), showed in 
Figure 4-1 (Han et al., 2006). Productive processing will produces functional pre-
miRNA, while abortive processing product does not contain full miRNA sequences. 
Functional pre-miRNAs are favourably produced in the productive orientation. Han and 
colleagues suggested that internal stem structure may inﬂuenced the choice of 
processing. If a bulge was found to be near to the productive site, productive processing 
will be suppressed and abortive processing will be facilitated (Han et al., 2006).  
 
 
 
Figure 4-1: Productive Processing versus Abortive Processing. The fragment from 
abortive processing are designated as F1′, F2′, and F3′ (Figure from Han et al., 2006). 
 
 In this study, the variant allele that introduced the RNA bulge was located on the 
32
th
 nt from the basal segment (3’-end) of miR-124-3 and on the 29th nt from the basal 
segment (3’-end) of miR-662; both variant alleles are slightly far away from the 
‘ssRNA–dsRNA junction-anchoring’ structure. The additional bulges are located close 
to the abortive processing site, which highly reduced the chance for abortive processing 
and facilated the productive processing which will produced the pre-miRNAs normally. 
Besides that, variant allele that were introduced in miR-124-3 and miR-662 did not 
affect the structure of ssRNA-dsRNA junction and hence do not affect the Drosha-
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DGCR8 cutting site. Drosha excision sites are structure based and not sequence based 
(Sun et al., 2010). Therefore, pre-miR-124-3 and miR-662 was normally expressed. 
 
4.5     Relationship between microRNA expression and disease predisposition 
MicroRNAs play an essential role in many biological functions. The synergistic 
effects of individual miRNAs that can bind to the same mRNA target enable a miRNA 
family the precise modulation of target gene expression (Lee et al., 2006; Zhang et al., 
2006; Sun et al., 2010).  
 
Function of miR-124-3:  
The mature miR124 family consists of miR-124-1, miR-124-2 and miR-124-3. 
In this study, only miR-124-3 show sequence variation on its seed region. miR-124-3 
(MI0000445) is located in chromosome 20q13.33, region 61809907-61809907; all of 
which contain CpG islands in their promoter regions. The 3’-UTR target messenger 
RNA (mRNA) for miR-124-3 was predicted through mining the public database – 
PicTar (http://pictar.mdc-berlin.de), TargetScan (www.targetscan.org/) and Diana-
Mirco lab (http://diana.cslab.ece.ntua.gr/microT/) programs. From the list of potential 
mRNA targets that were convergent among the three databases, only seven mRNA 
genes were ramdomly selected (Table 4.4): VAMP3 (Vesicle-associated membrane 
protein 3), CD164 (Sialomucin core protein 24), PTPN12 (Tyrosine-protein 
phosphatase non-receptor type 12), NEGR1 (Neuronal growth regulator 1), CDK6 
(Cyclin-dependent kinase 6), ITGB1 (Integrin Beta 1) and IGFBP7 (Insulin-like growth 
factor-binding protein 7). Some of these target mRNAs had been experimentally 
verified.  
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For example, miR-124 expression led to the down-regulation of endogenous 
PTPN12 (protein tyrosine phosphatase non-receptor type 12) protein levels. PTPN12 
regulate the equilibrium of tyrosine phosphorylation that plays a central role in cellular 
physiology and in cancer. PTPN12 also suppresses mammary epithelial cell 
proliferation and transformation. This suggests that miR-124 may mediate tumor 
suppressor RE1 silencing transcription factor’s (REST) ability to inhibit PTPN12 
protein expression. The inhibition of PTPTN12 tumor suppressor by miR-124 showed 
that miR-124 may function as an oncogene in human breast cancers and lung cancers 
(Sun et al., 2011). However in this study, miR-124-3 with a variant allele was predicted 
to target CREB5 (Cyclic AMP-responsive element-binding protein 5) and DCC (a novel 
gene, Deleted in Colorectal Cancer), instead of PTPN12 (predicted by public databases). 
This showed that the variant miR-124-3 may not be able to inhibit PTPTN12 tumor 
suppressor. Variant miR-124-3 may inversely act as tumor suppressor instead of 
oncogene in human breast cancers or lung cancers. On the other hand, variant miR-124-
3 may target CREB5 gene and the up-regulation of CREB5 gene would cause HIV 
Encephalitis. 
 
Besides that, Hunt and his colleagues had proven that miR-124 was able to 
suppress oral squamous cell carcinoma (OSCC) invasion by decreasing the ITGB1 
expression level. ITGB1 is known to maintain tissue homeostasis and direct regulatory 
intracellular signaling cascades. From their study, mir-124 showed great potential as a 
prognostic indicator in OSCC (Hunt et al., 2011).  
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Function of miR-662: Mature miR-662 (MI0003670) is located at chromosome 
16p13.3, position 820183-820277. The 3’-UTR target mRNA for miR-662 was 
identified using public database – TargetScan (www.targetscan.org/) and Diana-Mirco 
lab (http://diana.cslab.ece.ntua.gr/microT/). Among the potential targets, only those that 
were convergent among the two databases were selected (Table 4.3): NEGR1 (Neuronal 
growth regulator 1), CSF3 (colony stimulating factor 3) and MKX (Homeobox protein 
Mohawk). There is currently no studies done on miR-662, therefore the target mRNAs 
were not validated. Enfield and his colleagues (2011) had proven that miR-662 
transiently increased in response to high doses of X-ray radiation in human fibroblasts 
of lung cancer and may have a role in conferring chemoresistance to a number of lung 
cancer drugs (Enfield et al., 2011). The expression of miR-662 was shown to increase in 
human kidney tissue of lupus nephritis patient (Dai et al., 2009, Dalal and Kwon, 2010). 
Overall, miR-662 has a role in malignancies or in the control of growth and apoptosis 
(Dahiya et al., 2008).    
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Table 4.3: Predicted potential 3’ UTR mRNA targets for miR-124-3 and miR-662 
 
miRNAs 
Predicted 
mRNA 
target 
Functions 
Possible diseases or 
cancers 
Wild Type  
miR-124-3 
VAMP3 
Vesicular transport from the late 
endosomes to the trans-Golgi 
network 
Immunological 
disease 
CD164 
Promotes myogenesis by enhancing 
CXCR4-dependent cell motility. 
↑ Prostate cancer 
PTPN12 
Dephosphorylates cellular tyrosine 
kinases 
↓ Breast and lung 
cancer 
NEGR1 Cell-adhesion ↓ Ovarian cancer  
CDK6 
Control of the cell cycle and 
differentiation; promotes G1/S 
transition 
↓ Breast cancer 
ITGB1 
Receptors for collagen ↓ Oral squamous cell 
carcinoma 
IGFBP7 Stimulates cell adhesion ↑ Cervical cancer 
Variant 
miR-124-3 
CREB5  
Binds to the cAMP response 
element and activates transcription 
↑ HIV Encephalitis 
(HIVE) 
DCC  
Receptor for netrin required for 
axon guidance. 
↑ Colorectal cancer 
Wild Type  
miR-662 
NEGR1 cell-adhesion ↓ Ovarian cancer  
CSF3 
Induces granulocytes ↓ Smoking-induced 
chronic obstructive 
pulmonary disease. 
MKX 
Morphogenetic regulator of cell 
adhesion 
↑ Ovarian cancer 
Variant 
miR-662 
Zinc 
finger 
proteins 
Transcriptional regulation ↑ pancreatic 
carcinomas 
↓ Colorectal cancer 
 
Annotations: VAMP3(Vesicle-associated membrane protein 3), CD164 (Sialomucin 
core protein 24), PTPN12 (Tyrosine-protein phosphatase non-receptor type 12), NEGR1 
(Neuronal growth regulator 1), CDK6 (Cyclin-dependent kinase 6), ITGB1 (Integrin 
Beta 1), IGFBP7 (Insulin-like growth factor-binding protein 7), CREB5(Cyclic AMP-
responsive element-binding protein 5), DCC(Deleted in Colorectal Cancer), 
NEGR1(Neuronal growth regulator 1), CSF3(colony stimulating factor 3) and 
MKX(Homeobox protein Mohawk). 
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4.6     Future aspects 
Single nucleotide changes in the mature miRNA sequence may drive the 
evolution of new miRNA by altering their biological function. As nucleotide variation 
on seed region of miRNA genes are rare and their mutant allele frequencies are low, 
large studies will be needed to draw out the importance. Up-to-date, not many SNP 
information were available on the non-coding gene, where miRNAs genes are deposited. 
In additional, the complexity of the miRNA network, especially their pathways, can 
further intensified by the discovery of miRNA functions that mediated by changes in 
miRNA sequence and maturation. In order to gain accurate quantitative result and a 
convicing statistic data, usage of pri- and pre-miRNA Taqman probes would gives high 
specificity to the target gene and reliable result as compare to SYBR Green probe.  
 
The findings of these two single nucleotide variations of miRNAs can be used to 
further study the effect of genetic variation on one population risk of cancer or disorders. 
In future, Western blot, reporter assay and luciferase assay could be used to study the 
linkage between alterations in miRNA structure and the predicted target mRNAs and 
cancer risk. The study of genetic variation in miRNA networks has expanded our 
knowledge of the possible ways in which miRNAs can affect cancer.  
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CHAPTER 5      CONCLUSION 
The evolutionary conservation of mature miRNA genes within humans allows 
bioinformatic approaches to be used to predict the potential miRNA variations against 
the Single Nucleotide Polymorphism database. Among the 1344 mature miRNA 
sequences, 42 single nucleotide variants were found on the seed region of mature 
miRNA by using BLAT homology search. Two selected potential single nucleotide 
variation in seed-region of mature miRNAs had been experimentally validated for the 
pri-, pre- and mature miRNA expression by real-time PCR approach. These two single 
nucleotide variations in seed-region of mature miRNAs that had an additional RNA 
bulge, located slight further from the 5’-end of mature miRNA surprisingly provided a 
more stable structure of pri-miRNA and pre-miRNA. This outcome in return increases 
the expression of mature miRNAs. MicroRNAs are known to be important for gene 
regulation network by regulating gene expression at the post transcriptional stage. 
Therefore, the study of sequence variation on seed-region of miRNAs could enhance the 
understanding of miRNA biogenesis and the potential contribution of these nucleotide 
variations to normal human variation and disease pathogenesis. However, single 
nucleotide variations in seed-region mature miRNA that was associated to cancer 
development is very much in its infancy and hence further investigation on mRNA 
targeting is necessary. Future studies could include analyzing potential direct targets 
predicted by bioinformatics programs and assessing gene-silencing capabilities of both 
mutants through luciferase assay. In addition, association studies on cancer prone 
populations can be done to elucidate the frequency of miRNA allele polymorphisms and 
its effect on cancers development.      
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APPENDIX 
 
 Table A.1:  Homology search (BLAT) of 127 potential Homo sapiens single nucleotide variation on mature miRNA gene. 
 
  miRNA Mature miRNA Sequence SNP ID Position Strand Allele REGION 
1 hsa-mir-92a-1 MI0000093 AGGTTGGGATCGGTTGCAATGCT 
rs72631821  chr13:92003588-92003588  + C/T   
rs9589207  chr13:92003589-92003589  + A/G   
2 hsa-mir-105-2 MI0000112  TCAAATGCTCAGACTCCTGTGGT rs72631816  chrX:151562938-151562938  - A/T   
3 hsa-mir-34a MI0000268  TGGCAGTGTCTTAGCTGGTTGT rs35301225  chr1:9211802-9211802  + A/C/T   
4 hsa-mir-7-1 MI0000263  CAACAAATCACAGTCTGCCATA rs76662330  chr9:86584707-86584707  + G/T   
5 hsa-mir-183 MI0000273  TATGGCACTGGTAGAATTCACT rs41281222 chr7:129414806-129414806  + C/T   
6 hsa-mir-196a-2 MI0000279 CGGCAACAAGAAACTGCCTGAG rs11614913  chr12:54385599-54385599  + C/T   
7 hsa-mir-204 MI0000284  TTCCCTTTGTCATCCTATGCCT rs112062096  chr9:73424956-73424956  + A/G   
8 hsa-mir-221 MI0000298  
ACCTGGCATACAATGTAGATTT    
AGCTACATTGTCTGCTGGGTTT 
rs113054794  chrX:45605666-45605666  + A/C seed 
9 hsa-mir-122 MI0000442  
TGGAGTGTGACAATGGTGTTTG    
AACGCCATTATCACACTAAATA 
rs41292412  chr18:56118358-56118358  + C/T seed 
10 hsa-mir-124-3 MI0000445  
CGTGTTCACAGCGGACCTTGAT    
TAAGGCACGCGGTGAATGCC 
rs34059726  chr20:61809907-61809907  + G/T seed 
11 hsa-mir-125a MI0000469  
TCCCTGAGACCCTTTAACCTGTGA  
ACAGGTGAGGTTCTTGGGAGCC 
rs12975333  chr19:56888340-56888340  + G/T seed 
12 hsa-mir-146a MI0000477  
TGAGAACTGAATTCCATGGGTT    
CCTCTGAAATTCAGTTCTTCAG 
rs2910164  chr5:159844996-159844996  + C/G  seed 
13 hsa-mir-154 MI0000480  
TAGGTTATCCGTGTTGCCTTCG    
AATCATACACGGTTGACCTATT 
rs41286570  chr14:100595880-100595880  + A/G   
14 hsa-mir-299 MI0000744  
TGGTTTACCGTCCCACAT        
TATGTGGGATGGTAAACCGCTT 
rs41286566  chr14:100559898-100559898  + C/T   
15 hsa-mir-302b MI0000772  
ACTTTAACATGGAAGTGCTTTC    
TAAGTGCTTCCATGTTTTAGTAG 
rs114318553  chr4:113569695-113569695  + G/T   
16 hsa-mir-383 MI0000791  AGATCAGAAGGTGATTGTGGCT rs112302475  chr8:14711013-14711013  + G/T   
17 hsa-mir-412 MI0002464  ACTTCACCTGGTCCACTAGCCGT rs61992671  chr14:101531854-101531854  + A/G   
18 hsa-mir-373 MI0000781  
ACTCAAAATGGGGGCGCTTTCC    
GAAGTGCTTCGATTTTGGGGTGT 
rs80338016  chr19:54292016-54292016  + C/T   
 1
0
0
 
  miRNA Mature miRNA Sequence SNP ID Position Strand Allele REGION 
19 hsa-mir-379 MI0000787  
TGGTAGACTATGGAACGTAGG     
TATGTAACATGGTCCACTAACT 
rs61991156  chr14:101488414-101488414  + A/G seed 
rs72631818  chr14:101488424-101488424  + A/G   
20 hsa-mir-148b MI0000811  
AAGTTCTGTTATACACTCAGGC    
TCAGTGCATCACAGAACTTTGT 
rs74878365  chr12:54731071-54731071  + A/C   
21 hsa-mir-339 MI0000815  
TCCCTGTCCTCCAGGAGCTCACG   
TGAGCGCCTCGACGACAGAGCCG 
rs72631820  chr7:1062599-1062599  - A/G   
22 hsa-mir-431 MI0001721  
TGTCTTGCAGGCCGTCATGCA     
CAGGTCGTCTTGCAGGGCTTCT 
rs12884005  chr14:101347408-101347408  + A/G seed 
23 hsa-mir-485 MI0002469  
AGAGGCTGGCCGTGATGAATTC    
GTCATACACGGCTCTCCTCTCT 
rs112982830  chr14:101521764-101521764  + A/G   
24 hsa-mir-523 MI0003153  
CTCTAGAGGGAAGCGCTTTCTG    
GAACGCGCTTCCCTATAGAGGGT 
rs112495387  chr19:54201668-54201668  + A/G   
25 hsa-mir-520c MI0003158  
CTCTAGAGGGAAGCACTTTCTG    
AAAGTGCTTCCTTTTAGAGGGT 
rs7255628  chr19:54210734-54210734  + C/G   
26 hsa-mir-519d MI0003162  CAAAGTGCCTCCCTTTAGAGT rs116796400  chr19:54216670-54216670  + A/G   
27 hsa-mir-518e MI0003169  
CTCTAGAGGGAAGCGCTTTCTG    
AAAGCGCTTCCCTTCAGAG 
rs74177813  chr19:54233109-54233109  + -/C seed 
rs34416818  chr19:54233113-54233112  + -/A seed 
rs74177814  chr19:54233114-54233113  + -/G seed 
28 hsa-mir-518d MI0003171  
CTCTAGAGGGAAGCACTTTCTG  
CAAAGCGCTTCCCTTTGGAGC 
rs73602910  chr19:54238189-54238189  + A/G seed 
29 hsa-mir-516b-1 MI0003172  
ATCTGGAGGTAAGAAGCACTTT  
TGCTTCCTTTCAGAGGGT 
rs78861479  chr19:54240174-54240174  + A/G   
30 hsa-mir-499 MI0003183  
TTAAGACTTGCAGTGATGTTT   
AACATCACAGCAAGTCTGTGCT 
rs3746444  chr20:33578251-33578251  + C/T seed 
31 hsa-mir-501 MI0003185  AATGCACCCGGGCAAGGATTCT rs112489955  chrX:49774389-49774389  + A/G   
32 hsa-mir-513a-1 MI0003191  
TTCACAGGGAGGTGTCAT      
TAAATTTCACCTTTCTGAGAAGG 
rs35027589  chrX:146295068-146295067  + -/C seed 
33 hsa-mir-552 MI0003557  AACAGGTGACTGGTTAGACAA rs76067517  chr1:35135270-35135270  + A/G   
34 hsa-mir-92b MI0003560  
AGGGACGGGACGCGGTGCAGTG  
TATTGCACTCGTCCCGGCCTCC 
rs12759620  chr1:155165044-155165044  + C/G   
35 hsa-mir-556 MI0003562  
GATGAGCTCATTGTAATATGAG  
ATATTACCATTAGCTCATCTTT 
rs77585320  chr1:162312411-162312411  + C/T   
 1
0
1
 
  miRNA Mature miRNA Sequence SNP ID Position Strand Allele REGION 
36 hsa-mir-557 MI0003563  GTTTGCACGGGTGGGCCTTGTCT rs78825966  chr1:168344829-168344829  + C/T seed 
37 hsa-mir-568 MI0003574  ATGTATAAATGTATACACAC rs28632138  chr3:114035387-114035387  + G/T   
38 hsa-mir-576 MI0003583  
ATTCTAATTTCTCCACGTCTTT  
AAGATGTGGAAAAATTGGAATC 
rs71603032  chr4:110409923-110409923  + G/T   
39 hsa-mir-581 MI0003588  TCTTGTGTTCTCTAGATCAGT 
rs1694089  chr5:53247394-53247394  - G/T   
rs810917  chr5:53247400-53247400  + A/G   
40 hsa-mir-585 MI0003592  TGGGCGTATCTGTATGCTA rs62376935  chr5:168690635-168690635  + C/T seed 
41 hsa-mir-590 MI0003602  
GAGCTTATTCATAAAAGTGCAG  
TAATTTTATGTATAAGCTAGT 
rs6971711  chr7:73605599-73605599  + C/T   
42 hsa-mir-593 MI0003605  
AGGCACCAGCCAGGCATTGCTCAGC 
TGTCTCTGCTGGGGTTTCT 
rs73721294  chr7:127721934-127721934  + C/T   
43 hsa-mir-596 MI0003608  AAGCCTGCCCGGCTCCTCGGG rs61388742  chr8:1765425-1765425  + C/T   
44 hsa-mir-597 MI0003609  TGTGTGTCACTCGATGACCACTGT rs112056940  chr8:9599212-9599212  + C/T   
45 hsa-mir-605 MI0003618  TAAATCCCATGGTGCCTTCTCCT 
rs113212828  chr10:53059349-53059349  + A/G seed 
rs76759855  chr10:53059356-53059356  + A/G   
rs34610391  chr10:77312285-77312284  + -/A   
46 hsa-mir-608 MI0003621  AGGGGTGGTGTTGGGACAGCTCCGT rs4919510  chr10:102734778-102734778  + C/G   
47 hsa-mir-624 MI0003638  
TAGTACCAGTACCTTGTGTTCA   
CACAAGGTATTGGTATTACCT 
rs73251987  chr14:31483883-31483883  + C/G   
48 hsa-mir-625 MI0003639  
AGGGGGAAAGTTCTATAGTCC    
GACTATAGAACTTTCCCCCTCA 
rs12894182  chr14:65937889-65937889  + A/C   
49 hsa-mir-627 MI0003641  GTAGTGAGTCTCTAAGAAAAGAGGA 
rs76362052  chr15:42491832-42491832  + C/T   
 rs2620381  chr15:42491848-42491848  + A/C seed 
50 hsa-mir-628 MI0003642  
ATGCTGACATATTTACTAGAGG   
TCTAGTAAGAGTGGCAGTCGA 
rs80185076  chr15:55665154-55665154  + C/G   
51 hsa-mir-629 MI0003643  TGGGTTTACGTTGGGAGAACT rs78212770  chr15:70371777-70371777  + C/G   
52 hsa-mir-642a MI0003657  GTCCCTCTCCAAATGTGTCTTG rs78902025  chr19:46178206-46178206  + G/T seed 
53 hsa-mir-646 MI0003661  AAGCAGCTGCCTCTGAGGC rs6513497  chr20:58883605-58883605  + G/T   
54 hsa-mir-662 MI0003670  TCCCACGTTGTGGCCCAGCAG rs9745376  chr16:820249-820249  + A/G seed 
55 hsa-mir-449b MI0003673  AGGCAGTGTATTGTTAGCTGGC rs10061133  chr5:54466544-54466544  + A/G   
56 hsa-mir-208b MI0005570  ATATAAGACGAACAAAAGGTTTGT rs2754157  chr14:23887219-23887219  + A/T   
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  miRNA Mature miRNA Sequence SNP ID Position Strand Allele REGION 
57 hsa-mir-449c MI0003823  
TAGGCAGTGTATTGCTAGCGGCTGT  
TTGCTAGTTGCACTCCTCTCTGT 
rs35770269  chr5:54468124-54468124  + A/T seed 
58 hsa-mir-509-2 MI0005530  
TACTGCAGACAGTGGCAATCA    
TGATTGGTACGTCTGTGGGTAG 
rs36092315  chrX:146340339-146340339  + -/T   
59 hsa-mir-933 MI0005755  TGTGCGCAGGGAGACCTCTCCC rs79402775  chr2:176032376-176032376  + A/G   
60 hsa-mir-936 MI0005758  ACAGTAGAGGGAGGAATCGCAG rs79924817  chr10:105807928-105807928  + C/T seed 
61 hsa-mir-938 MI0005760  TGCCCTTAAAGGTGAACCCAGT rs12416605  chr10:29891260-29891260  + C/T seed 
62 hsa-mir-940 MI0005762  AAGGCAGGGCCCCCGCTCCCC rs35356504  chr16:2321820-2321820  + -/C   
63 hsa-mir-941-2 MI0005764 CACCCGGCTGTGTGCACATGTGC 
rs2427557  chr20:62551027-62551027  + A/G   
rs2427558  chr20:62551030-62551030  + C/G   
64 hsa-mir-941-4  MI0005766 CACCCGGCTGTGTGCACATGTGC rs76606291  chr20:62551216-62551216  + A/G seed 
65 hsa-mir-944 MI0005769  AAATTATTGTACATCGGATGAG rs77473380  chr3:189547778-189547778  + C/T   
66 hsa-mir-297 MI0005775  ATGTATGTGTGCATGTGCATG rs112636147  chr4:111781785-111781785  + A/G   
67 hsa-mir-1200 MI0006332  CTCCTGAGCCATTCTGAGCCTC rs77814495  chr7:36959015-36959015  + A/G   
68 hsa-mir-1203 MI0006335  CCGGAGCCAGGATGCAGCTC rs77574787  chr17:46233848-46233848  + G/T   
69 hsa-mir-1304 MI0006371  TTTGAGGCTACAGTGAGATGTG 
rs79759099  chr11:93466909-93466909  + A/G seed 
rs76857625  chr11:93466910-93466910  + A/G seed 
70 hsa-mir-1291 MI0006353  TGGCCCTGACTGAAGACCAGCAGT rs77994717  chr12:49048277-49048277  + A/G   
71 hsa-mir-1299 MI0006359  TTCTGGAATCCTACGTGAGGGA 
rs79965448  chr9:69002294-69002294  + C/T   
rs78546776  chr9:69002304-69002304  + A/C/G   
rs76266132  chr9:69002317-69002317  + C/T seed 
72 hsa-mir-548l MI0006361  AAAAGTATTTGCGGGTTTTGTC rs13447640  chr11:94199721-94199721  - C/T   
73 hsa-mir-1268 MI0006405  CGGGCGTGGTGGTGGGGG rs28599926  chr15:22513271-22513271  + C/T seed 
74 hsa-mir-1269 MI0006406  CTGGACTGAGCCGTGCTACTGG rs73239138  chr4:67142620-67142620  + A/G   
75 hsa-mir-548h-3 MI0006413  AAAAGTAATCGCGGTTTTTGTC rs9913045  chr17:13446924-13446924  + A/G   
76 hsa-mir-548h-4 MI0006414  AAAAGTAATCGCGGTTTTTGTC rs73235381  chr8:26906402-26906402  + C/T   
77 hsa-mir-1275 MI0006415  GTGGGGGAGAGGCTGTC rs77821659  chr6:33967796-33967796  + A/C   
78 hsa-mir-1276 MI0006416  TAAAGAGCCCTGTGGAGACA rs34381260  chr15:86313795-86313794  + -/T seed 
79 hsa-mir-1255b-1 MI0006435  CGGATGAGCAAAGAAAGTGGTT rs6841938  chr4:36428048-36428048  + A/G   
80 hsa-mir-1321 MI0006652  CAGGGAGGTGAATGTGAT rs36100620  chrX:85090853-85090852  + -/G   
81 hsa-mir-1322 MI0006653  GATGATGCTGCTGATGCTG rs59878596  chr8:10682894-10682894  + C/T   
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82 hsa-mir-1911 MI0008332  TGAGTACCGCCATGTCTGTTGGG rs79202905  chrX:113997768-113997768  + A/G   
83 hsa-mir-2053 MI0010487  GTGTTAATTAAACCTCTATTTAC rs10505168  chr8:113655752-113655752  - A/G   
84 hsa-mir-2277 MI0011284 
AGCGCGGGCTGAGCGCTGCCAGTC  
TGACAGCGCCCTGCCTGGCTC 
rs73772915  chr5:92956422-92956422  + C/G   
85 hsa-mir-3117 MI0014130  ATAGGACTCATATAGTGCCAG rs12402181  chr1:67094171-67094171  + A/G seed 
86 hsa-mir-3118-2 MI0014132  TGTGACTGCATTATGAAAATTCT rs11488501  chr1:143424165-143424165  + C/T seed 
87 hsa-mir-3118-3 MI0014133  TGTGACTGCATTATGAAAATTCT rs11488501  chr1:143424165-143424165  + C/T seed 
88 hsa-mir-3124 MI0014140  TTCGCGGGCGAAGGCAAAGTC rs12081872  chr1:249120584-249120584  + C/T seed 
89 hsa-mir-3125 MI0014142  TAGAGGAAGCTGTGGAGAGA rs33977954  chr2:12877503-12877502  + -/A   
90 hsa-mir-3128 MI0014145  TCTGGCAAGTAAAAAACTCTCAT rs61130794  chr2:178120681-178120681  + G/T seed 
91 hsa-mir-3130-1 MI0014147  
TACCCAGTCTCCGGTGCAGCC    
GCTGCACCGGAGACTGGGTAA 
rs2241347  chr2:207647981-207647981  - A/G   
92 hsa-mir-3152 MI0014179  TGTGTTAGAATAGGGGCAATAA rs13299349  chr9:18573360-18573360  + A/G   
93 hsa-mir-3130-2 MI0014148  
TACCCAGTCTCCGGTGCAGCC    
GCTGCACCGGAGACTGGGTAA 
rs2241347  chr2:207647981-207647981  - A/G   
94 hsa-mir-548u MI0014168  CAAAGACTGCAATTACTTTTGCGC 
rs2397267  chr6:57254986-57254986  + A/G   
rs2894843  chr6:57255001-57255001  + A/C   
95 hsa-mir-3144 MI0014169  
AGGGGACCAAAGAGATATATAG   
ATATACCTGTTCGGTCTCTTTA 
rs67106263  chr6:120336384-120336384  + A/G   
96 hsa-mir-3159 MI0014188  TAGGATTACAAGTGTCGGCCAC rs79957895  chr11:18409354-18409354  + A/G   
97 hsa-mir-3161 MI0014191  CTGATAAGAACAGAGGCCCAGAT 
rs11382316  chr11:48118350-48118349  + -/A seed 
rs35834266  chr11:48118351-48118350  + -/A seed 
rs74581179  chr11:48118351-48118351  + A/G   
99 hsa-mir-323b MI0014206  
AGGTTGTCCGTGGTGAGTTCGCA   
CCCAATACACGGTCGACCTCTT 
rs75330474 chr14:101522589-101522589 + C/T   
100 hsa-mir-3175 MI0014209  CGGGGAGAGAACGCAGTGACGT rs72647784  chr15:93447646-93447646  + -/GA   
101 hsa-mir-3195 MI0014240  CGCGCCGGGCCCGGGTT rs1886009  chr20:60639883-60639883  + C/T   
102 hsa-mir-3196 MI0014241  CGGGGCGGCAGGGGCCTC rs2273488  chr20:61870140-61870140  + C/T   
103 hsa-mir-3198 MI0014246  GTGGAGTCCTGGGGAATGGAGA rs56660112  chr22:18246960-18246960  + C/G   
104 hsa-mir-4293 MI0015826  CAGCCTGACAGGAACAG rs12220909  chr10:14425221-14425221  + C/G seed 
105 hsa-mir-4302 MI0015833  CCAGTGTGGCTCAGCGAG rs11048315  chr12:26026988-26026988  + A/G/T   
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106 hsa-mir-4257 MI0015856  CCAGAGGTGGGGACTGAG rs74743733  chr1:150524468-150524468  + A/G seed 
107 hsa-mir-4254 MI0015862  GCCTGGAGCTACTCCACCATCTC rs12731294  chr1:32224285-32224285  + G/T   
108 hsa-mir-4252 MI0015864  GGCCACTGAGTCAGCACCA 
rs3982072  chr1:6489910-6489910  + C/T   
rs3982073  chr1:6489914-6489914  + C/T   
109 hsa-mir-4265 MI0015869  CTGTGGGCTCAGCTCTGGG rs4676066  chr2:109757963-109757963  + C/T   
110 hsa-mir-4284 MI0015893  GGGGCTCACATCACCCCAT rs11973069  chr7:73125664-73125664  + C/T   
111 hsa-mir-3610 MI0016000  GAATCGGAAAGGAGGCGCCG rs10094194  chr8:117886982-117886982  + C/G   
112 hsa-mir-3618 MI0016008  TGTCTACATTAATGAAAAGAGC rs12159555  chr22:20073323-20073323  + C/G seed 
113 hsa-mir-3689b MI0016411  TGTGATATCATGGTTCCTGGGA rs116838571  chr9:137742067-137742067  + A/T seed  
114 hsa-mir-3622a MI0016013  
CAGGCACGGGAGCTCAGGTGAG  
TCACCTGACCTCCCATGCCTGT 
rs66683138  chr8:27559214-27559214  + A/G   
rs13276615  chr8:27559261-27559261  + A/C    
115 hsa-mir-4274 MI0015884  CAGCAGTCCCTCCCCCTG 
rs10655902  chr4:7461827-7461826  + -/A/C/CCA   
rs78759170  chr4:7461828-7461827  + -/CAC   
rs10655902  chr4:7461827-7461826  + -/A/C/CCA   
rs75530384  chr4:7461828-7461828  + C/T   
rs66511565  chr4:7461829-7461828  + -/AC/CAC   
116 hsa-mir-3622b MI0016014  
AGGCATGGGAGGTCAGGTGA    
TCACCTGAGCTCCCGTGCCTG 
rs66683138  chr8:27559214-27559214  + A/G   
rs13276615  chr8:27559261-27559261  + A/C   
117 hsa-mir-3678 MI0016079  
TCCGTACAAACTCTGCTGTG    
CTGCAGAGTTTGTACGGACCGG 
rs34571046  chr17:73402156-73402156  - C/T   
118 hsa-mir-3679 MI0016080  
TGAGGATATGGCAGGGAAGGGGA 
CTTCCCCCCAGTAATCTTCATC 
rs79705373  chr2:134884717-134884717  + A/G   
119 hsa-mir-3909 MI0016413  TGTCCTCTAGGGCCTGCAGTCT rs34874675  chr22:35731712-35731712  + -/G   
120 hsa-mir-3910-1 MI0016414  AAAAGGCATAAAACCAAGACA rs76084273  chr9:94398600-94398600  + A/C   
121 hsa-mir-3912 MI0016416  TAACGCATAATATGGACATGT rs34887287  chr5:170813685-170813684  + -/A   
122 hsa-mir-3910-2 MI0016431  AAAAGGCATAAAACCAAGACA rs76084273  chr9:94398600-94398600  + A/C seed 
123 hsa-mir-3924 MI0016432  ATATGTATATGTGACTGCTACT rs77767763  chr10:59064260-59064260  + C/G   
124 hsa-mir-3927 MI0016435  AGGTAGATATTTGATAGGCAT rs80350479  chr9:112273768-112273768  + A/C   
125 hsa-mir-3939 MI0016596  TACGCGCAGACCACAGGATGTC 
rs76608449  chr6:167411333-167411333  + C/G seed 
rs75823810  chr6:167411334-167411334  + C/T seed 
rs73024232  chr6:167411337-167411337  + A/G seed 
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126 hsa-mir-3928 MI0016438  GGAGGAACCTTGGAGCTTCGGC 
rs60197191  chr22:31556051-31556050  + 
-/AAAGCTC T 
TTGAAAA GCTGCC 
  
rs72358191  chr22:31556059-31556058  + 
-/TTTGAAA A 
GCTGCCG AAGCTC 
  
127 hsa-mir-642b MI0016685  AGACACATTTGGAGAGGGACCC rs78902025  chr19:46178206-46178206  + G/T   
 
Table A.2:  Homology search (BLAT) of 298 potential Homo sapiens SNPs in presursor miRNA (pre-miRNA) and mature miRNAs. 
  miRNA Mature miRNA Sequence SNP ID Position Strand Allele 
1 hsa-mir-16-1 MI0000070 AGTATTAACTGTGCTGCTGA rs72631826 chr13:50623143-50623143 - C/T 
2 hsa-mir-18a MI0000072  TAAGGTGCATCTAGTGCAGATAG rs41275866  chr13:92003009-92003009  + C/G 
3 hsa-mir-25 MI0000082  AGGCGGAGACTTGGGCAATTG rs41274221  chr7:99691200-99691200  + C/T 
4 
 
hsa-mir-27a MI0000085  AGGGCTTAGCTGCTTGTGAGCA rs895819  chr19:13947292-13947292  + A/C/G/T 
rs11671784  chr19:13947296-13947296  + A/G 
5 hsa-mir-28 MI0000086  AAGGAGCTCACAGTCTATTGAG rs78547906  chr3:188406636-188406636  + C/T 
6 hsa-mir-33a MI0000091  GTGCATTGTAGTTGCATTGCA rs71764233  chr22:42296506-42298976  + LARGE DELETION 
rs77809319  chr22:42296995-42296995  + A/G 
7 hsa-mir-93 MI0000095  AAAGTGCTGTTCGTGCAGGTAG rs72631824  chr7:99691429-99691429  - C/T 
8 hsa-mir-96 MI0000098  TTTGGCACTAGCACATTTTTGCT rs73159662  chr7:129414568-129414568  + A/G 
rs41274239  chr7:129414574-129414574  + A/G 
9 hsa-mir-30c-2 MI0000254  CTGGGAGAAGGCTGTTTACTCT rs113749278  chr6:72086720-72086720  + A/G 
10 hsa-mir-7-2 MI0000264  CAACAAATCCCAGTCTACCTAA rs41276930  chr15:89155073-89155073  + C/T 
rs75737367  chr15:89155084-89155084  + A/C 
11 hsa-mir-7-3 MI0000265  TGGAAGACTAGTGATTTTGTTGT rs76199191  chr19:4770697-4770697  + G/T 
12 hsa-mir-10a MI0000266  TACCCTGTAGATCCGAATTTGTG rs72631828  chr17:46657289-46657289  - A/G 
13 hsa-mir-34a MI0000268  TGGCAGTGTCTTAGCTGGTTGT rs72631823  chr1:9211782-9211782  - A/G 
14 hsa-mir-182 MI0000272  TTTGGCAATGGTAGAACTCACACT rs76481776  chr7:129410227-129410227  + C/T 
rs77586312  chr7:129410228-129410228  + A/G 
rs75953509  chr7:129410235-129410235  + C/T 
rs80041074  chr7:129410239-129410239  + C/T 
15 hsa-mir-183 MI0000273  TATGGCACTGGTAGAATTCACT rs72631833  chr7:129414804-129414804  - G/T 
16 hsa-mir-204 MI0000284  TTCCCTTTGTCATCCTATGCCT rs112971695  chr9:73424988-73424988  + A/G 
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17 hsa-mir-187 MI0000274  TCGTGTCTTGTGTTGCAGCCGG rs114964240  chr18:33484783-33484783  + C/T 
rs41274312  chr18:33484792-33484792  + A/G 
18 hsa-mir-199b MI0000282  CCCAGTGTTTAGACTATCTGTTC    
ACAGTAGTCTGCACATTGGTTA 
rs72631835  chr9:131007109-131007109  - C/T 
19 hsa-mir-205 MI0000285  TCCTTCATTCCACCGGAGTCTG rs113859371  chr1:209605546-209605546  + C/T 
20 hsa-mir-211 MI0000287  TTCCCTTTGTCATCCTTCGCCT rs34520022  chr15:31357246-31357245  + -/G 
21 hsa-mir-215 MI0000291  ATGACCTATGAATTGACAGAC rs72631834  chr1:220291292-220291292  - C/T 
22 hsa-mir-216a MI0000292  TAATCTCAGCTGGCAACTGTGA rs41291179  chr2:56216090-56216090  + A/T 
23 hsa-mir-217 MI0000293  TACTGCATCAGGAACTGATTGGA rs41291173  chr2:56210140-56210140  + A/G 
24 hsa-mir-222 MI0000299  CTCAGTAGCCAGTGTAGATCCT   
AGCTACATCTGGCTACTGGGT 
rs72631825  chrX:45606471-45606471  - A/G 
25 hsa-mir-223 MI0000300  CGTGTATTTGACAAGCTGAGTT   
TGTCAGTTTGTCAAATACCCCA 
rs34952329  chrX:65238768-65238767  + -/C 
26 hsa-mir-200b MI0000342  CATCTTACTGGGCAGCATTGGA   
TAATACTGCCTGGTAATGATGA 
rs72563729  chr1:1102563-1102563  + A/G 
27 hsa-mir-30b MI0000441  TGTAAACATCCTACACTCAGCT   
CTGGGAGGTGGATGTTTACTTC 
rs111424617  chr8:135812836-135812836  - C/T 
28 hsa-mir-124-2 MI0000444  CGTGTTCACAGCGGACCTTGAT   
TAAGGCACGCGGTGAATGCC 
rs72631829  chr8:65291808-65291808  + A/G 
29 hsa-mir-128-1 MI0000447  TCACAGTGAACCGGTCTCTTT rs117812383  chr2:136422988-136422988  + A/G 
30 hsa-mir-140 MI0000456  CAGTGGTTTTACCCTATGGTAG   
TACCACAGGGTAGAACCACGG 
rs7205289  chr16:68524506-68524506  + A/C 
31 hsa-mir-141 MI0000457  CATCTTCCAGTACAGTGTTGGA   
TAACACTGTCTGGTAAAGATGG 
rs34385807  chr12:6943606-6943605  + -/C 
32 hsa-mir-152 MI0000462  TCAGTGCATGACAGAACTTGG rs67214557  chr17:43468372-43473043  + LARGE DELETION 
33 hsa-mir-9-2 MI0000467  TCTTTGGTTATCTAGCTGTATGA  
ATAAAGCTAGATAACCGAAAGT 
rs41265488  chr5:87998503-87998503  + A/T 
34 hsa-mir-149 MI0000478  TCTGGCTCCGTGTCTTCACTCCC  
AGGGAGGGACGGGGGCTGTGC 
rs71428439  chr2:241044173-241044173  + A/G 
rs2292832  chr2:241044176-241044176  + C/T 
35 hsa-mir-184 MI0000481  TGGACGGAGAACTGATAAGGGT rs41280052  chr15:77289223-77289223  + G/T 
36 hsa-mir-193a MI0000487  TGGGTCTTTGCGGGCGAGATGA   
AACTGGCCTACAAAGTCCCAGT 
rs60406007  chr17:26911146-26911146  + G/T 
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37 hsa-mir-1-1 MI0000651  TGGAATGTAAAGAAGTATGTAT rs6122014  chr20:60561960-60561960  - C/T 
38 hsa-mir-194-2 MI0000732  CCAGTGGGGCTGCTGTTATCTG rs11231898  chr11:64415412-64415412  + A/G 
39 hsa-mir-106b MI0000734  TAAAGTGCTGACAGTGCAGAT    
CCGCACTGTGGGTACTTGCTGCTC 
rs72631827  chr7:99529588-99529588  - G/T 
40 hsa-mir-299 MI0000744  TGGTTTACCGTCCCACAT       
TATGTGGGATGGTAAACCGCTT 
rs72172875  chr14:100558894-100568278  + LARGE DELETION 
41 hsa-mir-130b MI0000748  ACTCTTTCCCTGTTGCACTAC    
CAGTGCAATGATGAAAGGGCAT 
rs72631822  chr22:20337634-20337634  + A/G 
42 hsa-mir-365-2 MI0000769  AGGGACTTTCAGGGGCAGCTGTGT 
TAATGCCCCTAAAAATCCTTAT 
rs35143473  chr17:29902519-29902519  + -/T 
43 hsa-mir-379 MI0000787  TGGTAGACTATGGAACGTAGG    
TATGTAACATGGTCCACTAACT 
rs115827677  chr14:101488430-101488430  + A/G 
44 hsa-mir-326 MI0000808  CCTCTGGGCCCTTCCTCCAG rs72561778  chr11:75046227-75046227  - A/G 
45 hsa-mir-339 MI0000815  TCCCTGTCCTCCAGGAGCTCACG  
TGAGCGCCTCGACGACAGAGCCG 
rs13232101  chr7:1062574-1062574  + G/T 
rs72631831  chr7:1062656-1062656  - A/G 
46 hsa-mir-133b MI0000822  TTGGTCCCCTTCAACCAGCTA rs112599381  chr6:52013754-52013754  + C/T 
47 hsa-mir-325 MI0000824  CCTAGTAGGTGTCCAGTAAGTGT rs72631830  chrX:76225915-76225915  - G/T 
48 hsa-mir-345 MI0000825  CTGACTCCTAGTCCAGGGCTC rs72631832  chr14:100774203-100774203  + C/T 
rs114693307  chr14:100774289-100774289  + A/C 
49 hsa-mir-423 MI0001445  TGAGGGGCAGAGAGCGAGACTTT   
AGCTCGGTCTGAGGCCCCTCAGT 
rs6505162  chr17:28444183-28444183  + A/C 
50 hsa-mir-449a MI0001648  TGGCAGTGTATTGTTAGCTGGT rs112310158  chr5:54466378-54466378  + A/G 
51 hsa-mir-431 MI0001721  TGTCTTGCAGGCCGTCATGCA     
CAGGTCGTCTTGCAGGGCTTCT 
rs76090066  chr14:101347355-101347355  + C/T 
52 hsa-mir-329-1 MI0001725  AACACACCTGGTTAACCTCTTT rs34557733  chr14:101493130-101493129  + -/A 
53 hsa-mir-412 MI0002464  ACTTCACCTGGTCCACTAGCCGT rs115831106  chr14:101531806-101531806  + C/T 
54 hsa-mir-484 MI0002468  TCAGGCTCAGTCCCCTCCCGAT rs112103086  chr16:15737217-15737217  + G/T 
rs112906136  chr16:15737218-15737218  + A/G 
55 hsa-mir-486 MI0002470  TCCTGTACTGAGCTGCCCCGAG   
CGGGGCAGCTCAGTACAGGAT 
rs59908561  chr8:41517960-41517959  + -/G 
rs72177614  chr8:41517961-41517960  + -/G 
56 hsa-mir-489 MI0003124  GTGACATCACATATACGGCAGC rs35930643  chr7:93113324-93113323  + -/A 
57 hsa-mir-496 MI0003136  TGAGTATTACATGGCCAATCT rs79307187  chr14:101526957-101526957  + A/C 
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  miRNA Mature miRNA Sequence SNP ID Position Strand Allele 
58 hsa-mir-146b MI0003129  TGAGAACTGAATTCCATAGGCT   
TGCCCTGTGGACTCAGTTCTGG 
rs76149940  chr10:104196269-104196269  + C/T 
rs117717575  chr10:104196300-104196300  + G/T 
59 hsa-mir-202 MI0003130  TTCCTATGCATATACTTCTTTG   
AGAGGTATAGGGCATGGGAA 
rs12355840  chr10:135061112-135061112  + C/T 
60 hsa-mir-492 MI0003131  AGGACCTGCGGGACAAGATTCTT rs75413415  chr12:95228179-95228179  + A/C 
rs2289030  chr12:95228286-95228286  - C/G 
61 hsa-mir-520f MI0003146  AAGTGCTTCCTTTTAGAGGGTT rs75598818  chr19:54185492-54185492  + A/G 
62 hsa-mir-525 MI0003152  CTCCAGAGGGATGCACTTTCT   
GAAGGCGCTTCCCTTTAGAGCG 
rs80268200  chr19:54200830-54200830  + A/G 
63 hsa-mir-521-2 MI0003163  AACGCACTTCCCTTTAGAGTGT rs13382089  chr19:54219854-54219854  + G/T 
64 hsa-mir-520g MI0003166  ACAAAGTGCTTCCCTTTAGAGTGT rs112328520  chr19:54225501-54225501  + C/T 
65 hsa-mir-516b-2 MI0003167  ATCTGGAGGTAAGAAGCACTTT  
TGCTTCCTTTCAGAGGGT 
rs10583889  chr19:54228774-54228774  + -/TT 
rs114381285  chr19:54228775-54228775  + C/T 
66 hsa-mir-526a-2 MI0003168  CTCTAGAGGGAAGCACTTTCTGT rs113349469  chr19:54230219-54230219  + A/T 
67 hsa-mir-518a-1 MI0003170  ACAAAGTGCTTCCCTTTAGAGTGT rs79646188  chr19:54225501-54225501  + C/T 
68 hsa-mir-516b-2 MI0003167  ATCTGGAGGTAAGAAGCACTTT  
TGCTTCCTTTCAGAGGGT 
rs10583889  chr19:54228774-54228774  + -/TT 
rs114381285  chr19:54228775-54228775  + C/T 
69 hsa-mir-526a-2 MI0003168  CTCTAGAGGGAAGCACTTTCTGT rs113349469  chr19:54230219-54230219  + A/T 
70 hsa-mir-518a-1 MI0003170  CTGCAAAGGGAAGCCCTTTC rs79646188  chr19:54234340-54234340  + G/T 
71 hsa-mir-518d MI0003171  CTCTAGAGGGAAGCACTTTCTG  
CAAAGCGCTTCCCTTTGGAGC 
rs116220629  chr19:54238182-54238182  + C/T 
rs74704964  chr19:54238208-54238208  + C/T 
72 hsa-mir-516b-1 MI0003172  ATCTGGAGGTAAGAAGCACTTT  
TGCTTCCTTTCAGAGGGT 
rs79235448  chr19:54240136-54240136  + C/G 
73 hsa-mir-517c MI0003174  ATCGTGCATCCTTTTAGAGTGT rs114627055  chr19:54244647-54244647  + C/T 
74 hsa-mir-520h MI0003175  ACAAAGTGCTTCCCTTTAGAGT rs56013413  chr19:54245788-54245788  + A/G 
75 hsa-mir-521-1 MI0003176  AACGCACTTCCCTTTAGAGTGT rs2561251  chr19:54251937-54251937  + A/G 
76 hsa-mir-516a-1 MI0003180  TTCTCGAGGAAAGAAGCACTTTC 
TGCTTCCTTTCAGAGGGT 
rs2569389  chr19:54260002-54260002  - A/G 
77 hsa-mir-516a-2 MI0003181  TTCTCGAGGAAAGAAGCACTTTC 
TGCTTCCTTTCAGAGGGT 
rs115975528  chr19:54264394-54264394  + C/T 
78 hsa-mir-499 MI0003183  TTAAGACTTGCAGTGATGTTT   
AACATCACAGCAAGTCTGTGCT 
rs7267163  chr20:33578276-33578276  + C/T 
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  miRNA Mature miRNA Sequence SNP ID Position Strand Allele 
79 hsa-mir-513a-2 MI0003192  TTCACAGGGAGGTGTCAT      
TAAATTTCACCTTTCTGAGAAGG 
rs111970838  chrX:146307449-146307449  + G/T 
80 hsa-mir-514-1 MI0003198  ATTGACACTTCTGTGAGTAGA rs113816728  chrX:146360845-146360845  + C/T 
81 hsa-mir-532 MI0003205  CATGCCTTGAGTGTAGGACCGT  
CCTCCCACACCCAAGGCTTGCA 
rs456615  chrX:49767832-49767832  + A/G 
rs456617  chrX:49767835-49767835  + A/G 
82 hsa-mir-553 MI0003558  AAAACGGTGAGATTTTGTTTT rs112891767  chr1:100746855-100746855  + C/T 
83 hsa-mir-554 MI0003559  GCTAGTCCTGACTCAGCCAGT rs79661940  chr1:151518284-151518284  + G/T 
84 hsa-mir-555 MI0003561  AGGGTAAGCTGAACCTCTGAT rs113306711  chr1:155316214-155316214  + C/T 
85 hsa-mir-558 MI0003564  TGAGCTGCTGTACCAAAAT rs72089144  chr2:32757231-32757230  + -/GTGT 
rs71953654  chr2:32757232-32757231  + -/TGTGTGTGTG 
rs35999329  chr2:32757239-32757238  + -/TGTG 
rs72215615  chr2:32757240-32757239  + -/TGTG 
86 hsa-mir-559 MI0003565  TAAAGTAAATATGCACCAAAA rs114803590  chr2:47604856-47604856  + C/T 
rs58450758  chr2:47604866-47604866  + C/T 
87 hsa-mir-561 MI0003567  CAAAGTTTAAGATCCTTGAAGT rs112456539  chr2:189162257-189162257  + A/G 
88 hsa-mir-564 MI0003570  AGGCAACATGGCCGAGAGGC rs114636202  chr3:44903385-44903385  + A/G 
rs2292181  chr3:44903434-44903434  + C/G 
89 hsa-mir-567 MI0003573  AGTATGTTCTTCCAGGACAGAAC rs115707679  chr3:111831722-111831722  + A/C 
rs76778672  chr3:111831736-111831736  + -/AA 
rs67780840  chr3:111831725-111831724  + -/A 
rs71704738  chr3:111831738-111831737  + -/AAAA 
90 hsa-mir-569 MI0003576  AGTTAATGAATCCTGGAAAGT rs73037390  chr3:170824453-170824453  + A/C 
rs116867000  chr3:170824459-170824459  + A/G 
91 hsa-mir-570 MI0003577  CGAAAACAGCAATTACCTTTGC rs9860655  chr3:195426305-195426305  + C/T 
92 hsa-mir-581 MI0003588  TCTTGTGTTCTCTAGATCAGT rs788517  chr5:53247386-53247386  - A/G 
93 hsa-mir-573 MI0003580  CTGAAGTGATGTGTAACTGATCAG rs76014664  chr4:24521902-24521902  + A/G 
rs113070835  chr4:24521822-24521822  + C/T 
rs77543406  chr4:24521910-24521910  + A/T 
rs78830737  chr4:24521904-24521904  + A/G 
94 hsa-mir-576 MI0003583  ATTCTAATTTCTCCACGTCTTT  
AAGATGTGGAAAAATTGGAATC 
rs77639117  chr4:110409933-110409933  + A/T 
95 hsa-mir-583 MI0003590  CAAAGAGGAAGGTCCCATTAC rs10697860  chr5:95414852-95414851  + -/ATAAA 
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96 hsa-mir-577 MI0003584  TAGATAAAATATTGGTACCTG  rs79560193  chr4:115577921-115577921  + A/G 
rs34115976  chr4:115577997-115577997  + C/G 
97 hsa-mir-580 MI0003587  TTGAGAATGATGAATCATTAGG rs115089112  chr5:36148057-36148057  + C/T 
rs73080005  chr5:36148054-36148054  + G/T 
98 hsa-mir-585 MI0003592  TGGGCGTATCTGTATGCTA rs115473017  chr5:168690611-168690611  + C/T 
rs62376934  chr5:168690612-168690612  + A/G 
99 hsa-mir-548a-1 MI0003593  CAAAACTGGCAATTACTTTTGC rs12197631  chr6:18572056-18572056  + G/T 
100 hsa-mir-586 MI0003594  TATGCATTGTATTTTTAGGTCC rs73735310  chr6:45165473-45165473  + A/G 
101 hsa-mir-550a-1 MI0003600  AGTGCCTGAGGGAGTAAGAGCCC 
TGTCTTACTCCCTCAGGCACAT 
rs71528599  chr7:30329467-30329467  + C/T 
102 hsa-mir-550a-2 MI0003601  AGTGCCTGAGGGAGTAAGAGCCC 
TGTCTTACTCCCTCAGGCACAT 
rs113464681  chr7:32772637-32772639  + -/TGT 
103 hsa-mir-595 MI0003607  GAAGTGTGCCGTGGTGTGTCT rs117344178  chr7:158325411-158325411  + C/T 
rs114151270  chr7:158325415-158325415  + C/T 
rs4909237  chr7:158325503-158325503  + C/T 
104 hsa-mir-596 MI0003608  AAGCCTGCCCGGCTCCTCGGG rs116450906  chr8:1765409-1765409  + C/T 
rs111606748  chr8:1765435-1765435  + C/T 
105 hsa-mir-597 MI0003609  TGTGTGTCACTCGATGACCACTGT rs79397096  chr8:9599276-9599276  + A/G 
106 hsa-mir-548a-3 MI0003612  AAAAGTAATTGCGAGTTTTACC rs71297276  chr8:105496638-105496638  + -/TGAAAGTAAT 
107 hsa-mir-602 MI0003615  GACACGGGCGACAGCTGCGGCCC rs116636751  chr9:140732963-140732963  + C/T 
108 hsa-mir-603 MI0003616  CACACACTGCAATTACTTTTGCT rs79500031  chr10:24564632-24564632  + G/T 
rs11014002  chr10:24564653-24564653  + C/T 
109 hsa-mir-604 MI0003617 AGGCTGCGGAATTCAGGAC rs2368393  chr10:29833998-29833998  - C/T 
rs2368392  chr10:29834003-29834003  - C/T 
110 hsa-mir-605 MI0003618  TAAATCCCATGGTGCCTTCTCCT rs2043556  chr10:53059406-53059406  - A/G 
111 hsa-mir-607 MI0003620  GTTCAAATCCAGATCTATAAC rs115264283  chr10:98588440-98588440  + A/G 
rs12778876  chr10:98588495-98588495  + A/T 
rs12780546  chr10:98588496-98588496  + A/T 
112 hsa-mir-609 MI0003622  AGGGTGTTTCTCTCATCTCT rs74154754  chr10:105978581-105978581  + C/G 
113 hsa-mir-611 MI0003624  GCGAGGACCCCTCGGGGTCTGAC rs111585800  chr11:61560026-61560026  + A/T 
114 hsa-mir-612 MI0003625 GCTGGGCAGGGCTTCTGAGCTCCTT rs550894  chr11:65211940-65211940  - G/T 
rs12803915  chr11:65211979-65211979  + A/G 
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115 hsa-mir-548c MI0003630  AAAAGTAATTGCGGTTTTTGCC  
CAAAAATCTCAATTACTTTTGC 
rs17120527  chr12:65016300-65016300  + A/G 
116 hsa-mir-617 MI0003631  AGACTTCCCATTTGAAGGTGGC rs12815353  chr12:81226326-81226326  + C/G 
rs113739044  chr12:81226358-81226358  + A/G 
117 hsa-mir-618 MI0003632  AAACTCTACTTGTCCTTCTGAGT rs2682818  chr12:81329536-81329536  + A/C 
118 hsa-mir-619 MI0003633  GACCTGGACATGTTTGTGCCCAGT rs34651680  chr12:109230733-109230732  + -/G 
119 hsa-mir-631 MI0003645  AGACCTGGCCCAGACCTCAGC rs5745925  chr15:75645967-75645967  + -/CT 
120 hsa-mir-633 MI0003648  CTAATAGTATCTACCACAATAAA rs75781970  chr17:61021604-61021604  + G/T 
rs17759989  chr17:61021611-61021611  + A/G 
121 hsa-mir-635 MI0003650  ACTTGGGCACTGAAACAATGTCC rs77279010  chr17:66420592-66420592  + A/G 
122 hsa-mir-639 MI0003654  ATCGCTGCGGTTGCGAGCGCTGT rs45556632  chr19:14640403-14640403  + C/G 
rs35149836  chr19:14640439-14640439  + A/G 
123 hsa-mir-645 MI0003660  TCTAGGCTGGTACTGCTGA rs35645123  chr20:49202355-49202354  + -/A 
124 hsa-mir-646 MI0003661  AAGCAGCTGCCTCTGAGGC rs6513496  chr20:58883534-58883534  + C/T 
125 hsa-mir-647 MI0003662  GTGGCTGCACTCACTTCCTTC     rs73147065  chr20:62574006-62574006  + A/G 
126 hsa-mir-650 MI0003665  AGGAGGCAGCGCTCTCAGGAC rs5996397  chr22:23165340-23165340  + C/G 
127 hsa-mir-662 MI0003670  TCCCACGTTGTGGCCCAGCAG rs74656628  chr16:820215-820215  + A/T 
128 hsa-mir-656 MI0003678  AATATTATACAGTCAACCTCT rs58834075  chr14:101533093-101533093  + C/T 
129 hsa-mir-758 MI0003757  TTTGTGACCTGGTCCACTAACC rs72172875  chr14:101489141-101498525  + LARGE DELETION 
130 hsa-mir-620 MI0003634  ATGGAGATAGATATAGAAAT rs77703604  chr12:116586414-116586414  + A/C 
rs10549054  chr12:116586415-116586416  + -/TA 
rs5801168  chr12:116586426-116586427  + -/AT 
rs3043743  chr12:116586435-116586436  + -/T/TA 
rs34551929  chr12:116586436-116586436  + -/A 
rs34380284  chr12:116586436-116586437  + -/C 
131 hsa-mir-663 MI0003672  AGGCGGGGCGCCGCGGGACCGC rs28670321  chr20:26188824-26188824  + C/T 
rs2019798  chr20:26188846-26188846  - G/T 
rs7266947  chr20:26188912-26188912  + A/C 
132 hsa-mir-1323 MI0003786  TCAAAACTGAGGGGCATTTTCT rs78952474  chr19:54175287-54175287  + G/T 
133 hsa-mir-1185-2 MI0003821  AGAGGATACCCTTTGTATGTT rs11844707  chr14:101510613-101510613  + A/G 
134 hsa-mir-449c MI0003823  TAGGCAGTGTATTGCTAGCGGCTGT 
TTGCTAGTTGCACTCCTCTCTGT 
rs75661995  chr5:54468166-54468166  + C/T 
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135 hsa-mir-1283-1 MI0003832  TCTACAAAGGAAAGCGCTTTCT rs57111412  chr19:54191743-54191743  + A/G 
136 hsa-mir-759 MI0004065  GCAGAGTGCAAACAATTTTGAC rs77079459  chr13:53384256-53384256  + G/T 
137 hsa-mir-891a MI0005524  TGCAACGAACCTGAGCCACTGA rs5965990  chrX:145109356-145109356  + A/G 
138 hsa-mir-300 MI0005525  TATACAAGGGCAGACTCTCTCT rs12894467  chr14:101507727-101507727  + C/T 
139 hsa-mir-888 MI0005537  TACTCAAAAAGCTGTCAGTCA    
GACTGACACCTCTTTGGGTGAA 
rs5965660  chrX:145076302-145076302  + G/T 
140 hsa-mir-147b MI0005544  GTGTGCGGAAATGCTTCTGCTA rs56073218  chr15:45725255-45725255  + C/G 
141 hsa-mir-543 MI0005565  AAACATTCGCGGTGCACTTCTT rs72172875  chr14:101489141-101498525  + LARGE DELETION 
142 hsa-mir-920 MI0005712  GGGGAGCTGTGGAAGCAGTA rs66686007  chr12:24365358-24365358  + -/GTTGT 
143 hsa-mir-934 MI0005756  TGTCTACTACTGGAGACACTGG rs73558572  chrX:135633045-135633045  + A/G 
144 hsa-mir-941-1  CACCCGGCTGTGTGCACATGTGC rs4809383  chr20:62550780-62550780  + C/T 
rs7262125  chr20:62550791-62550791  + A/G 
rs56202554  chr20:62550794-62550794  + C/T 
rs7268785  chr20:62550806-62550806  + C/G 
rs55795631  chr20:62550877-62550877  + C/T 
145 hsa-mir-944 MI0005769  AAATTATTGTACATCGGATGAG rs75715827  chr3:189547735-189547735  + C/T 
146 hsa-mir-941-1 CACCCGGCTGTGTGCACATGTGC rs6089780  chr20:62550880-62550880  + A/G 
rs6090019  chr20:62550890-62550890  + C/T 
147 hsa-mir-941-2  CACCCGGCTGTGTGCACATGTGC rs55795631  chr20:62550877-62550877  + C/T 
rs6089780  chr20:62550880-62550880  + A/G 
rs6090019  chr20:62550890-62550890  + C/T 
rs72366056  chr20:62551075-62551101  + -/AGGACAGC GC 
CACGGAAGAGGACGCAC 
rs34604519  chr20:62551169-62551169  + C/G 
rs7360929  chr20:62551199-62551199  + C/T 
148 hsa-mir-943  CTGACTGTTGCCGTCCTCCAG rs3034718  chr4:1988189-1988188  + -/CT 
rs35401110  chr4:1988190-1988189  + -/CT 
rs1077020  chr4:1988193-1988193  + C/T 
149 hsa-mir-941-4  CACCCGGCTGTGTGCACATGTGC rs7360929  chr20:62551199-62551199  + C/T  
rs12625445  chr20:62551225-62551225  + C/G 
rs35544770  chr20:62551272-62551272  + A/G 
rs12625454  chr20:62551281-62551281  + C/G 
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150 hsa-mir-297 MI0005775  ATGTATGTGTGCATGTGCATG rs113258805  chr4:111781746-111781746  + A/G 
151 hsa-mir-1181 MI0006274  CCGTCGCCGCCACCCGAGCCG rs2569788  chr19:10514159-10514159  + C/G 
152 hsa-mir-1178 MI0006271  TTGCTCACTGTTCTTCCCTAG rs7311975  chr12:120151493-120151493  + C/T 
rs74614893  chr12:120151501-120151501  + A/G 
153 hsa-mir-1227 MI0006316  CGTGCCACCCTTTTCCCCAG rs74807305  chr19:2234086-2234086  + A/T 
154 hsa-mir-1229 MI0006319  CTCTCACCACTGCCCTCCCACAG rs2291418  chr5:179225324-179225324  + C/T 
155a hsa-mir-1234 MI0006324  TCGGCCTGACCACCCACCCCAC rs75169642  chr8:145625535-145625535  + C/G 
rs2291134  chr8:145625536-145625536  + C/G 
155b hsa-mir-1234 MI0006324 TCGGCCTGACCACCCACCCCAC rs66769762  chr8:145625537-145625537  + -/GG 
rs76908615  chr8:145625542-145625542  + -/CC 
156 hsa-mir-1206 MI0006339  TGTTCATGTAGATGTTTAAGC rs2114358  chr8:129021179-129021179  - C/T 
157 hsa-mir-1286 MI0006348  TGCAGGACCAAGATGAGCCCT  rs71312743  chr22:20236701-20236701  + A/C 
158 hsa-mir-1287 MI0006349  TGCTGGATCAGTGGTTCGAGTC rs78666598  chr10:100155019-100155019  + A/T 
159 hsa-mir-663b MI0006336  GGTGGCCCGGCCGTGCCTGAGG rs62165009  chr2:133014579-133014579  + A/G 
rs75245503  chr2:133014602-133014602  + C/G 
rs74853538  chr2:133014612-133014612  + A/C 
rs78327226  chr2:133014619-133014619  + C/T 
rs78867621  chr2:133014640-133014640  + C/T 
160 hsa-mir-1208 MI0006341  TCACTGTTCAGACAGGCGGA rs56863230  chr8:129162366-129162366  + C/G 
rs2648841  chr8:129162433-129162433  - A/C 
rs4822739  chr22:26951185-26951185  + C/G 
rs12161068  chr22:26951215-26951215  + C/T 
161 hsa-mir-1289-2  TGGAGTCCAGGAATCTGCATTTTT rs35296450  chr5:132763295-132763295  + C/G 
rs35731356  chr5:132763305-132763304  + -/G 
rs74634410  chr5:132763305-132763305  + G/T 
rs75310044  chr5:132763335-132763335  + A/C 
162 hsa-mir-1290 MI0006352  TGGATTTTTGGATCAGGGA rs75705742  chr1:19223639-19223639  + A/G 
163 hsa-mir-1294 MI0006356  TGTGAGGTTGGCATTGTTGTCT rs13186787  chr5:153726769-153726769  + A/G 
164 hsa-mir-1299 MI0006359  TTCTGGAATCCTACGTGAGGGA rs62555121  chr9:69002271-69002271  + A/T 
165 hsa-mir-548l MI0006361  AAAAGTATTTGCGGGTTTTGTC rs11020790  chr11:94199710-94199710  + C/T 
166 hsa-mir-1302-1 MI0006362 TTAAATTTGAATTTCAAGTAAA rs74647838  chr12:113132901-113132901  + A/G 
167 hsa-mir-548f-5 MI0006378  AAAAACTGTAATTACTTTT rs60180387  chrX:32659592-32659592  + C/T 
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168a hsa-mir-1303 MI0006370  TTTAGAGACGGGGTCTTGCTCT rs77055126  chr5:154065348-154065348  + C/T 
rs75378399  chr5:154065368-154065368  + A/T 
rs75538180  chr5:154065383-154065383  + A/T 
168b hsa-mir-1303 MI0006370 TTTAGAGACGGGGTCTTGCTCT rs34889453  chr5:154065383-154065383  + -/A 
rs33982250  chr5:154065385-154065385  + -/A 
169 hsa-mir-1304 MI0006371  TTTGAGGCTACAGTGAGATGTG rs2155248  chr11:93466866-93466866  - A/C 
rs79462725  chr11:93466919-93466919  + C/G 
170 hsa-mir-1248 MI0006383  ACCTTCTTGTATAAGCACTGTGCTAAA rs73063489  chr3:186504532-186504532  + C/T 
171 hsa-mir-1255a MI0006389  AGGATGAGCAAAGAAAGTAGATT rs28664200  chr4:102251501-102251501  + C/T 
172 hsa-mir-1253 MI0006387  AGAGAAGAAGATCAGCCTGCA rs7217038  chr17:2651377-2651377  + A/T 
rs77498226  chr17:2651405-2651405  + G/T 
173 hsa-mir-1260 MI0006394  ATCCCACCTCTGCCACCA rs28909969  chr14:77732628-77732628  - -/T 
174 hsa-mir-1265 MI0006401  CAGGATGTGGTCAAGTGTTGTT rs11259096  chr10:14478618-14478618  + C/T 
175 hsa-mir-548o MI0006402  CCAAAACTGCAGTTACTTTTGC rs79628069  chr7:102046296-102046296  + G/T 
176 hsa-mir-1267 MI0006404  CCTGTTGAAGTGTAATCCCCA rs76080861  chr13:108183538-108183538  + C/T 
177 hsa-mir-1274a MI0006410  GTCCCTGTTCAGGCGCCA rs318039  chr5:41475766-41475766  + C/T 
178 hsa-mir-548h-4 MI0006414  AAAAGTAATCGCGGTTTTTGTC rs73235382  chr8:26906437-26906437  + A/G/T 
rs74273836  chr8:26906437-26906441  + -/AGTAA 
179 hsa-mir-1275 MI0006415  GTGGGGGAGAGGCTGTC rs76156362  chr6:33967787-33967787  + A/T 
180 hsa-mir-548i-1 MI0006421  AAAAGTAATTGCGGATTTTGCC rs34864809  chr3:125509375-125509374  + -/G 
181 hsa-mir-548i-4 MI0006424  AAAAGTAATTGCGGATTTTGCC rs72632467  chrX:83480764-83480764  + A/G 
182 hsa-mir-1282 MI0006429  TCGTTTGCCTTTTTCTGCTT rs11269  chr15:44085909-44085909  + G/T 
183 hsa-mir-1283-2 MI0006430  TCTACAAAGGAAAGCGCTTTCT rs71363366  chr19:54261549-54261549  + C/G 
184 hsa-mir-1292 MI0006433  TGGGAACGGGTTCCGGCAGACGCT rs73576045  chr20:2633466-2633466  + C/T 
185 hsa-mir-1255b-2 MI0006436  CGGATGAGCAAAGAAAGTGGTT rs79639536  chr1:167967958-167967958  + A/G 
186 hsa-mir-1307 MI0006444  ACTCGGCGTGGCGTCGGTCGTG rs7911488  chr10:105154089-105154089  + A/G 
187 hsa-mir-1322 MI0006653  GATGATGCTGCTGATGCTG rs76657610  chr8:10682923-10682923  + C/T 
188 hsa-mir-1324 MI0006657  CCAGACAGAATTCTATGCACTTTC rs75174508  chr3:75680010-75680010  + C/T 
189 hsa-mir-320d-1 MI0008190  AAAAGCTGGGTTGAGAGGA rs74826059  chr13:41301987-41301987  + A/G 
190 hsa-mir-1908 MI0008329  CGGCGGGGACGGCGATTGGTC rs174561  chr11:61582708-61582708  + C/T 
191 hsa-mir-1911 MI0008332  TGAGTACCGCCATGTCTGTTGGG rs79553157  chrX:113997746-113997746  + A/G 
192 hsa-mir-2276 MI0011282  TCTGCAAGTGTCAGAGGCGAGG rs74399078  chr13:24736638-24736638  + C/G 
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  miRNA Mature miRNA Sequence SNP ID Position Strand Allele 
193 hsa-mir-2110 MI0010629  TTGGGGAAACGGCCGCTGAGTG rs75407574  chr10:115933876-115933876  + A/G 
rs17091403  chr10:115933905-115933905  + C/T 
194 hsa-mir-2116 MI0010635  GTTCTTAGCATAGGAGGTCT    
CCTCCCATGCCAAGAACTCCC 
rs3838847  chr15:59463451-59463451  - -/A 
195 hsa-mir-2117 MI0010636  TGTTCTCTTTGCCAAGGACAG rs7207008  chr17:41522213-41522213  + A/T 
rs76511826  chr17:41522221-41522221  + A/G 
196 hsa-mir-2278 MI0011285  GAGAGCAGTGTGTGTTGCCTGG rs356125  chr9:97572244-97572244  + A/G 
197 hsa-mir-3118-3 MI0014133  TGTGACTGCATTATGAAAATTCT rs9440733  chr1:143424215-143424215  + G/T 
198 hsa-mir-3119-1 MI0014134  TGGCTTTTAACTTTGATGGC rs58602811  chr1:170120575-170120575  + G/T 
199 hsa-mir-3119-2 MI0014135  TGGCTTTTAACTTTGATGGC rs58602811  chr1:170120575-170120575  + G/T 
200 hsa-mir-3123 MI0014139  CAGAGAATTGTTTAATC rs78240175  chr1:241295617-241295617  + A/G 
201 hsa-mir-3125 MI0014142  TAGAGGAAGCTGTGGAGAGA rs72536414  chr2:12877501-12877500  + -/A 
rs78852835  chr2:12877501-12877501  + A/G 
rs5829384  chr2:12877502-12877501  + -/A 
202 hsa-mir-3131 MI0014151  TCGAGGACTGGTGGAAGGGCCTT rs71974827  chr2:219923412-219923411  + -/G 
rs57408770  chr2:219923419-219923418  + -/AAG 
203 hsa-mir-3132 MI0014152  TGGGTAGAGAAGGAGCTCAGAGGA rs12996671  chr2:220413812-220413812  + A/T 
rs12997198  chr2:220413813-220413813  + C/G 
204 hsa-mir-3135 MI0014156  TGCCTAGGCTGAGACTGCAGTG rs6787734  chr3:20179097-20179097  + C/T 
205 hsa-mir-544b MI0014159  ACCTGAGGTTGTGCATTTCTAA rs10934682  chr3:124451312-124451312  + G/T 
206 hsa-mir-548t MI0014164  CAAAAGTGATCGTGGTTTTTG rs73872515  chr4:174189360-174189360  + A/C 
207 hsa-mir-3141 MI0014165  GAGGGCGGGTGGAGGAGGA rs936581  chr5:153975576-153975576  + A/G 
208 hsa-mir-3143 MI0014167  ATAACATTGTAAAGCGCTTCTTTCG rs17737028  chr6:27115467-27115467  + A/G 
209 hsa-mir-548u MI0014168  CAAAGACTGCAATTACTTTTGCGC rs4994089  chr6:57254939-57254939  + G/T 
rs5876554  chr6:57254951-57254950  + -/T 
rs33917213  chr6:57254952-57254951  + -/T 
rs67187462  chr6:57254953-57254952  + -/T 
rs2894842  chr6:57254955-57254955  + A/G 
210 hsa-mir-3144 MI0014169  AGGGGACCAAAGAGATATATAG   
ATATACCTGTTCGGTCTCTTTA 
rs68035463  chr6:120336327-120336327  + A/C 
211 hsa-mir-3151 MI0014178  GTGGGGCAATGGGATCAGGT rs35605502  chr8:104166903-104166902  + -/C 
rs72544670  chr8:104166905-104166904  + -/C 
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  miRNA Mature miRNA Sequence SNP ID Position Strand Allele 
212 hsa-mir-3161 MI0014191  CTGATAAGAACAGAGGCCCAGAT rs73466882  chr11:48118374-48118374  + A/T 
213 hsa-mir-3166 MI0014196  GCAGACAATGCCTACTGGCCTA rs35854553  chr11:87909673-87909673  - A/T 
214 hsa-mir-1260b MI0014197  ATCCCACCACTGCCACCAT rs34913856  chr11:96074649-96074649  + -/G 
215 hsa-mir-3167 MI0014198  AGGATTTCAGAAATACTGGTGT rs670637  chr11:126858392-126858392  - C/T 
rs634171  chr11:126858406-126858406  - A/T 
216 hsa-mir-3170 MI0014201  CTGGGGTTCTGAGACAGACAGT rs76289985  chr13:98860827-98860827  + C/G 
217 hsa-mir-3171 MI0014202  AGATGTATGGAATCTGTATATATC rs35170395  chr14:28102477-28102478  + -/TA 
rs67062245  chr14:28102484-28102485  + -/AT 
218 hsa-mir-323b MI0014206  AGGTTGTCCGTGGTGAGTTCGCA   
CCCAATACACGGTCGACCTCTT 
rs56103835  chr14:101522556-101522556  + C/T 
219 hsa-mir-3175 MI0014209  CGGGGAGAGAACGCAGTGACGT rs1439619  chr15:93447631-93447631  - A/C 
220 hsa-mir-3176 MI0014210  ACTGGCCTGGGACTACCGG rs8054514  chr16:593277-593277  + G/T 
221 hsa-mir-3177 MI0014211  TGCACGGCACTGGGGACACGT rs28575325  chr16:1785038-1785038  + A/G 
222 hsa-mir-3183 MI0014225  GCCTCTCTCGGAGTCGCTCGGA rs72812091  chr17:925742-925742  + A/G 
rs2663345  chr17:925764-925764  - C/T 
223 hsa-mir-3188 MI0014232  AGAGGCTTTGTGCGGATACGGGG rs7247237  chr19:18392894-18392894  + C/T 
rs7247767  chr19:18392913-18392913  + A/G 
rs41510649  chr19:18392936-18392936  - A/G 
224 hsa-mir-3189 MI0014233  CCCCTTGGGTCTGATGGGGTAG rs71779635  chr19:18497275-18499093  + LARGE DELETION 
225 hsa-mir-320e MI0014234  AAAGCTGGGTTGAGAAGG rs10423365  chr19:47212593-47212593  + A/G 
226 hsa-mir-3192 MI0014237  TCTGGGAGGTTGTAGCAGTGGAA rs6111978  chr20:18451300-18451300  + C/T 
rs11907020  chr20:18451325-18451325  + C/T 
227 hsa-mir-3196 MI0014241  CGGGGCGGCAGGGGCCTC rs7363975  chr20:61870162-61870162  + A/C 
228 hsa-mir-3156-3 MI0014242  AAAGATCTGGAAGTGGGAGACA rs2747232  chr21:14778721-14778721  - A/T 
229 hsa-mir-3199-1 MI0014247  AGGGACTGCCTTAGGAGAAAGTT rs78805657  chr22:28316591-28316591  + G/T 
rs80166589  chr22:28316592-28316591  + -/G 
rs75321888  chr22:28316593-28316592  + -/G 
230 hsa-mir-4293 MI0015826  CAGCCTGACAGGAACAG rs12780876  chr10:14425204-14425204  + A/T 
231 hsa-mir-4294 MI0015827  GGGAGTCTACAGCAGGG rs12776349  chr10:50193625-50193625  + A/G 
232 hsa-mir-4298 MI0015830  CTGGGACAGGAGGAGGAGGCAG rs75966923  chr11:1880730-1880730  + A/C 
233 hsa-mir-4305 MI0015835  CCTAGACACCTCCAGTTC rs67976778  chr13:40238175-40238175  + C/T 
rs4636784  chr13:40238258-40238258  + C/G 
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  miRNA Mature miRNA Sequence SNP ID Position Strand Allele 
234 hsa-mir-4309 MI0015837  CTGGAGTCTAGGATTCCA rs78860350  chr14:103006026-103006026  + A/T 
rs12879262  chr14:103006047-103006047  + C/G 
235 hsa-mir-4308 MI0015839  TCCCTGGAGTTTCTTCTT rs28477407  chr14:55344901-55344901  + C/T 
236 hsa-mir-4312 MI0015842  GGCCTTGTTCCTGTCCCCA rs79711957  chr15:69094259-69094259  + A/C 
237 hsa-mir-4318 MI0015847  CACTGTGGGTACATGCT rs11873400  chr18:35237129-35237129  + A/G 
238 hsa-mir-4320 MI0015849  GGGATTCTGTAGCTTCCT rs4430847  chr18:47652913-47652913  - A/G 
239 hsa-mir-4317 MI0015850  ACATTGCCAGGGAGTTT rs74513330  chr18:6374394-6374394  + A/G 
240 hsa-mir-4324 MI0015854  CCCTGAGACCCTAACCTTAA rs79465964  chr19:49812123-49812123  + C/T 
241 hsa-mir-4259 MI0015858  CAGTTGGGTCTAGGGGTCAGGA rs35180578  chr1:159869829-159869828  + -/C 
242 hsa-mir-4260 MI0015859  CTTGGGGCATGGAGTCCCA rs7544976  chr1:209796810-209796810  + G/T 
243 hsa-mir-4253 MI0015860  AGGGCATGTCCAGGGGGT rs66652227  chr1:23189707-23189707  + -/G 
244 hsa-mir-4326 MI0015866  TGTTCCTCTGTCTCCCAGAC rs6062431  chr20:61918164-61918164  + C/G 
245 hsa-mir-4267 MI0015871  TCCAGCTCGGTGGCAC rs55940978  chr2:110827551-110827551  + C/T 
rs59793833  chr2:110827558-110827558  + A/G 
246 hsa-mir-4268 MI0015874  GGCTCCTCCTCTCAGGATGTG rs4674470  chr2:220771223-220771223  + C/T 
247 hsa-mir-4270 MI0015878  TCAGGGAGTCAGGGGAGGGC rs79922312  chr3:15537776-15537776  + A/G 
248 hsa-mir-4274 MI0015884  CAGCAGTCCCTCCCCCTG rs12512664  chr4:7461769-7461769  + A/G 
249 hsa-mir-4281 MI0015885  GGGTCCCGGGGAGGGGGG rs34983866  chr5:176056492-176056492  - -/C 
250 hsa-mir-4277 MI0015886  GCAGTTCTGAGCACAGTACAC rs12523324  chr5:1708983-1708983  + A/G 
251 hsa-mir-4279 MI0015887  CTCTCCTCCCGGCTTC rs34157017  chr5:31936264-31936263  + -/A 
252 hsa-mir-4285 MI0015891  GCGGCGAGTCCGACTCAT rs34606939  chr7:101936373-101936372  + -/G 
rs2960269  chr7:101936374-101936374  - C/G 
rs2906714  chr7:101936375-101936375  + -/C/T 
rs1293864  chr7:101936397-101936397  - G/T 
rs35647990  chr7:101936420-101936419  + -/C 
rs1293863  chr7:101936422-101936422  - -/A/G 
rs1293862  chr7:101936435-101936435  - A/T 
253 hsa-mir-4286 MI0015894  ACCCCACTCCTGGTACC rs80245767  chr8:10524531-10524531  + A/C 
254 hsa-mir-4328 MI0015904  CCAGTTTTCCCAGGATT rs35376760  chrX:78156694-78156693  + -/G 
255 hsa-mir-3605 MI0015995  TGAGGATGGATAGCAAGGAAGCC   
CCTCCGTGTTACCTGTCCTCTAG 
rs80176156  chr1:33798031-33798031  + C/G 
256 hsa-mir-3609 MI0015999  CAAAGTGATGAGTAATACTGGCTG rs34109026  chr7:98479274-98479274  + -/T 
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  miRNA Mature miRNA Sequence SNP ID Position Strand Allele 
257 hsa-mir-3612 MI0016002  AGGAGGCATCTTGAGAAATGGA rs1683709  chr12:128778703-128778703  - C/T 
258 hsa-mir-3615 MI0016005  TCTCTCGGCTCCTCGCGGCTC rs745666  chr17:72744798-72744798  - C/G 
259 hsa-mir-3617 MI0016007  AAAGACATAGTTGCAAGATGGG rs80142005  chr20:44333749-44333749  + A/G 
260 hsa-mir-3619 MI0016009  TCAGCAGGCAGGCTGGTGCAGC rs73888764  chr22:46486996-46486996  + A/G 
261 hsa-mir-3620 MI0016011  TCACCCTGCATCCCGCACCCAG rs2070960  chr1:228284991-228284991  + C/T 
262 hsa-mir-3647 MI0016047  CTGAAGTGATGATTCACATTCAT   
AGAAAATTTTTGTGTGTCTGATC 
rs28429778  chr16:70563410-70563410  + A/C 
263 hsa-mir-3659 MI0016060  TGAGTGTTGTCTACGAGGGCA rs553122  chr1:38554942-38554942  - A/G 
264 hsa-mir-3652 MI0016052  CGGCTGGAGGTGTGAGGA rs62747560  chr12:104324231-104324231  + -/GGGGTGG 
rs71440517  chr12:104324238-104324244  + -/GGGGTGG 
rs17797090  chr12:104324266-104324266  + A/G 
265 hsa-mir-3657 MI0016057  TGTGTCCCATTATTGGTGATT rs77419179  chr12:112475403-112475403  + C/T 
rs71083196  chr12:112475428-112475427  + -/C 
rs71083197  chr12:112475430-112475429  + -/G 
rs71719442  chr12:112472575-112476739  + LARGE DELETION 
266 hsa-mir-3660 MI0016061  ACTGACAGGAGAGCATTTTGA rs34630557  chr5:89312452-89312451  + -/C 
rs75102645  chr5:89312487-89312487  + A/G 
267 hsa-mir-3664 MI0016065  AACTCTGTCTTCACTCATGAGT rs75728268  chr11:70718466-70718466  + G/T  
268 hsa-mir-3667 MI0016068  AAAGACCCATTGAGGAGAAGGT   
ACCTTCCTCTCCATGGGTCTTT 
rs76749295  chr22:49937076-49937076  + A/G 
269 hsa-mir-3671 MI0016072  ATCAAATAAGGACTAGTCTGCA rs521188  chr1:65523519-65523519  + A/G 
270 hsa-mir-3679 MI0016080  TGAGGATATGGCAGGGAAGGGGA 
CTTCCCCCCAGTAATCTTCATC 
rs10175383  chr2:134884697-134884697  + C/G 
rs6430498  chr2:134884700-134884700  + A/G 
271a hsa-mir-3673 MI0016074  ATGGAATGTATATACGGAATA rs57824231  chr8:130508130-130508130  + -/AT 
rs55921050  chr8:130508142-130508142  + C/T 
rs60861880  chr8:130508149-130508149  + C/T 
271b hsa-mir-3673 MI0016074 ATGGAATGTATATACGGAATA rs60525947  chr8:130508165-130508165  + G/T 
rs58699099  chr8:130508172-130508172  + C/T 
rs58872489  chr8:130508179-130508178  + -/CA 
272 hsa-mir-3674 MI0016075  ATTGTAGAACCTAAGATTGGCC rs75404472  chr8:1749333-1749333  + C/T 
273 hsa-mir-3682 MI0016083  TGATGATACAGGTGGAGGTAG rs1047873  chr2:54076332-54076332  - A/G 
274 hsa-mir-3686 MI0016087  ATCTGTAAGAGAAAGTAAATGA rs6997249  chr8:130496365-130496365  + A/G 
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275 hsa-mir-3683 MI0016084  TGCGACATTGGAAGTAGTATCA rs6943868  chr7:7106600-7106600  + A/T 
rs6977967  chr7:7106636-7106636  + A/G 
276 hsa-mir-3714 MI0016135  GAAGGCAGCAGTGCTCCCCTGT rs55835744  chr3:16974725-16974725  + C/T 
rs75653184  chr3:16974739-16974739  + A/C 
277 hsa-mir-3180-4 MI0016408  TGGGGCGGAGCTTCCGGAG rs5016496  chr16:15248707-15248707  - C/G 
rs5016497  chr16:15248717-15248717  - C/G 
rs75000738  chr16:15248720-15248720  + A/C 
278 hsa-mir-3180-5 MI0016409  TGGGGCGGAGCTTCCGGAG rs2855372  chr16:2186054-2186054  - G/T 
rs2021041  chr16:2186129-2186129  - C/T 
279 hsa-mir-3689b MI0016411  TGTGATATCATGGTTCCTGGGA rs74405398  chr9:137741987-137741987  + A/G 
rs71506933  chr9:137741989-137741989  + C/G 
rs34933499  chr9:137741993-137741993  + A/C/G 
rs76317538   chr9:137741994-137741994  + A/G 
rs71483239  chr9:137742013-137742013  + C/G 
rs76578598  chr9:137742017-137742017  + A/G 
rs79438120  chr9:137742018-137742018  + A/G 
rs35679521  chr9:137742041-137742041  + A/G 
rs113626871  chr9:137742043-137742043  + G/T 
280 hsa-mir-3688 MI0016089  TATGGAAAGACTTTGCCACTCT rs70962655  chr4:160050032-160050031  + -/C 
281 hsa-mir-3910-1 MI0016414  AAAAGGCATAAAACCAAGACA rs12344333  chr9:94398543-94398543  + C/T 
rs67339585  chr9:94398581-94398581  + C/T 
282 hsa-mir-3908 MI0016412  GAGCAATGTAGGTAGACTGTTT rs74446573  chr12:124021052-124021052  + G/T 
rs61953551  chr12:124021054-124021054  + G/T 
283 hsa-mir-3909 MI0016413  TGTCCTCTAGGGCCTGCAGTCT rs9607265  chr22:35731697-35731697  + A/G 
284 hsa-mir-3911 MI0016415  TGTGTGGATCCTGGAGGAGGCA rs75848623  chr9:130452968-130452968  + G/T 
285 hsa-mir-3922 MI0016429  TCTGGCCTTGACTTGACTCTTT rs61938575  chr12:104985443-104985443  + A/G 
286 hsa-mir-3910-2 MI0016431  AAAAGGCATAAAACCAAGACA rs67339585  chr9:94398581-94398581  + C/T 
287 hsa-mir-3928 MI0016438  GGAGGAACCTTGGAGCTTCGGC rs5997893  chr22:31556103-31556103  + A/G 
288 hsa-mir-3936 MI0016592  TAAGGGGTGTATGGCAGATGCA rs61745813  chr5:131701185-131701185  + C/T 
rs367805  chr5:131701279-131701279  - A/G 
289 hsa-mir-550b-1 MI0016686  TCTTACTCCCTCAGGCACTG  rs71528599  chr7:30329467-30329467  + C/T 
290 hsa-mir-548z MI0016688  CAAAAACCGCAATTACTTTTGCA rs17120527  chr12:65016300-65016300  + A/G 
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291 hsa-mir-3938 MI0016594  AATTCCCTTGTAGATAACCCGG rs35071197  chr3:55886523-55886522  + -/G 
rs59684995  chr3:55886574-55886574  + A/T 
rs10575780  chr3:55886581-55886582  + -/AA 
rs28647346  chr3:55886608-55886608  + A/G 
292 hsa-mir-3939 MI0016596  TACGCGCAGACCACAGGATGTC rs80032204  chr6:167411298-167411298  + C/T 
rs77840042  chr6:167411300-167411300  + C/T 
rs75692943  chr6:167411301-167411301  + A/G 
rs70979794  chr6:167411314-167411313  - 1552 BP INSERTION 
rs13216014  chr6:167411314-167411314  + C/T 
rs12200860  chr6:167411344-167411344  + C/T 
rs77072520  chr6:167411362-167411362  + A/G 
rs73024234  chr6:167411388-167411388  + C/G 
293 hsa-mir-941-3 MI0005765  CACCCGGCTGTGTGCACATGTGC rs6089780  chr20:62550880-62550880  + A/G 
rs6090019  chr20:62550890-62550890  + C/T 
rs55795631  chr20:62550877-62550877  + C/T 
294 hsa-mir-3689a MI0016090  TGTGATATCATGGTTCCTGGGA  
CTGGGAGGTGTGATATCGTGGT 
rs71501303  chr9:137741197-137741803  + CCACGAT/GCACGGG 
295 hsa-mir-3171 MI0014202  AGATGTATGGAATCTGTATATATC rs61972532  chr14:28102427-28102427  + A/G 
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Table A.3: Relative Quantification (RQ) of mature miRNA-125a was calculated by applying to the 2 
- ∆∆CT
 analyses. 
 
Sample 
Wild Type 
Probe 
Mutant 
Probe 
Endo 
miR-16 
Endo 
RNU44 
Average 
endogenous 
Wild type 
∆CT 
Mutant 
∆CT  
Sample 
Wild type 
∆CT 
Mutant 
∆CT 
∆∆CT 
Relative 
Quatification (RQ) 
Average 
RQ 
Log 
RQ 
Average 
Log 
SD 
CV 
(%) 
Empty 
Vector  
(EV) 
30.99 37.32 27.31 26.30 26.80 4.18 10.52 
 
Empty 
Vector  
(EV) 
4.18 10.52 0.00 1.00 1.00 0.00 0.00 0.00 0.00 
30.58 36.36 27.28 25.40 26.34 4.24 10.03 
 
4.24 10.03 0.00 1.00 
     
30.67 36.00 27.56 25.52 26.54 4.13 9.46 
 
4.13 9.46 0.00 1.00 
     
30.84 36.11 27.34 26.55 26.95 3.89 9.17 
 
3.89 9.17 0.00 1.00 
     
31.22 37.35 27.82 26.50 27.16 4.06 10.19 
 
4.06 10.19 0.00 1.00 
     
31.41 37.23 27.59 27.00 27.29 4.11 9.93 
 
4.11 9.93 0.00 1.00 
     
29.28 34.90 26.14 23.06 24.60 4.68 10.30 
 
4.68 10.30 0.00 1.00 
     
29.34 34.20 26.27 23.29 24.78 4.56 9.42 
 
4.56 9.42 0.00 1.00 
     
29.33 35.14 25.40 23.34 24.37 4.96 10.76 
 
4.96 10.76 0.00 1.00 
                        
Sample 
Wild Type 
Probe 
Mutant 
Probe 
Endo 
miR-16 
Endo 
RNU44 
Average 
endogenous 
Wild type 
∆CT 
Mutant 
∆CT  
Wild 
Type  
miR-125a 
-3.90 
 
-8.08 270.50 192.39 2.43 2.28 0.07 3.24 
Wild Type  
miR-125a 
23.33 
 
28.03 26.43 27.23 -3.90 
  
-3.43 
 
-7.67 203.59 
 
2.31 
   
23.32 
 
27.34 26.17 26.75 -3.43 
  
-3.42 
 
-7.55 187.53 
 
2.27 
   
23.31 
 
27.15 26.31 26.73 -3.42 
  
-3.51 
 
-7.40 168.90 
 
2.23 
   
23.18 
 
27.14 26.23 26.68 -3.51 
  
-3.35 
 
-7.41 169.84 
 
2.23 
   
23.12 
 
27.83 25.12 26.47 -3.35 
  
-3.44 
 
-7.55 187.01 
 
2.27 
   
23.15 
 
27.59 25.59 26.59 -3.44 
  
-2.51 
 
-7.19 145.61 
 
2.16 
   
21.65 
 
25.17 23.14 24.16 -2.51 
  
-3.08 
 
-7.64 198.78 
 
2.30 
   
21.74 
 
26.10 23.53 24.82 -3.08 
  
-2.68 
 
-7.64 199.74 
 
2.30 
   
21.71 
 
25.57 23.22 24.39 -2.68 
  
Mutant  
miR-
125aM 
 
-3.93 -14.45 22334.71 11197.50 4.35 3.99 0.25 6.23 
                 
Sample 
Wild Type 
Probe 
Mutant 
Probe 
Endo 
miR-16 
Endo 
RNU44 
Average 
endogenous 
Wild type 
∆CT 
Mutant 
∆CT   
-3.42 -13.45 11186.72 
 
4.05 
   
Mutant  
miR-125aM 
 
21.77 26.48 24.92 25.70 
 
-3.93 
  
-3.73 -13.18 9309.58 
 
3.97 
   
 
22.46 26.76 25.01 25.89 
 
-3.42 
  
-3.15 -12.32 5102.54 
 
3.71 
   
 
21.71 26.66 24.21 25.44 
 
-3.73 
  
-3.63 -13.82 14462.21 
 
4.16 
   
 
22.93 27.08 25.09 26.08 
 
-3.15 
  
-2.22 -12.15 4546.37 
 
3.66 
   
 
22.31 27.58 24.31 25.94 
 
-3.63 
  
-3.03 -13.32 10254.72 
 
4.01 
   
 
23.11 26.44 24.22 25.33 
 
-2.22 
  
-2.97 -12.39 5363.65 
 
3.73 
   
 
22.01 25.59 24.48 25.03 
 
-3.03 
  
-3.39 -14.15 18217.03 
 
4.26 
   
 
22.16 25.58 24.67 25.13 
 
-2.97 
 
 
         
 
21.79 25.69 24.66 25.18 
 
-3.39 
   
 
 Key for Table A.3: [miR-16 and RNU44 = endogenous controls; ∆CT = delta CT (CT sample – CT endogenous control); ∆∆CT = delta delta CT (∆CT 
wild-type miRNA-125a - ∆CT mutagenized miRNA-125a); RQ = relative quantification; CV = correlation variation; SD = standard deviation] 
 
Pt- test = 1.119 x 10
-12 
 1
2
2
 
Table A.4: Relative Quantification (RQ) of mature miRNA-124-3 was calculated by applying to the 2 
- ∆∆CT
 analyses. 
 
 
Sample 
Wild Type 
Probe 
Mutant 
Probe 
Endo 
miR-16 
Endo 
RNU44 
Average 
endogenous 
Wild type 
∆CT 
Mutant 
∆CT  
Sample  
Wild type 
∆CT 
Mutant 
∆CT 
∆∆CT 
Relative 
Quatification (RQ) 
Average 
RQ 
Log 
RQ 
Average 
Log 
SD CV (%) 
Empty 
Vector  
(EV) 
28.48 32.14 20.15 21.80 20.97 7.50 11.17 
 
Empty 
Vector  
(EV) 
7.50 11.17 0.00 1.00 1.00 0.00 0.00 0.00 0.00 
28.46 32.37 20.29 22.08 21.19 7.27 11.18 
 
7.27 11.18 0.00 1.00           
28.92 32.26 20.36 22.06 21.21 7.71 11.05 
 
7.71 11.05 0.00 1.00           
28.87 35.79 24.41 27.08 25.74 3.13 10.05 
 
3.13 10.05 0.00 1.00           
29.01 36.67 24.56 27.15 25.86 3.15 10.82 
 
3.15 10.82 0.00 1.00           
29.07 37.92 24.33 26.80 25.57 3.50 12.36 
 
3.50 12.36 0.00 1.00           
28.84 38.46 23.41 24.09 23.75 5.09 14.71 
 
5.09 14.71 0.00 1.00           
29.02 37.57 23.34 24.13 23.73 5.29 13.84 
 
5.29 13.84 0.00 1.00           
29.23 38.84 23.92 24.24 24.08 5.15 14.76 
 
5.15 14.76 0.00 1.00           
                   
Sample 
Wild Type 
Probe 
Mutant 
Probe 
Endo 
miR-16 
Endo 
RNU44 
Average 
endogenous 
Wild type 
∆CT 
Mutant 
∆CT  
Wild 
Type  
miR-124 
3.08   -4.42 21.45 112.83 1.33 1.83 0.45 24.75 
Wild 
Type  
miR-124 
27.54   23.75 25.18 24.46 3.08   
 
2.26   -5.01 32.31   1.51       
27.30   24.30 25.77 25.04 2.26   
 
1.94   -5.78 54.83   1.74       
27.15   24.12 26.32 25.22 1.94   
 
-5.43   -8.56 376.11   2.58       
25.08   27.21 33.79 30.50 -5.43   
 
-4.91   -8.06 266.78   2.43       
25.14   26.71 33.37 30.04 -4.91   
 
-3.72   -7.22 149.03   2.17       
25.26   26.60 31.36 28.98 -3.72   
 
0.17   -4.92 30.26   1.48       
26.63   25.48 27.42 26.45 0.17   
 
-0.47   -5.76 54.06   1.73       
26.45   25.65 28.18 26.92 -0.47   
 
0.21   -4.94 30.65   1.49       
26.76   25.26 27.84 26.55 0.21   
 
Mutant  
miR-
124M 
  -1.74 -12.91 7691.24 30330.34 3.89 4.03 0.68 16.97 
          
 
             
Sample 
Wild Type 
Probe 
Mutant 
Probe 
Endo 
miR-16 
Endo 
RNU44 
Average 
endogenous 
Wild type 
∆CT 
Mutant 
∆CT  
  -0.21 -11.40 2693.94   3.43       
Mutant  
miR-
124M 
  24.01 26.06 25.44 25.75   -1.74 
 
  0.29 -10.77 1743.78   3.24       
  23.92 24.83 23.44 24.13   -0.21 
 
  -1.78 -11.83 3628.10   3.56       
  24.52 25.25 23.22 24.23   0.29 
 
  -1.12 -11.93 3914.20   3.59       
  24.28 23.12 29.00 26.06   -1.78 
 
  -0.43 -12.79 7067.58   3.85       
  24.48 22.97 28.23 25.60   -1.12 
 
  -1.68 -16.40 86295.64   4.94       
  24.68 23.61 26.62 25.12   -0.43 
 
  -1.76 -15.60 49529.49   4.69       
  24.69 25.21 27.53 26.37   -1.68 
 
  -2.00 -16.75 110409.13   5.04       
  24.86 25.28 27.95 26.61   -1.76 
  
  
          24.64 25.51 27.76 26.63   -2.00 
  
  
        
 
 
Key for Table A.4: [miR-16 and RNU44 = endogenous controls; ∆CT = delta CT (CT sample – CT endogenous control); ∆∆CT = delta delta CT (∆CT 
wild-type miRNA-124-3 - ∆CT variant miRNA-124-3); RQ = relative quantification; CV = correlation variation; SD = standard deviation] 
 
Pt- test = 5.163 x 10
-7 
 1
2
3
 
Table A.5: Relative Quantification (RQ) of mature miRNA-662 was calculated by applying to the 2 
- ∆∆CT
 analyses. 
 
Sample 
Wild Type 
Probe 
Mutant 
Probe 
Endo 
miR-16 
Endo 
RNU44 
Average 
 endogenous 
Wild type 
∆CT 
Mutant 
∆CT  
Sample  
Wild type 
∆CT 
Mutant 
∆CT 
∆∆CT 
Relative 
Quatification (RQ) 
Average 
RQ 
Log 
RQ 
Average 
Log 
SD CV (%) 
Empty 
Vector  
(EV) 
36.54 35.25 24.56 27.15 25.86 10.68 9.39 
 
Empty 
Vector  
(EV) 
10.68 9.39 0.00 1.00 1.00 0.00 0.00 0.00 0.00 
35.69 35.98 24.33 26.80 25.57 10.13 10.41 
 
10.13 10.41 0.00 1.00           
36.31 35.15 23.41 24.09 23.75 12.56 11.40 
 
12.56 11.40 0.00 1.00           
35.88 34.41 23.34 24.13 23.73 12.15 10.68 
 
12.15 10.68 0.00 1.00           
34.65 32.23 20.15 21.80 20.97 13.68 11.26 
 
13.68 11.26 0.00 1.00           
35.52 31.04 20.29 22.08 21.19 14.34 9.85 
 
14.34 9.85 0.00 1.00           
         
                    
Sample 
Wild Type 
Probe 
Mutant 
Probe 
Endo 
miR-16 
Endo 
RNU44 
Average 
 endogenous 
Wild type 
∆CT 
Mutant 
∆CT  
Wild Type  
miR-662 
7.48   -3.21 9.23 9.40 0.97 0.89 0.32 36.38 
Wild 
Type  
miR-662 
34.77   24.95 29.64 27.29 7.48   
 
7.30   -2.83 7.09   0.85       
34.80   25.38 29.61 27.50 7.30   
 
11.39   -1.18 2.26   0.36       
37.62   24.42 28.04 26.23 11.39   
 
9.68   -2.46 5.52   0.74       
35.80   24.18 28.06 26.12 9.68   
 
9.91   -3.77 13.63   1.13       
36.57   26.18 27.15 26.66 9.91   
 
10.12   -4.22 18.66   1.27       
36.23   25.48 26.75 26.11 10.12   
 
Mutant  
miR-662M 
  3.68 -5.71 52.35 56.30 1.72 1.70 0.22 13.05 
         
  
 
              
Sample 
Wild Type 
Probe 
Mutant 
Probe 
Endo 
miR-16 
Endo 
RNU44 
Average 
 endogenous 
Wild type 
∆CT 
Mutant 
∆CT  
  5.52 -4.89 29.65   1.47       
Mutant  
miR-
662M 
  34.18 28.11 32.89 30.50   3.68 
 
  5.20 -6.20 73.41   1.87       
  36.01 27.71 33.27 30.49   5.52 
 
  5.92 -4.76 27.01   1.43       
  31.88 25.30 28.06 26.68   5.20 
 
  5.52 -5.74 53.54   1.73       
  32.87 25.62 28.28 26.95   5.92 
 
  3.18 -6.67 101.83   2.01       
  31.29 24.20 27.33 25.77   5.52 
 
 
 
          29.44 24.48 28.04 26.26   3.18 
  
          
Key for Table A.5: [miR-16 and RNU44 = endogenous controls; ∆CT = delta CT (CT sample – CT endogenous control); ∆∆CT = delta delta CT (∆CT 
type wild miRNA-662 - ∆CT variant miRNA-662); RQ = relative quantification; CV = correlation variation; SD = standard deviation] 
 
Pt- test = 4.551x 10
-4 
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Figure A.1: Dissociation curve for Beta-actin primers showing one peak (above); 
standard curve for Beta-actin primers (below). 
 
 
Figure A.2: Dissociation curve for GAPDH primers showing one peak (above); 
standard curve for GAPDH primers (below). 
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Figure A.3: Dissociation curve for primary miR-125a primers showing one peak 
(above); standard curve for primary miR-125a primers (below). 
 
 
Figure A.4: Dissociation curve for pri-miR-124-3 primers showing one peak (above); 
standard curve for for pri-miR-124-3 primers (below). 
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Figure A.5: Dissociation curve for pri-miR-662 primers showing one peak (above); 
standard curve for pri-miR-662 primers (below). 
 
 
Figure A.6: Dissociation curve for precursor miR-125a primers showing one peak 
(above); standard vurce for precursor miR-125a primers (below). 
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Figure A.7: Dissociation curve for pre-miR-124-3 primers showing one peak (above); 
standard curve for pre-miR-124-3 primers (below). 
 
 
Figure A.8: Dissociation curve for pre-miR-662 primers showing one peak (above); 
standard curve for pre-miR-662 primers (below). 
